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Validitet og relevans av internasjonale retningslinjer for
forebygging av hjerte- og karsykdom i allmennpraksis
De siste tiårene har forebygging av hjerte- og karsykdom (HKS) blitt et svært sentralt
tema i klinisk praksis, helsepolitikk og offentlig debatt. I vår del av verden er det først
og fremst allmennlegene som arbeider med forebygging av HKS på individuelt nivå.
For dette formålet er det utformet kliniske retningslinjer som skal gjøre det mulig for
legene å gjøre en best mulig forebyggende jobb. Retningslinjene er ment å formidle
nødvendig og oppdatert kunnskap til legene og slik fungere som et instrument for
klinisk kvalitetsforbedring. Retningslinjer legger føringer for hva som regnes som
forsvarlig klinisk praksis og kan bli styringsverktøy for helsemyndighetene med
mulighet for økonomiske sanksjoner om de ikke følges. Flere studier har imidlertid vist
at allmennleger i beskjeden grad følger retningslinjer for forebygging av HKS, og at
anbefalte behandlingsmål ofte ikke oppnås. Enkelte vil forklare dette med at
allmennlegene gjør en dårlig jobb, mens andre har pekt på svakheter ved grunnlaget for
og utformingen av retningslinjene.
Målet med prosjektet var å analysere validitet og relevans av autoritative, internasjonale
retningslinjer for forebygging av hjerte- og karsykdom i allmennpraksis.
Mer spesifikt:
- Å dokumentere HKS- risikoprofilen til en generell befolkning hvis
risikodefinisjonene som retningslinjene anvender appliseres som anbefalt.
- Å estimere arbeidsbyrden for allmennlegene om retningslinjene ble tatt i bruk i
en gitt populasjon.
- Å identifisere mulige årsaker til at retningslinjene synes å overestimere risiko,
med utgangspunkt i analyse av isolerte risikofaktorer: total-kolesterol og
kroppsmasseindeks.
Avhandlingen bygger på analyser av data fra Helse-undersøkelsen i Nord-Trøndelag
(HUNT 2) som er en befolkningsstudie med over 65 000 deltakere. Hovedfunn:
Majoriteten av befolkningen hadde risiko for HKS med behov for regelmessig
oppfølging i helsetjenesten ut fra retningslinjenes definisjoner av risiko. Om
retningslinjene ble implementert i norsk allmennpraksis ville det destabilisere
fastlegetjenesten.
To delstudier ble gjennomført for å finne ut om det overraskende høye antallet av
personer med medisinsk risiko (‘risikanter’) som retningslinjene definerer evt. kan
forklares av hvordan to isolerte risikofaktorer, nemlig kolesterol og fedme, behandles av
retningslinjene.
Total-kolesterol viste seg å ikke være en så entydig prediktiv markør for dødelighet som
generelt antatt. Måten kolesterol betraktes på ble dermed identifisert som en mulig
svakhet ved retningslinjene. Dersom våre resultater kan reproduseres og er
generaliserbare, må anbefalinger knyttet til kolesterol revideres, både for klinisk bruk og
i folkehelsekampanjer.
Kroppsmasseindeks (KMI) / body mass index (BMI) har til nå vært den mest anvendte
og anbefalte metoden for å måle kroppssammensetning og definere fedme. KMI viste
seg i vår analyse å være en dårligere prediktor for dødelighet enn følgende tre mål var:
forholdet mellom liv- og hoftevidde (waist-to-hip ratio; WHR), forholdet mellom
livvidde og høyde (waist-to-height ratio; WHtR), eller kun livvidden. WHR og WHtR
predikerte dødelighet best. På bakgrunn av dagens kunnskap virker det rimelig å
anbefale WHR for å måle kroppssammensetning med tanke på sykdomsforebygging.
I avhandlingen identifiseres og diskuteres også andre faktorer som potensielt kan
begrense retningslinjenes validitet og relevans.
Samlet dokumenterer avhandlingens fire delstudier problemer med retningslinjene som
har vesentlig betydning, både for klinisk praksis, ressursbruk og planlegging av
helsetjeneste. I praksis overestimerer retningslinjene hjerte-kar risiko og de hjelper
dermed ikke allmennlegene til å gjøre en god og målrettet jobb. En strategi som i
utgangspunktet skulle bidra til å gjøre det enklere for legene å identifisere og prioritere
pasienter med høy risiko, ender i praksis opp som en dårlig planlagt massestrategi som
ikke synes bærekraftig og heller ikke ansvarlig å implementere.
Resultatene som presenteres i avhandlingen har en rekke implikasjoner. Det vil trolig
kreve mye nytenkning og ytterligere forskning å utarbeide forebyggende retningslinjer
som fungerer godt i klinisk praksis. Avhandlingen inneholder noen forslag til hvordan
man kan starte arbeidet med å forbedre retningslinjene.
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4ABSTRACT
Background
Cardiovascular diseases (CVD) are currently the leading cause of death worldwide, and
a major cause of disability. CVD, including supervision of risk factors with respect to
prevention, have in recent decades become an increasingly important topic for general
practice. These issues have also become prominent in public debate and health care
policy. Specific strategies of individual prevention are to a large extent, at least in the
Western world, in the hands of the general practitioners (GPs). In recent years, there has
been much emphasis on clinical practice guidelines to aid GPs in their preventive work
and guide them to the most cost-effective management. This refers both to
recommendations on therapeutic options as well as methods to identify those who
would benefit the most from preventive treatment. These guidelines can provide
important and updated information for clinicians and function as an instrument for
quality improvement and potentially also performance assessment in clinical practice.
However, various studies have shown that GPs only follow the guidelines to a certain
extent, and that recommended treatment goals are often not reached. Some authors have
explained this in terms of physicians' inadequacy, whilst others have pointed out that at
least part of the explanation is likely to lie in the nature of the guidelines as such. The
quality and usefulness of clinical guidelines for prevention of CVD are of great
importance to many, both on the level of individual health care and from the perspective
of resource allocation.
Aims
The objective of this project was to study and discuss the validity and relevance of
international CVD prevention guidelines for general practice. More specifically:
- To document the CVD risk profile of a general population as defined by
selected, authoritative preventive clinical guidelines, by means of modelling
studies.
- To estimate the workload associated with following the recommendations of the
selected guidelines for a well-defined general population in whole.
- To identify potential causes of guidelines' overestimation of risk, focusing on
individual risk factors.
Material and methods
This dissertation is based on analyses of data from the Norwegian HUNT 2 population
survey, including roughly 65 000 participants. Two studies were conducted to document
the CVD risk profile of this general population and to model the implications of
implementing current clinical guidelines, regarding the proportion of the population
identified at “increased risk”, and the clinical workload associated with following the
guideline recommendations. Subsequently, two studies were conducted to analyse
whether potential causes of guidelines' overestimation of CVD risk might stem from the
way two individual risk factors, cholesterol and obesity, are handled in the guidelines.
The dissertation further includes analysis and identification of additional factors
potentially limiting the validity and relevance of preventive CVD guidelines.
5Results
If authoritative guideline recommendations for CVD prevention are literally applied, a
vast majority of adults in Norway would exhibit “unfavourable” CVD risk profiles and
thus be considered in need of individual, clinical attention and follow-up. The potential
workload associated with implementing current European clinical guidelines could
destabilise the healthcare system in Norway, one of the world's most long- and healthy-
living nations, by international comparison.
Total cholesterol was not found to be as predictive of mortality as generally
assumed. Thus, possible errors regarding the role of total cholesterol in the CVD risk
algorithms of many clinical guidelines were identified. If our findings are generalisable,
clinical and public health recommendations regarding the “dangers” of cholesterol
should be revised.
Body mass index, the most widely recommended measure of obesity in
preventive CVD guidelines, was found to be inferior to waist-to-hip ratio (WHR),
waist-to-height ratio (WHtR), and waist circumference in relation to predicting
mortality. WHR and WHtR exhibited the best predictive properties. It appears
reasonable to recommend WHR as the primary clinical measure of body composition
and obesity for preventive purposes.
Conclusion
There currently appears to be a range of factors limiting the validity and relevance of
clinical practice guidelines on prevention of CVD, at least in Norway. Such limitations
may have important effects on clinical practice and resource allocation, as well as
population health. The guidelines appear to overestimate CVD risk and fail to correctly
identify a manageable proportion of the population as “high-risk individuals”, for whom
individual preventive strategies would be effective and beneficial. The strategy of
targeting individuals at risk ends up being recommended at the level of mass strategy,
which can hardly be regarded as sustainable or responsible. A number of factors
potentially limiting the validity and relevance of current guidelines were identified. The
dissertation includes a proposal of ways to improve the guidelines.
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91. INTRODUCTION
Cardiovascular diseases (CVD, see definition in the next paragraph), including
supervision of risk factors with respect to prevention, have in recent decades become an
increasingly important topic for general practice. These issues have also become
prominent in public debate and health care policy. Recently a global campaign against
non-communicable diseases (NCD) was initiated, aimed at CVD, diabetes, cancer, and
chronic respiratory diseases. This campaign is led by the NCD Alliance (see:
www.ncdalliance.org) and supported by numerous organisations, such as the United
Nations and the World Health Organization (WHO) (NCD Alliance 2011). The aim of
the alliance and the campaign is to reduce the burden of NCDs (including CVD)
worldwide through various means. It is, perhaps, not strange that CVD receives
enormous attention, since it is the number one cause of death worldwide, and a major
cause of disability (NCD Alliance 2011). But besides being important to patients,
populations at risk, health care systems, and governments, treatment and prevention of
CVD are of huge interest to the pharmaceutical industry and various other commercial
actors, for whom CVD prevention is a tremendously lucrative field. Thus, it is obvious
that CVD prevention is a very important theme from many perspectives.
In this thesis the term CVD refers to atherosclerotic disease, where coronary heart
disease (CHD) and cerebral stroke are the major components. Strategies to prevent
CVD can be directed at either populations as a whole, such as restrictions of tobacco
sales, or individuals, such as blood pressure (BP) lowering treatment (Rose 1985).
Specific strategies of individual prevention are to a large extent, at least in the Western
world, in the hands of the general practitioners (GPs). In recent years, there has been
much emphasis on clinical practice guidelines to aid GPs in their preventive work and
guide them to the most cost-effective management. This refers both to
recommendations on therapeutic options as well as methods to identify those who
would benefit the most from preventive treatment. These guidelines have the potential
to provide important and updated information for clinicians and function as an
instrument for quality improvement in clinical practice. However, various studies have
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shown that GPs only follow the guidelines to a certain extent, and that recommended
treatment goals are often not reached (Fretheim et al. 2006; Hetlevik et al. 1997 i and
ii). Some authors have explained this in terms of physicians' inadequacy (Philips et al.
2001), whilst others have pointed out that at least part of the explanation is likely to lie
in the nature of the guidelines as such (Getz et al. 2004 and 2005; Getz 2006; Hartz et
al. 2005; Hetlevik 1999; Hetlevik et al. 2008; Lindman et al. 2007).
The quality and usefulness of clinical guidelines for prevention of CVD are of great
importance to many, both on the level of individual health care and from the perspective
of resource allocation. This thesis investigates the validity and relevance of guidelines
for prevention of CVD, with a focus on primary prevention. The thesis' aim is not to
study the epidemiological impact of individual risk factors on the development of CVD
or the effect of specific therapeutic options. The focus is on how the guidelines function
as working tools for GPs.
To fully comprehend the current guidelines and their recommendations (i.e., the current
status of mainstream preventive medicine) it is crucial to appreciate the context in
which they are developed. I will therefore begin with a short overview of the secular
trends in CVD mortality, followed by a discussion of some of the major CVD risk
factors in a historical perspective. Then before introducing the present study, I will
focus on evidence-based medicine (EBM) and the guideline development processes. In
the background section I will focus on the risk factors BP, cholesterol, and obesity
because they are specifically addressed empirically in the present study. I will also
discuss some important CVD risk factors that have received far less attention in the
guidelines than the above-mentioned ones. After introducing the present study, I will
discuss limitations to the guidelines' validity and relevance and reflect on potential ways
forward, with the aim of improving future guidelines.
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2. BACKGROUND
2.1. Secular trends in cardiovascular disease mortality
In the first half of the 20th century an “epidemic” of CVD was on the rise in the Western
world. The incidence and mortality from CHD and stroke rose sharply in many Western
countries, primarily among men (Lawlor et al. 2001). The age-standardised death rate
from CHD among 35- to 74-year-old men in England and Wales increased from 150 per
100 000 persons in the 1920s to 500 in the 1960s when the incidence peak was reached
(Lawlor et al. 2001; Mirzaei et al. 2009 and 2011). For both sexes combined, these
numbers reached 700 per 100 000 in Finland; 600 in the US, Australia, and Scotland;
and 350-400 in Norway, Sweden, and Denmark (Mirzaei et al. 2009). Quite
understandably, a strong interest in CVD awoke, leading to, among other things, the
establishment of major scientific projects.
A number of epidemiological studies were set up in the mid-20th century to identify
causal and prognostic factors of CVD. The Framingham Heart Study (see:
www.framinghamheartstudy.org), which was established in 1948, is the most renowned
among these. Although the original study population included only 5 209 individuals in
the town of Framingham, Massachusetts, it has become an important source of
innovative knowledge in the field of CVD, including a series of highly influential
publications (see: www.framinghamheartstudy.org/biblio/index.html). Surveys such as
the Framingham Study led to the identification of various risk factors of CVD and
marked the beginning of an era of primary preventive medicine. The focus on risk and
prevention would further increase in the upcoming decades, with the introduction of a
range of drugs for lowering risk factor levels, starting with antihypertensives and later
followed by cholesterol-lowering drugs.
In the 1970s the CHD mortality rates began to fall in most Western countries (Lawlor et
al. 2001; Mirzaei et al. 2009). The mortality from stroke, in fact, began to decrease even
earlier (Mirzaei et al. 2011). This decrease has continued into the 21st century
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(Scarborough et al. 2010; Scholte op Reimer et al. 2006). It is intriguing to note that the
mortality from CVD began to fall before the introduction of effective medical
interventions, and also that the decrease has subsequently been more dramatic than can
be explained by progress in preventive and therapeutic medical treatment alone. The
scale of the “epidemic” (or rather, pandemic) also varied tremendously across countries.
The Mediterranean countries, for instance, maintained relatively low CVD mortality
rates throughout the 20th century, while the mortality increased in the latter half of the
century in many of the Eastern European countries, until the 1990s (Lawlor et al. 2001;
Mirzaei et al. 2009 and 2011).
At the dawn of the 21st century, treatment of risk factors for CVD had become an
established part of clinical practice, and a wide range of therapeutic agents (constantly
increasing in number) was available for that purpose. With the introduction of EBM in
the 1990s (Guyatt et al. 2008), an increasing emphasis was put on the development of
clinical practice guidelines as decision aids for clinicians in their everyday practice of
preventive medicine. These clinical guidelines are the main theme of this thesis. To gain
a deeper understanding of the complexity of the guidelines, both their theoretical
foundation and practical usefulness, one has to be familiar, with both the risk factors
they incorporate and the process of guideline development.
2.2. Risk factors of cardiovascular disease
2.2.1. Blood pressure
When Stephen Hales, in 1733, became the first person to document BP measurement
(Booth 1977) it must have been impossible to imagine the future consequences of his
finding. For example, roughly two centuries later hardly anyone could be admitted to a
hospital without having their BP measured – luckily, by means of dramatically different
measurement methods. But advances have not only been made in the method of
measuring BP. The understanding of this phenomenon has changed drastically;
associations with diseases have been discovered as well as methods to control BP. High
BP has gone from being an interesting physiological phenomenon to being a
13
complication of diseases and a risk factor, to being regarded as a disease – even a “silent
killer” (Seedat 1981). This chapter offers a short overview of BP as a medical
phenomenon in a historical perspective, leading to the recommendations of the current
clinical guidelines.
Measuring blood pressure
In 1733 Stephen Hales inserted a brass pipe into the crural artery of a lying horse,
attached it to a vertical glass tube, and watched the blood rise inside the tube to about
2.5 meters (Booth 1977). No significant improvement was made in the field until a
century later when scientists, such as Poiseuille, developed easier methods for intra-
arterial BP measurements. Though it was von Basch that invented the non-invasive
sphygmomanometer in 1881, it was Scipione Riva-Rocci who made the first really
practical version of it in 1896. The utility of the instrument was then increased in 1905
when Korotkoff introduced a way to identify both diastolic (DBP) and systolic blood
pressure (SBP) by auscultation of the brachial artery distal to the arm-cuff (Booth
1977). Riva-Rocci's mercury sphygmomanometer, without any fundamental alterations,
still holds its status as the gold standard for BP measurements, although the use of
aneroid manometers and automatic oscillometers has become widespread (Moe et al.
2010).
Hazards of hypertension begin to reveal
Fundamental research in the field of BP was done late in the 19th century and at the
dawn of the 20th century. Theories that high blood pressure was secondary only to
arteriosclerosis, heart and kidney diseases were proposed. But with the efforts of
scientists, such as Allbutt, Mahomed and Janeway, hypertension was identified in
patients with no organ damage, and the term essential hypertension (hypertension
without a [known] primary cause) was introduced (Esunge 1991; Sinclair 1969; Ventura
et al. 2001). In 1914 Volhard and Fahr described and classified glomerular diseases in
more detail than had previously been done. They identified hypertension associated
with kidney diseases to have poor prognosis, while hypertensive patients without
nephritis did better (Ventura et al. 2001). In 1928 Keith et al. proposed the term
malignant hypertension for the clinical entity of very elevated BP with retinal damage,
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papilloedema, hypertrophy of the heart, and affected kidneys (Keith et al. 1928; Ventura
et al. 2001). The term was found to be appropriate because of the extremely high fatality
– with life expectancy of less than one year if untreated (McMichael 1952).
Anti-hypertensive treatment
Salt restriction was first recommended for hypertensive patients in 1904 but induced
very mixed response (not to mention the patients' adherence) in the following decades.
Salt restriction gained some support in Europe in the 1920s and in USA in the 1940s
(Esunge 1991; Moser 1997 and 2006; Piepho and Beal 2000; Ventura et al. 2001). In
recent years it has achieved a fundamental status in BP-lowering treatment and
individual CVD prevention, and has been discussed as a public health issue (mass
strategy of CVD prevention) (Graham et al. 2007; Institute of Medicine 2010; Norheim
et al. 2009; WHO 2007).
During the first half of the 20th century, no really effective and harmless BP-lowering
treatments existed. Conservative treatment was recommended for “mild benign
hypertension” with salt restriction, weight reduction, sedatives (such as phenobarbital
and bromides), bed rest and avoidance of stress (Moser 2006; Piepho and Beal 2000).
Further drug treatment was only recommended for malignant hypertension and BP
above 200/100 mmHg. And the list of drugs used was not appealing, including, e.g.,
veratrum alkaloids, rauwolfia derivatives, thiocyanates, and ganglion blocking agents
like hexamethonium (McMichael 1952; Moser 1997 and 2006; Piepho and Beal 2000;
Ventura et al 2001). Few of the drugs were very effective, and they all had unacceptable
side-effects' profiles. Even intravenous bacterial pyrogens were used to lower BP in the
1940s and 1950s (Ventura et al. 2001; McMichael 1952). Because of the lack of good
drugs and because of the poor prognosis, surgical sympathectomy, introduced in the
1920s, became a much used treatment for malignant hypertension (Esunge 1991; Moser
1997 and 2006; Piepho and Beal 2000; Ventura et al. 2001).
The major breakthrough came in 1958 with the introduction of the diuretic
chlorothiazide (Freis et al. 1958). For the first time, BP could be lowered considerably
by means of a well-tolerated oral agent. With the addition of β-blockers in 1962 (Black
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and Stephenson 1962; Prichard 1964; Prichard and Gillam 1964), the anti-hypertensive
armamentarium again improved significantly.
Decades of dramatic changes
The 1960s and 1970s were times of turmoil, some great events and even paradigm shifts
in the history of mankind – also in the field of BP. The thiazides and β-blockers
changed BP-lowering treatment significantly, and treatment goals and indications were
also about to change. In 1959 WHO defined BP below 140/90 mmHg as normal range
and BP ≥160/95 mmHg as “abnormal (hypertensive) range” (WHO 1959:10). This
seems to have been the first international definition on the matter, but no
recommendations regarding treatment were given: “The values given are for statistical
application to population studies and no significance for the individual person is
implied” (WHO 1959:10). In the WHO report in 1962 on preventive aspects of
hypertension and ischaemic heart disease (WHO 1962), the cut-off points remained
unchanged but BP-lowering drug treatment was recommended if signs of organ damage
(such as left ventricular hypertrophy) were identified. About hypertension without
complications the report stated that inadequate evidence existed at the time to support
that early treatment delayed the disease progress. Interestingly, it further states:
The Committee feels [sic] that different factors may contribute to the hypertension at
this stage. Thus in some patients nervous or emotional stress appears to be of major
importance. (...) that what may be described as “common-sense psychotherapy” is the
most effective treatment (...) Apart from sedation, treatment with drugs is usually
unnecessary and ineffective (WHO 1962:11).
In 1961 data from the Framingham Heart Study for the first time identified hypertension
as a strong risk factor for CHD (Kannel et al. 1961). This was one of the first papers
from Framingham, a study which would in the following decades have huge impact on
the field of cardiology. But other influential studies were on the horizon. In 1964
Hamilton et al. (Hamilton et al. 1964) published results from a placebo-controlled trial
of BP-lowering treatment (including a thiazide) in symptomless patients with severe
hypertension (DBP ≥110 mmHg) without signs of atherosclerosis or organ damage. The
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treatment proved to have considerable effect reducing the incidence of stroke and other
BP-related complications.
The idea of recommending potentially life-long medical intervention to individuals who
were free from both subjective symptoms and objective signs of organs damage when
therapy is instituted, motivated by the presence of what could be considered a disease
risk factor only, represents something completely new in medicine (Getz 2006:278).
Decades later this idea became the norm. Similar results from the “Veterans Study”
were published in 1967-72 (Veterans Administration 1967, 1970 and 1972), showing
the effect of BP-lowering treatment for symptomless patients with DBP ≥105 mmHg
and less effect if DBP was in the range of 90-105 mmHg. As a result DBP became the
focus of treatment. The American Joint National Committee on Detection, Evaluation
and Treatment of High Blood Pressure (JNC), in their first report (JNC 1977) in 1977,
as well as WHO in 1978 (WHO 1978), recommended drug treatment of DBP ≥105
mmHg. The definition of hypertension remained unchanged, but borderline
hypertension was defined as BP in the range of 140/90-160/95 mmHg. Because of little
evidence of effect, more conservative treatment was recommended for patients above 65
years of age, and SBP levels of 100 + age were regarded as “normal” (JNC 1977; Moser
1997 and 2006; WHO 1978).
Both JNC (JNC 1977) and WHO (WHO 1978) advocated opportunistic BP screenings
in the general population, identification and follow-up of patients with diagnosed
hypertension. However, WHO emphasised that “unless the existing health care system
is able to cope with the identified hypertensive patients a programme of detection and
follow-up should not be initiated” (WHO 1978:43). This statement is of interest in a
larger context in this thesis. This consideration of practical applicability became less
prevalent in later guidelines and recommendations on the matter.
Interestingly, the feelings of the consulting experts towards “common sense
psychotherapy” seemed to have changed since 1962 (WHO 1962), as the report in 1978
stated:
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There is no definite evidence that behavioural procedures such as biofeedback,
relaxation, psychotherapy, yoga, and transcendental meditation can lead to sustained
lowering of blood pressure. (...) Prolonged adverse psychological and social factors
have not been proved to contribute to blood pressure elevation (WHO 1978:41).
New drugs and new definitions
The last quarter of the 20th century brought many new drugs. Most notably were the
angiotensin converting enzyme (ACE) inhibitors in the late 1970s (Ondetti et al. 1977),
the calcium channel blockers in the 1980s (Moser 1997; Rosenthal 2004), and the
angiotensin receptor blockers (ARB) in the 1990s (Goldberg et al. 1995). And many
trials were conducted, that had implications for the standard treatment of BP, such as
the SHEP study (SHEP Cooperative 1991) and the STOP-Hypertension trial (Dahlöf et
al. 1991), which proved BP-lowering treatment to be beneficial in older patients.
In 1993 the definition of hypertension was lowered to 140/90 mmHg and, if persistent,
regarded as an sufficient indication for drug treatment at all ages, both in the fifth JNC
report (Moser 1997; Schillaci et al. 2009) and in the guidelines by a joint committee of
the WHO and the International Society of Hypertension (ISH) (WHO 1993). However,
WHO/ISH recommended conservative treatment and observation if BP was in the range
of 140/90-160/95 mmHg if no other CVD risk factors were present. The upper cut-off
was lowered to 150/95 mmHg in the 1999 WHO/ISH guidelines (WHO 1999) and the
BP range 130/85-139/89 mmHg defined as high normal, <130/85 as normal, and
<120/80 as optimal, as in the JNC 6 report in 1997 (JNC 1997).
In 2002, a meta-analysis (Prospective Studies 2002) of 61 studies, including almost one
million participants in total, indicated that a continuous and graded association existed
between blood pressure and mortality (in total as well as from CVD specifically)
without a threshold level, at least down to BP of 115/75 mmHg. As a response the JNC
in their seventh report (JNC 2003) defined a new concept - prehypertension.
Prehypertension was defined as BP in the range of 120/80-139/89 mmHg and regarded
a strong risk factor for hypertension – i.e., a risk factor of a risk factor of CVD. At that
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time the recommended levels for initiating of BP-lowering drug treatment for patients
with diabetes or signs of target organ damage were down to 130/85 mmHg (De Backer
2003; JNC 2003).
Risk stratification
As early as the 1970s algorithms for estimating CVD risk were designed on the basis of
data from the Framingham study (Anderson et al. 1991). The idea, brilliant in nature,
was to identify those at highest risk of CVD, who would benefit the most from
preventive medical intervention. Instead of focusing on individual risk factors,
estimating the combined effects of multiple factors was proposed to be more
informative. This combined risk approach was in 1994 recommended by a joint
European task force on prevention of CHD (Pyörala et al. 1994) and the simple four-
level risk stratification chart in the 1999 WHO/ISH guidelines (WHO 1999) was based
on the Framingham risk score. The combined risk approach has since become the
standard for recommendations on managing CVD risk factors. European risk estimation
charts were introduced with the SCORE Project (Conroy et al. 2003) in 2003, which
have been recommended in the European guidelines (De Backer 2003; Graham et al.
2007; Mancia et al. 2007), while many national guidelines base their recommendations
on risk calculators derived from local data (Hippisley-Cox et al. 2010; Norheim et al.
2009). In recent years most guidelines on management of hypertension and prevention
of CVD have based the treatment recommendations on combined risk estimates, and the
BP cut-offs have become less clear. Some guidelines recommend medical intervention
at BP 140/90 mmHg and lower for high-risk individuals (Graham et al. 2007; JNC
2003; Mancia et al. 2007), while others are more conservative, recommending a cut-off
of 160/100 mmHg in general and 140/90 mmHg for high-risk individuals (Norheim et
al. 2009; WHO 2007). For further discussion of risk stratification algorithms see chapter
2.3.2.
Blood pressure, an important risk factor
When all debate on specific cut-off points is set aside, agreement is unanimous that high
BP is an important risk factor for mortality and CVD. Persistently high arterial BP can
accelerate atherogenesis (development of atherosclerosis) and cause excessive strain on
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the cardiovascular system, leading to complications, such as left ventricular
hypertrophy, nephrosclerosis, retinal haemorrhages, and strokes (Kaplan and Domino
2011). BP is associated with CVD and mortality in a log-linear fashion, with an increase
in SBP of 20 mmHg roughly doubling the estimated relative risk of a fatal CVD event
among 40-69 year olds (Prospective Studies 2002), and BP-lowering treatment has been
shown to be effective in reducing morbidity and mortality (Kaplan and Domino 2011).
However, the appropriateness of BP-lowering interventions, on the population level as
well as the individual level, has to be evaluated in the context of the distribution of BP
levels in the population.
Danaei and co-workers (Danaei et al. 2011) estimated the change in mean age-
standardised SBP from 1980-2008 globally, combining data on 5.4 million study
participants from 199 countries. In men this estimated global average decreased from
131 to 128 mmHg, and in women from 127 to 124 mmHg. In Western Europe the
change in mean age-standardised SBP was estimated from ca. 138 to 132 mmHg in men
and from ca. 134 to 123 mmHg in women (according to figures, detailed numbers not
given) (Danaei et al. 2011). WHO estimated the world mean SBP (not age-standardised)
in 2004 at 127 mmHg in men and 126 mmHg in women, and the prevalence of
hypertension (SBP ≥140 mmHg) was estimated at 23% (WHO 2009). In Europe the
estimated mean was 134 mmHg and the prevalence of hypertension 36%. In 2008 the
estimated prevalence of hypertension (BP ≥140/90 mmHg) in Norway was 50% among
men and 43% among women (WHO 2011 i). In the Norwegian HUNT studies the
prevalence of hypertension decreased among men from 48% in 1995-97 (HUNT 2) to
34% in 2006-08 (HUNT 3), and among women from 38% to 26%, the same years
(Krokstad og Knudtsen 2011). Thus, mean BP levels have been decreasing worldwide
(although not in all regions) in recent decades, and the greatest decrease has been seen
in high-income countries (Danaei et al. 2011).
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2.2.2. Cholesterol
Anitschkow and the early works
The work of Nikolai Anitschkow in 1913 (Anitschkow and Chalatow 1983) might be
considered the first major step towards identifying serum cholesterol as a risk factor for
CVD. He fed rabbits with purified cholesterol and found that this diet induced vascular
lesions comparable to human atherosclerosis. His research was most notably inspired by
the works of Alexander Ignatowski (Ignatowski 1908), who suspected animal-derived
proteins of being the harmful agent. Others (Windaus 1908) had previously identified
cholesterol within human atherosclerotic plaques. Among them was Rudolf Virchow,
who was the first to write a detailed review on atherosclerosis (Virchow 1856 and
1858).
The Norwegian professor of internal medicine, Carl Müller, published a paper in 1939,
reviewing the literature on associations of hereditary xanthomatosis (familial
hypercholesterolemia) with hypercholesterolemia and heart disease, adding his own
observations from Norwegian cases (Müller 1939). His conclusion was that this
hereditary disease caused xanthomatous deposits in the coronary arteries (i.e.,
atherosclerosis), as well as other parts of the body, resulting in myocardial ischemia,
often at a young age. Since then studies involving patients with familial
hypercholesterolemia have been important in the field of cholesterol research (Brown
and Goldstein 1974 and 1976; Goldstein and Brown 1973 and 1977).
Epidemiology, eating habits, and an evolving theory
Cholesterol gained its status as a major risk factor for CVD in the 1960s with
publications of several epidemiological studies (Dawber et al. 1957; Doyle et al. 1957;
Kannel et al. 1961; Keys et al. 1963). The Framingham Heart Study is without a doubt
the most renowned of these. A strong, continuous, and graded association was found
between cholesterol and CHD events (Dawber et al. 1957; Doyle et al. 1957; Kannel et
al. 1961). Since then, this relationship has been found in various studies, both regarding
CHD events and CHD mortality (Anderson et al. 1987; Asia Pacific 2003; Chen et al.
1991; Clarke et al. 2009; Iso et al. 1994; Klag et al. 1993; Law et al. 1994; Neaton and
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Wentworth 1992; Neaton et al. 1992; Njølstad et al. 1996; Prospective Studies 2007;
Rose and Shipley 1986; Smith et al. 1992; Stamler et al. 1986 and 2000; Verschuren et
al. 1995; Wannamethee et al. 1995; Wilson et al. 1998).
One of the early major epidemiological studies linking high cholesterol levels to CHD
was The Seven Countries Study (1958-1970) (Keys 1980; Keys et al. 1984), led by
Ancel Keys. One of the primary findings was that populations with high levels of serum
cholesterol tend to have high mortality rates from CHD, compared to populations with
lower cholesterol levels (Keys 1980; Keys et al. 1984). A second important finding of
Keys and his colleagues was that serum cholesterol levels were proportional to the
dietary saturated fat intake (Keys 1980), which, in fact, had been shown earlier (Keys et
al. 1955; Keys 1957; Keys and Grande 1957; de Langen 1916 and 1922). Although
Keys' results suggested a strong association of cholesterol with CHD, the study
populations were heterogenous and the association was likely to be confounded by
selection bias and other factors (Ravnskog 2000).
Many later (and earlier) observational studies, as well as clinical trials, have shown
association of “Mediterranean diet” (low in saturated fats) with low levels of cholesterol
and other biological risk factors and supported Keys' conclusions (Ehnholm et al. 1982;
Giugliano et al. 2006; Hjermann et al. 1981; Kastorini et al. 2011; Leren 1968 and
1970; Mensink and Katan 1992; Rahilly-Tierney et al. 2011; Tortosa et al. 2007). The
association of “Mediterranean diet” with lower mortality rates has also been confirmed
in observational studies (Fung et al. 2009; Knoops et al. 2004; Martínez-González et al.
2011; Trichopoulou et al. 2003). Some trials involving secondary prevention of CVD
have shown lifestyle changes, such as adopting “Mediterranean diet”, to be associated
with decreased mortality and coronary events rate compared to standard treatment
(Ketola et al. 2000; King et al. 2007; Leren 1968 and 1970; de Lorgeril et al. 1999). The
same has not been shown decisively to apply in primary prevention even though one
Norwegian study indicated so (Hjermann et al. 1981). The most famous trial involving
lifestyle intervention in primary prevention was the Multiple Risk Factor Intervention
Trial (MRFIT) (Multiple Risk 1982), conducted in 1972-1978 in the USA. This was a
study of primary prevention where over 350 000 men, aged 35-57 years, were screened
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and 12 866 high-risk individuals were randomly assigned to either a control group,
receiving the usual care in their community, or an intervention group, receiving
thorough, protocol-based treatment for high blood pressure, counselling for smoking
cessation, and dietary advice for cholesterol lowering (Multiple Risk 1982). Although a
significant reduction in risk factors was achieved in the intervention group, compared to
the controls in the six years of follow-up, only a small, non-significant reduction of
CHD mortality was observed (17.9 deaths per 1 000 compared to 19.3 in the control
group), and the difference was even smaller in all-cause mortality (Multiple Risk 1982).
As a more recent example, an even bigger intervention trial, the Women's Health
Initiative Randomized Controlled Dietary Modification Trial (Howard et al. 2006), also
failed to show any benefit, regarding mortality, from dietary intervention. So, even
though lifestyle interventions have been shown to affect serum cholesterol levels
(Kastorini et al. 2011; Kelley et al. 2004 and 2011; Ketola et al. 2000), there are still
limited or no data showing clinical benefit, regarding mortality or CVD events, from
lifestyle interventions in primary prevention, as a recent Cochrane report shows
(Ebrahim et al. 2011).
Sub-fractions of certain interest
The interest in sub-fractions of cholesterol came later. Low density lipoprotein (LDL)
was found to have even stronger association with CHD and mortality than total
cholesterol (Besterman 1957; Pekkanen et al. 1990; Williams and Feldman 2011;
Wilson et al. 1980 and 1998). Today, LDL is most often regarded as the primary target
of lipid lowering treatment (Graham et al. 2007; Mancia et al. 2007; National
Cholesterol 2002; WHO 2007). On the other hand, high density lipoprotein (HDL) was
found to have an inverse association with CHD (Asia Pacific 2005; Assmann et al.
1996; Barr et al. 1951; Castelli et al. 1986; Després et al. 2000; Emerging Risk 2009;
Goldbourt et al. 1985; Gordon et al. 1989; Miller and Miller 1975; Pekkanen et al.
1990; Williams and Feldman 2011; Wilson et al. 1980 and 1998). Both LDL and HDL
are today much used in the estimation of CVD risk on the individual level as well as in
monitoring lipid lowering treatment (Graham et al. 2007; Mancia et al. 2007; National
Cholesterol 2002; Norheim et al. 2009; WHO 2007). Much of the knowledge about
these lipoproteins stems from the works of John Gofman (Gofman et al. 1949 and 1950;
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Gofman 1956; Lindgren et al. 1951; Lyon et al. 1956). His work was followed by
Goldstein and Brown, who were awarded with the Nobel Prize in Medicine in the year
1985 for their research on LDL and the pathogenesis of atherosclerosis (Brown and
Goldstein and 1976; Goldstein and Brown 1973 and 1977), where data from patients
with familial hypercholesterolemia played a crucial role.
The drugs
Further evidence to support the “cholesterol hypothesis” appeared in the 1970s and
1980s with some clinical drug studies (Carlson and Rosenhamer 1988; Dewar and
Oliver 1971; Committee of Principal 1978; Frick et al. 1987; Manninen et al. 1988;
Oliver 1984; WHO 1984). At that time, primarily three main groups of lipid-lowering
drugs were shown to be effective and are currently still in use for CVD prevention.
These are fibrates (e.g., clofibrate, gemfibrozil) (Abourbih et al. 2009; BIP Study 2000;
Carlson and Rosenhamer 1988; Dewar and Oliver 1971; Committee of Principal 1978;
Frick et al. 1987; Jun et al. 2010; Lalloyer and Staels 2010; Lee et al. 2011; Loomba
and Arora 2010; Manninen et al. 1988; Rubins et al. 1999; Tenkanen et al. 2006; WHO
1984), nicotinic acid (niacin) (Altschul and Hoffer 1958; Birjmohun et al. 2005;
Bruckert et al. 2010; Canner et al. 1986; O´Reilly et al. 1959; Parsons 1963), and bile
acid sequestrants (also called resins, e.g., cholestyramine, cholestipol) (Lipid Research
1984 i and ii; Oliver 1984; Thompson 1971). All of these drugs can lower LDL. The
resins are, however, less effective than fibrates and nicotinic acid in increasing HDL
and can increase triglycerides, whereas fibrates and nicotinic acid lower them (National
Cholesterol 2002). Drugs from all of these three groups have been shown to beneficially
affect lipid-profile and reduce CHD events but decisive evidence of reduction in
mortality is lacking (Abourbih et al. 2009; Altschul and Hoffer 1958; BIP Study 2000;
Birjmohun et al. 2005; Bruckert et al. 2010; Canner et al. 1986; Carlson and
Rosenhamer 1988; Costa et al. 2006; Frick et al. 1987; Jun et al. 2010; Lee et al. 2011;
Loomba and Arora 2010; Manninen et al. 1988; Muldoon et al. 1990; O´Reilly et al.
1959; Parsons 1963; Rubins et al. 1999; Tenkanen et al. 2006; Thompson 1971; WHO
1984). Today, the primary use of these drugs in CVD prevention is in addition to statin
drugs or instead of statins when they cannot be used.
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The statin era
The “statin era” began in 1987 when lovastatin was the first statin drug to be marketed
(Endo 2010). By then, the “lipid hypothesis” was generally accepted, but disagreement
remained regarding treatment, since none of the available lipid-lowering drugs had
shown clear reduction in mortality. The Scandinavian Simvastatin Survival Study (4S)
(Scandinavian 1994) was a major breakthrough, both regarding further acceptance of
the “lipid theory”, and for lipid-lowering treatment. It showed not only considerably
more reduction in total cholesterol and LDL than trials of earlier drugs but also
reduction in coronary events, and, most importantly, significant reduction in all-cause
mortality was demonstrated for the first time. The 4S study was a trial of secondary
prevention in patients with clinical CHD and high cholesterol levels (5.5 – 8.0 mmol/L)
(Scandinavian 1994). In 1995, a year later than publication of the 4S paper, Shepherd
and co-workers (Shepherd et al. 1995) published their results from the West of Scotland
Coronary Prevention Study (WOSCOPS). This was a trial of pravastatin in
hypercholesterolemic (total cholesterol ≥ 6.5 mmol/L and LDL ≥ 4.5 mmol/L) men
(supposedly) without evident CHD (5% had angina pectoris and 3% intermittent
claudication); it also showed an impressive reduction in cholesterol and CHD outcomes
as well as all-cause mortality (statistically non-significant) (Shepherd et al. 1995). These
important results warranted the use of statins for primary prevention in “high-risk”
patients.
In the years to come, results from a number of statin trials were published, steadily
increasing their popularity as well as widening the criteria of eligibility for statin
treatment. In 1996 Sacks and co-workers (Sacks et al. 1996) published the next
important paper on statins, results from the Cholesterol and Recurrent Events (CARE)
trial. They demonstrated the beneficial role of statin treatment in secondary prevention
for patients with low or average levels of cholesterol (total cholesterol <6.2 mmol/L and
LDL 3.0-4.5), as did the Long-term Intervention with Pravastatin in Ischemic Disease
(LIPID) study (Long-term Intervention 1998) in 1998 (total cholesterol 4.0-7.0
mmol/L), and the Heart Protection Study (HPS) (Heart Protection 2000) in 2000 (total
cholesterol >3.5 mmol/L). The HPS study is the largest statin trial conducted, with over
20 000 participants. The Air Force/Texas Coronary Atherosclerosis Prevention Study
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(AFCAPS/TexCAPS) (Downs et al. 1998) demonstrated reduction of CVD events and
mortality in primary prevention in individuals with average cholesterol levels but did
not show reduction in all-cause mortality (Downs et al. 2001).
Further publications during the next decade further supported what was already evident,
that statins were well tolerated and powerful lipid-lowering agents that reduced
mortality significantly. Recent meta-analyses showed a relative risk reduction of about
20% in CVD mortality and about 10% risk reduction in all-cause mortality (Cholesterol
Treatment 2010; Mills et al. 2011 ii), even in primary prevention (Mills et al. 2008;
Taylor et al. 2011), although this has been a subject of debate (de Lorgeril et al. 2010;
Ray et al. 2010; Therapeutics Initiative 2010). Trials have also indicated that higher
doses give better clinical results (Mills et al. 2011 i), and supported the hypothesis that
the lower the cholesterol, the better (Verschuren et al. 1995). Hence, the possible market
for the product is gigantic, and it is no wonder that the pharmaceutical companies have
made a fortune from selling statins. For instance, atorvastatin (brand name Lipitor) has
been generating annual revenues of more than $10 billion each year since 2004, making
it the best selling drug in history, and the only drug ever to achieve such sales (Jack
2009; Pfizer 2011).
The impressive results and good sales inspired pharmaceutical companies and their
associates to conquer new markets. The study aims kept getting more aggressive with
trials like the Atorvastatin Versus Revascularisation Treatments (AVERT) study (Pitt et
al. 1999), which compared treatment with atorvastatin with angioplasty in stable CHD,
and the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering
(MIRACL) study (Schwartz et al. 2001), a trial of statin treatment in acute coronary
syndrome. One study deserves special mention in this context, the Justification for the
Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
(Ridker et al. 2008). The study included 17 802 healthy men (aged 50 or older) and
women (aged 60 or older) with LDL levels below 3.4 mmol/L and high-sensitivity C-
reactive protein (hs-CRP) levels of 2.0 mg/L or more. The participants were randomly
assigned to being administered either rosuvastatin or a placebo; the planned length of
follow-up was five years. There was a statistically significant reduction in CVD events
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(HR: 0.53) and all-cause mortality (HR: 0.80) and the number needed to treat (NNT) for
one year to avoid a clinical endpoint was 190. This study raised a number of serious
concerns regarding ethical and methodological issues (de Lorgeril et al. 2010), a few of
which will be mentioned. First, the name of the study clearly indicates an intention to
justify the use of a drug in certain circumstances, rather than reducing the burden of
CVD for individuals and society. Second, there are conflicts of interest. As with most
pharmaceutical intervention trials, this one was supported by a drug company,
AstraZeneca, the manufacturer of the drug (rosuvastatin). Additionally, 11 of the 14
authors reported having received fees from pharmaceutical companies, 10 of them from
AstraZeneca. Third, the first author, Paul Ridker, is listed as a coinventor on patents
licensed to AstraZeneca that relate to the use of hs-CRP in the evaluation of patients’
risk of CVD. Fourth, the study was terminated early, with a median follow-up of 1.9
years (Ridker et al. 2008).
The financial ties and the early termination severely damage the credibility of the study
(de Lorgeril et al. 2010). The question arises whether concern for patients and good
research ethics took second place to eagerness to expand possible markets (including
registered indications) of the drug and increase the use of hs-CRP in CVD risk
estimation, even if neither would be cost-effective. Because of the early termination,
valuable information was lost, and it cannot be taken as given that the results would
have been the same if the five-year follow-up had been carried out. This was an
especially poor decision since the standard care for the participants in the placebo group
did not include statin treatment, since these were individuals at low CVD risk without
raised cholesterol levels, and hence, they were not being denied life-saving treatment.
Their alternative would have been no treatment at all (Graham et al. 2007; National
Cholesterol 2002). In spite of its shortcomings the JUPITER study has greatly impacted
the debate regarding CVD prevention (Fricker 2009; Hirschler 2008; Hlatky 2008;
Kolata 2009; de Lorgeril et al. 2010; O'Keefe et al. 2009; Shishehbor and Hazen 2009)
and has succeded in expanding the registered indications of rosuvastatin (U.S. Food and
Drug 2010). The JUPITER study group has continued its work to justify statin use in
primary prevention and published further sub-analyses, such as regarding the older
participants (Glynn et al. 2010).
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Even though some have touted statins as miracle drugs and compared their importance
to that of penicillin (Roberts 1996), they have their drawbacks, and important adverse
effects have emerged. The most common side-effects are myopathy and myalgia, and
the most important one, although rare, is a more serious form of the same problem,
rhabdomyolysis (Ballantyne et al. 2003; Pasternak et al. 2002; Silva et al. 2006). These
adverse events have been shown to increase with larger statin doses (Silva et al. 2007),
and in combination with certain other drugs (Gruer et al. 1999; Pasternak et al. 2002),
most notably fibrates (Pierce et al. 1990, Ballantyne et al. 2003). In fact, in 2001
cerivastatin had to be withdrawn from the market because of this (Pasternak et al. 2002).
An increase in the incidence of diabetes has also been shown to be associated with statin
use (Preiss et al. 2011; Sattar et al. 2010).
Statins currently hold the position of the first-line lipid-lowering agents and are
recommended for secondary CVD prevention as well as for primary prevention in
individuals at high risk of CVD and elevated levels of cholesterol (Cooper et al. 2008;
Graham et al. 2007; National Cholesterol 2002; Norheim et al. 2009; WHO 2007).
However, they have not gained acceptance in primary prevention for individuals with
low cholesterol levels or low combined CVD risk because of debatable effect (de
Lorgeril et al. 2010; Peretta et al. 2010; Ray et al. 2010; Therapeutics Initiative 2010)
and issues of cost-effectiveness (Taylor et al. 2011).
The end of the cholesterol controversy?
Although many have regarded the statins' effective mortality reduction as the ultimate
proof of the “cholesterol hypothesis” (Steinberg 2004 v; Thompson 2009), opposing
arguments have also been raised (see, for instance: www.THINCS.org). The classic
belief that total cholesterol has a strong, graded association with CVD (Dawber et al.
1957; Doyle et al. 1957; Kannel et al. 1961) and mortality (Clarke et al. 2009; Stamler
et al. 2000; Verschuren et al. 1995) without a threshold has been challenged. This
association has primarily been shown regarding IHD, whereas many studies have
reported no association of cholesterol with all-cause mortality (Chen et al. 1991;
Jonsson et al. 1997; Krumholz et al. 1994; Neaton and Wentworth 1992; Neaton et al.
1992; Weverling-Rijnsburger et al. 1997), a “U-shaped association” (Harris et al. 1992;
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Higgins and Keller 1992; Onder et al. 2003), or even an inverse one (Beaglehole et al.
1980; Forette et al. 1989; Iso et al. 1994; Kozarevic et al. 1981; Petersen et al. 2010;
Schatz et al. 2001; Tuikkala et al. 2010). This has been explained by the inverse or U-
shaped association often found between cholesterol and non-CVD death, such as from
cancer (Ibarren et al. 1995; Jacobs et al. 1992; Ravnskog 2003; Rossouw and Gotto
1993). The phrase “U-shaped association” (or alternatively “J-shaped” (Forette et al.
1989)) means that higher mortality (or incidence) is seen in individuals with both low
levels and high levels of cholesterol, compared to those in between. This phrase does
not necessarily indicate that both arms of the 'U' are equal in terms of mortality rates or
the proportion of the population belonging to each arm. An inverse or U-shaped
association has also been described between cholesterol and CVD mortality, as well as a
lack of association (Anderson et al. 1987; Forette et al. 1982; Lindquist et al. 2002;
Nissinen et al. 1989; Petersen et al. 2010; Tsuji 2011; Weverling-Rijnsburger et al.
1997). This has been explained by the association with death from stroke. Positive
association has been found with ischaemic stroke, but inverse or no association with
haemorrhagic stroke (Asia Pacific 2003; Cui et al. 2007; Eastern Stroke 1998; Iso et al.
1989; Li et al. 2008; O´Donnell et al. 2010; Prospective Studies 1995 and 2007; Tsuji
2011). Interestingly, some studies have also found a U-shaped (Okamura et al. 2007;
Petersen et al. 2010; Shestov et al. 1993; Simons et al. 2001; Weijenberg et al. 1994 and
1996) or an inverse (Krumholz et al. 1994; Räihä et al. 1997; Tsuji 2011) association
with IHD incidence and mortality, primarily among individuals over 60.
The fact that statins are the only lipid-lowering treatment shown to reduce mortality
(Bruckert et al. 2010; Cholesterol Treatment 2010; Ebrahim et al. 2011; Lee et al. 2011;
Mills et al. 2008 and 2011 ii; Muldoon et al. 1990; Taylor et al. 2011) is another
counterargument to the “lipid hypothesis”. The most recent example is the drug
ezetimibe, which is an effective lipid-lowering agent without proven mortality reduction
(Tenenbaum and Fishman 2010). Also, statins have been shown to reduce mortality
more than the lipid effects would suggest (Gould et al. 1998), compared to
observational data (Verschuren et al. 1995). A range of non lipid-related, pleiotropic
effects of statins has been documented (Meng 2005; Vaughan et al. 1996). Statins have
anti-inflammatory effects (Meng 2005; Vaughan et al. 1996) and reduce blood
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concentrations of inflammatory markers such as CRP (Libby et al. 2002; Ridker et al.
1999). They inhibit smooth muscle cell proliferation (Rodríguez-Vita et al. 2008;
Vaughan et al. 1996), affect platelet function (Schrör et al. 1989; Tsai et al. 2011;
Vaughan et al. 1996), and reduce the adhesion of monocytes to endothelial cells (Meng
2005; Teupser et al. 2001; Vaughan et al. 1996). All of these mechanisms are important
in the pathogenesis of atherosclerosis (Meng 2005; Ross 1999; Vaughan et al. 1996).
Alternative lipid measures have been suggested to be better markers of risk than total
cholesterol, which might indicate different atherogenic properties of different particles
(Miller et al. 2011; Packard 2003; Triglyceride Coronary 2010; Welin et al. 1992). As
mentioned above, LDL is the lipid measure most often recommended, along with total
cholesterol, to be used for CVD risk estimation and for defining treatment goals
(Graham et al. 2007; National Cholesterol 2002; Norheim et al. 2009; WHO 2007).
HDL and the total cholesterol/HDL ratio are often recommended for estimation of risk
but rarely as treatment goals (Graham et al. 2007; National Cholesterol 2002; Norheim
et al. 2009; WHO 2007). The value of triglycerides as a risk factor has been debated for
more than half a century (Kannel and Vasan 2009), and it has been associated with
increased risk of CHD (Asia Pacific 2004; Harchaoui et al. 2009; Mora et al. 2008;
Sarwar et al. 2007) and all-cause mortality (Langsted et al. 2011). Guidelines often
recommend triglycerides be included in CVD risk estimation but recommendation of
treatment goals are often lacking (Graham et al. 2007; National Cholesterol 2002;
Norheim et al. 2009; WHO 2007). More recently the apolipoproteins A1 (ApoA1)
(O'Brien et al. 1995) and B (ApoB) (Sniderman et al. 2003), as well as the
ApoB/ApoA1 ratio, have been recommended to replace the conventional measures of
total cholesterol, LDL, and HDL (Ip et al. 2009; McQueen et al. 2008; Sniderman et al.
2011; Walldius et al. 2001; Yusuf et al. 2004). ApoA1 is a sub-fraction of HDL,
whereas ApoB is primarily a sub-fraction of LDL (Walldius et al. 2001). These markers
have, however, not been found to yield enough additional information to the
conventional markers to justify the additional cost (Brunzell et al. 2008; Ingelsson et al.
2007; Mora 2009; van der Steeg et al. 2007), and guideline authors (Graham et al. 2007;
National Cholesterol 2002; Norheim et al. 2009; WHO 2007) have been reluctant to
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include them in their recommendations. Thus, it is apparent that the field of cholesterol
is still a much debated theme of constantly progressing evidence.
For decades there has been an ongoing debate on cholesterol and its importance in
CVD, and this discussion between scholars has not always been civilised (Steinberg
2004 i-v). The current mainstream view is that cholesterol is an important risk factor for
CVD with a strong and graded association and should be lowered in high-risk
individuals. Because of research led by the pharmaceutical industry (Long-term
Intervention 1998; Ridker et al. 2008; Scandinavian 1994; Sacks et al. 1996; Shepherd
et al. 1995), there has been a trend toward widening the definition of “high-risk”.
Fortunately, those striving to point out flaws in the mainstream opinion are still to be
found (see, for instance: www.THINCS.org). The current focus of the debate is in
whom cholesterol should be lowered by drug treatment, by how much, and at what cost.
Despite all “Cholesterol controversy” (Steinberg 2004 i; Unknown 1962) it cannot be
denied that it plays a crucial role in the pathogenesis of atherosclerosis. Russell Ross
wrote an excellent paper on the matter (Ross 1999), reviewing the evidence for the
currently most widely accepted hypothesis of the pathogenesis of atherosclerosis. In
short, it is believed that the process starts with injury of some sort to the endothelium
(caused, e.g., by hyperglycaemia, high blood pressure, infection, etc.), causing
endothelial dysfunction or denudation leading to an inflammatory response. Endothelial
adhesiveness to leukocytes and platelets increases, as well as permeability of the
endothelium. LDL undergoes oxidative modification and stimulates further
inflammatory response as it gets trapped in the arterial wall. Macrophages gather the
LDL and become “foam cells”, and smooth muscle cells undergo proliferation and
migration in response to inflammatory cytokines. A soup of hydrolytic enzymes,
cytokines, chemokines, and further influx of LDL and mononuclear cells gradually
becomes a necrotic lipid core of the atherosclerotic lesion, surrounded by a “fibrous
cap” of smooth muscle cells and fibrous tissue. This process also makes the
endothelium pro-thrombotic. This can lead to arterial stenosis and atherothrombosis.
This is a very simplified explanation of this hypothesis (Ross 1999).
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Whether unmodified LDL can cause the initial endothelial injury (making it a primary
causal factor of atherosclerosis) or not (making it dependent on other causal factors of
endothelial injury), it is clear that LDL is an important factor in the process of
atherosclerosis. This association, however, is complex and needs further clarification.
At least it is plausible that the view and the emphasis on cholesterol as a risk factor for
CVD will change in the coming decades.
2.2.3. Obesity and body configuration
Obesity is an established risk factor for a range of diseases, such as CVD, type-2
diabetes, and osteoarthritis (Kulie et al. 2011; WHO 2000). This is thoroughly
documented in the medical literature as well as regarded as common lay knowledge
(American Heart 2011; International Association 2011; WHO 2000). The harmfulness
of obesity has been increasingly emphasised in the past few decades alongside the rise
of the “obesity epidemic” (James 2004). But in the mind of today's general public,
fatness has not only been associated with detrimental effects on health but also
unaesthetic qualities (Kwan 2009), and even poor personality properties (Rosengren and
Lissner 2008). However, it has not always been thus, as the famous Venus von
Willendorf (Naturhistorisches museum 2011; Witcombe 2011) and various paintings
from the Renaissance (Woodhouse 2008) bear witness. Throughout history corpulence
has, in various cultures, been associated with wealth, fertility, and general prosperity
(Woodhouse 2008), especially in times of shortage. This view has changed in current
period of bounty in many parts of the world.
This chapter will discuss obesity and body configuration in relation to CVD. It will
focus on the definition and measurement of obesity, and the importance of the
distribution of body fat.
The obesity epidemic
In the twentieth century, and especially after the Second World War, general living
conditions improved dramatically throughout the Western world. A more sedentary
lifestyle, combined with the abundance of affordable food available to the general
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public, led to the rise of a health problem, previously of low prevalence – “the obesity
epidemic” (James 2004). Of course, this happened gradually, with the support of the
fast-food culture, television, video games, and carbonated beverages, to name a few
aggravating factors, and it was not until 1997 that the WHO defined obesity as a global
epidemic (i.e., pandemic) (Caballero 2007; WHO 2000).
The worldwide prevalence of adult obesity (body mass index [BMI] ≥30 kg/m2) has
almost doubled in the last three decades, with an estimated number of 500 million obese
individuals in 2008 (WHO 2011 ii). Finucane et al. (Finucane et al. 2011) estimated that
the age-standardised prevalence of obesity increased among men from 4.8% in 1980 to
9.8% in 2008, with an age-standardised global average increase in BMI of 0.4 kg/m2 per
decade. Among women the estimated average BMI increase was 0.5 kg/m2 per decade,
with an age-standardised worldwide increase in prevalence of obesity from 7.9% in
1980 to 13.8% in 2008. The global age-standardised mean BMI in 2008 was estimated
to be 23.8 kg/m2 for men and 24.1 kg/m2 for women. The largest rise in BMI was seen
in Oceania for both sexes, and the highest age-standardised average BMI (>28 kg/m2)
was seen in North America among men, and among women in North America, north
Africa and Middle East, and southern Africa (Finucane et al. 2011). In the Norwegian
HUNT studies (1985-2008) the average BMI (not age-standardised) has increased
among men from 25.3 kg/m2 (HUNT 1) to 27.5 kg/m2 (HUNT 3), and among women
from 25.1 kg/m2 to 26.9 kg/m2 (Krokstad and Knudtsen 2011). In 2008 the prevalence
of obesity (not age-standardised) was estimated 23% in men and 20% in women in
Norway (WHO 2011 i).
The Quetelet Index
The currently most common measure of obesity, the Quetelet index, better known as the
BMI, was first described in 1832, by the Belgian statistician Adolphe Quételet
(Eknoyan 2008). In his search for a measure to describe the weight of the “average
person” in a population adjusted for the height, he found the ratio of weight (kg) divided
by the height (m) squared (kg/m2) to be the most appropriate. He did not, however,
show any special interest in identifying those who were over- or underweight, and his
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index did not achieve status in clinical practice until more than a hundred years later
(Eknoyan 2008).
Although the association of obesity with some of its complications had already been
documented in the 18th and 19th century (Bray 2009), the increased mortality risk was
first acknowledged early in the 20th century by insurance companies, which derived the
“ideal weight” for a given height from their actuarial tables (Association of Life 1912).
It was not until the 1970s that the use of the Quetelet index became widespread. In
1972, Ancel Keys and coworkers showed the Quetelet index to be better correlated with
body fat (defined by skinfold thickness) than the various other widely used
anthropometric measures derived from height and weight, such as the simple weight to
height ratio and the ponderal index (cube root of weight divided by height) (Keys et al.
1972). Keys et al. suggested the Quetelet index be called body mass index. And that it
be used as the primary anthropometric measure of body configuration and obesity.
In 1985, the US National Institutes of Health (NIH) defined obesity by the 85th
percentile of BMI for each sex (derived from a study population, aged 20-29), 27.8
kg/m2 for men and 27.3 for women (National Institutes 1985). Doctors were urged to
use these cut-offs as warning signals for patients at high risk for obesity-related
complications. The following decade various organisations published similar
recommendations, some including age-specific cut-offs since body weight tends to
increase with age (Committee on Diet 1989; Kuczmarski and Flegal 2000). After a
WHO consultation meeting in 1997, the WHO published (in 2000) revised cut-offs and
recommendations made by the International Obesity Task Force (WHO 2000). These
were the cut-offs currently in use. For both sexes underweight was defined as BMI
<18.5 kg/m2, normal weight as 18.5-24.9, overweight as 25.0-29.9, and obesity as ≥30.0
(WHO 2000). Although the new recommendations offered some simplicity, compared
to earlier methods, with the same cut-offs for both sexes at all ages and easier to
remember numbers, it might be seen as problematic that this consensus increased
dramatically the number of individuals defined as being overweight. It is also known
that the International Obesity Task Force received generous financial support from the
pharmaceutical industry (Moynihan 2006).
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The BMI is currently the most frequently used marker of body composition and obesity
worldwide. This is true in research as well as clinical practice, and use of the index has
also become widespread among the general public, fitness trainers, and dietitians. The
index is easy to obtain and use, and rather simple to understand, although most people
will require a calculator to divide by the squared height. Generally thought to be a good
marker of adiposity, BMI has been found to be more strongly correlated with body fat
percentage than most other anthropometric measures (Shiwaku et al. 2005), although
some studies have not found it to be superior to waist circumference (Flegal et al. 2009).
But the index has its drawbacks. One limitation to the official WHO cut-offs is ethnic
difference. For a given BMI value, the fat percentage has been shown to vary with
ethnicity (Chang et al. 2003; Deurenberg et al. 1998 and 2002; Deurenberg-Yap 2002;
Gurrici et al. 1998 and 1999; Ko et al. 2001; Misra et al. 2005), as well as the
association with patient-important outcomes (Deurenberg-Yap 2002; Misra et al. 2005).
Another limitation to the use of BMI is that it can wrongly define lean, muscular
individuals as being overweight. The BMI does not take body configuration and fat
distribution into account. Perhaps the most important limitation to the use of BMI is
related to this fact. The BMI is more weakly associated with mortality, both overall
(Lindqvist et al. 2006; Pischon et al. 2008; Price et al. 2006; Schneider et al. 2010;
Taylor et al. 2010) and regarding CVD specifically (Price et al. 2006; Yusuf et al. 2005;
Schneider et al. 2010), than the anthropometric measures of obesity discussed below:
waist circumference (Pischon et al. 2008; Schneider et al. 2010; Taylor et al. 2010;
Yusuf et al. 2005), waist-to-hip ratio (WHR) (Lindqvist et al. 2006; Pischon et al. 2008;
Price et al. 2006; Schneider et al. 2010; Taylor et al. 2010; Yusuf et al. 2005), and
waist-to-height ratio (WHtR) (Schneider et al. 2010; Yusuf et al. 2005; Taylor et al.
2010). Partly, this is because the BMI has a J-shaped association with mortality (Flegal
et al. 2007; Waaler 1988), and the lowest mortality rates are usually found in the range
of 23.5-25 kg/m2 (Berrington de Gonzalez et al. 2010; Canoy et al. 2007; Lindqvist et
al. 2006; Orpana et al. 2009; Pischon et al. 2008). In addition, a meta-analysis from
2008 found BMI to have weaker associations with diabetes, hypertension, and
dyslipidaemia than the other measures although the difference was small (Lee et al.
2008).
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Android and gynoid obesity
In the 1940s Frenchman Jean Vague began writing about what he called “android and
gynoid obesity” (Vague 1947 and 1956). From his studies and those of others he
concluded that central or abdominal accumulation of fat (android obesity) was
associated with atherosclerosis, diabetes mellitus, gout, and urolithiasis, while fat
located on the lower part of the body, the hips and thighs (gynoid fat distribution), was
not (Vague 1956). He attributed this to a complex (not fully understood) interaction of
neural, hormonal, and metabolic factors, including hypothalamo-pituitary-adrenal
(HPA) axis activity and difference in metabolic activity of fat depending on its
anatomical location (Vague 1956). Decades later, this complex interaction and its
complications became known as “the metabolic syndrome” (Reaven 1988).
Waist circumference has by many been regarded as superior to BMI because of better
correlation with the metabolically unfavourable android fat distribution (Huxley et al.
2010). Numerous studies have also shown this simple measure to have stronger
association with mortality (Pischon et al. 2008; Schneider et al. 2010; Taylor et al.
2010) and CVD than BMI (Asia Pacific 2006; Gelber et al. 2008; Oliveira et al. 2010;
Page et al. 2009; Schneider et al. 2010; Taylor et al. 2010; Yusuf et al. 2005). Although
BMI still holds its place as the primary marker of obesity, guidelines often recommend
waist circumference to be used in addition to BMI, with the cut-off points for obesity at
102 cm for men and 88 cm for women (Graham et al. 2007; JNC 2003; Mancia et al.
2007; Norheim et al. 2009; WHO 2000) – European derived cut-offs.
Hip, hip, hurrah!
WHR (waist circumference divided by hip circumference) was first reported in 1984 in
the Swedish Gothenburg population studies (Lapidus et al. 1984; Larsson et al. 1984).
Numerous studies have since shown WHR to have stronger association with mortality
than both BMI (Bengtsson et al. 2009; Canoy et al. 2007; Lindqvist et al. 2006; Pischon
et al. 2008; Price et al. 2006; Schneider et al. 2010; Taylor et al. 2010; Yusuf et al.
2005) and waist circumference (Canoy et al. 2007; Price et al. 2006; Yusuf et al. 2005).
This has been shown for mortality in total (Lapidus et al. 1984; Larsson et al. 1984;
Lindqvist et al. 2006; Pischon et al. 2008; Price et al. 2006; Schneider et al. 2010;
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Taylor et al. 2010) as well as from CVD in particular (Canoy et al. 2007; Price et al.
2006; Schneider et al. 2010; Yusuf et al. 2005). For the followers of Vague's hypotheses
(Vague 1956), this comes as no surprise since WHR is better suited to identifying
android and gynoid obesity than waist circumference alone, not to mention BMI. In
fact, when adjusting for the waist circumference, increasing hip or thigh circumference
has even been found to be inversely associated with mortality – i.e., to be protective
(Bigaard et al. 2004; Canoy et al. 2007; Heitmann et al. 2004; Heitmann and
Frederiksen 2009; Lissner et al. 2001; Yusuf et al. 2005; Zhang et al. 2008)! Despite
this, WHR has gained far less popularity than BMI and waist circumference, and its use
is rarely recommended in clinical guidelines. The usual WHR cut-offs defining obesity
are ≥0.90 (or ≥0.95) for men and ≥0.80 for women (Misra et al. 2005; WHO 2011 ii).
Another ratio useful for identifying obesity was reported in 1995, the WHtR (waist
circumference divided by height) (Hsieh and Yoshinaga 1995). Various studies
indicated WHtR to be a superior predictor of mortality and CVD than both BMI
(Ashwell and Hsieh 2005; Page et al. 2009) and waist circumference, and similar
(Gelber et al. 2008; Taylor et al. 2010; Yusuf et al. 2005) or superior (Schneider et al.
2010) to WHR. WHtR offers the benefit of taking height into account but does not
discriminate android from gynoid obesity as well as WHR. No consensus on how to
define obesity with WHtR has been reached, but the cut-off point of 0.50 has been
suggested (Ashwell and Hsieh 2005). To my knowledge, no guidelines have
recommended the use of this measure.
Other methods available
In addition to the anthropometric measures mentioned above, there is a range of
available methods to estimate adiposity that will not be discussed in detail. Some of
these measures are used practically only for research, such as magnetic resonance
imaging (MRI) (Heymsfeld 2008), while others have been applied in clinical practice to
some degree, such as measuring skinfold thickness (Oliveira et al. 2010). Although
some of these methods yield more precise estimates of fat percentage or total body fat
volume than the measures mentioned above, they rarely offer better predictive abilities
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regarding patient-important outcomes (Menke et al. 2007; Simpson et al. 2007; Stevens
et al. 2008; Sun et al. 2010).
The apple and the pear
The difference between apples and pears is not confined to the taste alone. Likewise, the
difference between apple (android) and pear (gynoid) body shapes lies not only in their
aesthetic qualities. The apple shape refers to abdominal subcutaneous and visceral fat
accumulation while subcutaneous fat on the hips, thighs, and buttocks result in the pear
form. It has become clear that metabolic activity of adipose tissue differs depending on
its localisation (Després et al. 1990; Manolopoulos et al. 2010; Perrini et al. 2008;
Shively et al. 2009; Snijder et al. 2006), and where it accumulates, again, is dependent
on a number of hormonal and metabolic factors (Björntorp 1990; Després et al. 1990;
Epel et al. 2000; Jayo et al. 1993; Kyrou and Tsigos 2009; Manolopoulos et al. 2010;
Moyer et al. 1994; Müssig et al. 2010; Shively et al. 2009; Snijder et al. 2006).
Compared with subcutaneous fat, visceral adipose tissue is more sensitive to lipolytic
stimuli and less sensitive to anti-lipolytic stimuli, such as insulin (Björntorp 1990;
Després et al. 1990; Krotkiewski et al. 1983; Manolopoulos et al. 2010; Perrini et al.
2008; Snijder et al. 2006). Visceral fat is, therefore, more likely to cause increased
levels of free fatty acids in the circulation (Björntorp 1990; Després et al. 1990;
Krotkiewski et al. 1983; Manolopoulos et al. 2010). In particular visceral fat affects the
liver because of increased fatty acids in portal circulation, which, e.g., inhibits hepatic
insulin uptake, leading to hyperinsulinaemia (Björntorp 1990). Removal of visceral fat
has also been shown to have more beneficial effect on insulin resistance and glucose
intolerance than removal of subcutaneous fat, both in experimental animals (Barzilai et
al. 1999; Gabriely et al. 2002) and (less documented) in humans (Thörne et al. 2002). A
difference has also been suggested between deep and superficial abdominal
subcutaneous adipose tissue (divided by fascia Camper) – the deep adipocytes being
more lipolytic and more strongly associated with insulin resistance (Kelley et al. 2000;
Monzon et al. 2002). Likewise, gluteofemoral adipose tissue is less lipolytic than
subcutaneous abdominal fat, and better suited for lipid storage without increasing levels
of free fatty acids (Björntorp 1990; Manolopoulos et al. 2010). Regional differences
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also exist in the secretion of cytokines involved in, e.g., inflammation and development
of insulin resistance (Manolopoulos 2010; Perrini et al. 2008).
Glucocorticoids, glucocorticoid receptor concentration, and HPA activity play a crucial
role in insulin resistance as well as explaining some of the regional difference in adipose
tissue metabolic activity (Björntorp 1997; Després et al. 1990; Manolopoulos et al.
2010). Insulin resistance and high levels of circulating free fatty acids increase ectopic
fat storage (lipotoxicity), i.e., accumulation of fat in the liver, muscles and other organs,
which in turn promotes further insulin resistance (McGarry 2002; Snijder et al. 2006).
Various factors affect the localisation of fat accumulation. These factors include
hormones (glucocorticoids, sex hormones, growth hormone) (Després et al. 1990; Jayo
et al. 1993; Kyrou and Tsigos 2009; Manolopoulos et al. 2010; Moyer et al. 1994;
Müssig et al. 2010; Shively et al. 2009), behaviour (smoking, diet, physical activity)
(Björntorp 1990 and 1997; Jayo et al. 1993), demographic factors (sex, age, ethnicity)
(Cozier et al. 2009; Gurrici et al. 1998; Krotkiewski et al. 1983; Misra et al. 2005), and
autonomic nervous system function (and dysfunction) (Cozieret al. 2009; Kyrou and
Tsigos 2009; Müssig et al. 2010). The details will not be discussed here. Many of these
factors affect metabolism and disease risk through other mechanisms. In these ways
obesity and body configuration become surrogate markers for a range of risk factors.
Defining obesity
Defining obesity is a multifactorial challenge. First, the phenomenon itself has to be
defined clearly, and then the most appropriate measure has to be identified. The
Merriam-Webster dictionary defines obesity as “a condition characterized by the
excessive accumulation and storage of fat in the body” (Obesity 2011), and WHO
states: “Overweight and obesity are defined as abnormal or excessive fat accumulation
that may impair health” (WHO 2011 ii). However, WHO has a second definition of
obesity as BMI ≥30 kg/m2 (WHO 2000 and 2011 ii). Relying on these definitions, the
BMI seems to be a suitable and easily applicable measure, arguably a better measure of
body fat percentage than the other anthropometric measures mentioned above.
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Alternatively, the definition of obesity could emphasise the hazardous effects on health
instead of merely suggesting the possibility, as the WHO definition does (WHO 2011ii).
This kind of a definition would emphasise patient-important outcomes, such as
mortality and obesity-related metabolic disorder. Measures of central adiposity and
body configuration (waist circumference, WHR, and WHtR) would be better suited than
BMI in that case.
A third option would be to define body configuration as a more important risk factor
than “obesity” (meaning body-fat percentage). In any case, considering the physiology
of different types of adiposity as well as data on mortality associations, it seems
reasonable to recommend measures of body configuration (WHR and WHtR) to be used
in clinical practice instead of BMI, at least when evaluating mortality and CVD risk.
However, because of its strong status and widespread use, the BMI will not be easily
abandoned. The limitations to the “new” anthropometric measures also have to be taken
into account and compared to the advantage of adopting them. Some people might find
it uncomfortable and stigmatising to have the measuring tape wrapped around their
belly and buttocks. It might be seen as more intrusive than measuring height and
stepping on a weighing scale – having to undress further adds to the vulnerability. It has
also been pointed out that waist and hip circumferences are subject to more
measurement error than BMI (Sebo et al. 2008). This problem can be addressed by
adhereing to standardised measurement procedures (WHO 2011 ii) and adequate
training (Sebo et al. 2008).
When defining cut-offs, gender and ethnic difference has to be taken into account. Such
differences exist for all of the anthropometric measures discussed above, whether the
reference point is fat percentage or mortality (Chang et al. 2003; Deurenberg et al. 1998
and 2002; Deurenberg-Yap et al. 2002; Gurrici et al. 1998 and 1999; Jackson et al.
2002; Ko et al. 2001; Misra et al. 2005; Yusuf et al. 2005). In part, this difference can
be explained by ethnic variance in muscularity and skeletal structure (Deurenberg et al.
1998 and 2002; Gurrici et al. 1999; Jackson et al. 2002). Recommended threshold levels
are primarily based on data from people of European origin but some suggestions for
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ethnic-specific cut-off points have been made (Chang et al. 2003; Deurenberg-Yap et al.
2002; Gurrici et al. 1998; Ko et al. 2001; Misra et al. 2005).
2.2.4. Other physical and psychosocial risk factors
A whole range of risk factors have been associated with CVD, and their number is
constantly growing. Age is by far the strongest known risk factor of CVD, and very few
other factors add any substantial information to a prediction model already including
age (Wald and Law 2003). Male sex (Lawlor et al. 2001), smoking (Dawber et al. 1959;
Huxley 2011; Yusuf et al. 2004), diabetes mellitus (Wilson 2011; Yusuf et al. 2004),
and a family history of CVD at a young age (Andresdottir et al. 2002; Wilson 2011) are
the risk factors generally considered the most important, in addition to those mentioned
in sections 2.2.1-2.2.3. Physical inactivity (Yusuf et al. 2004), diet (Dauchet et al. 2005;
Yusuf et al. 2004), ethnicity (Cooper 2001), some infectious agents (Anderson 2011),
various genes (Lovely et al. 2011; Rosenson and de Ferranti 2011), and (systemic)
inflammation (Koenig et al. 1999; Libby and Crea 2010; Ridker et al. 1998) are also
among the factors associated with increased risk of CVD. Guidelines mention these
factors to various degrees. Detailed discussion of them is outside the scope of this
thesis, but it is worth bearing in mind that the identified risk factors are numerous, and
the importance of each of them is understood only to a certain extent. The development
of atherosclerosis and CVD is a complex phenomenon that can only be predicted to a
small degree, even with information on all of these factors.
The common denominator of the risk factors already mentioned is that they can be
measured in some way without any personal subjective interpretation. They therefore
fit well into the Cartesian tradition of biomedicine. There are, however, other risk
factors that may not be as easily quantified and have been included in the CVD
guidelines to a much less extent. These include psychosocial factors, such as adverse
childhood experiences, harsh working conditions, experiences of trauma, and
detrimental social relations (Getz et al. 2011; Kirkengen et al. 2008).
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The social gradient
In 1967 the Whitehall Study was established. In the study, led by Donald Reid and
Geoffrey Rose, 17 530 civil servants in London, all male, were classified according to
their employment grade, and their mortality was recorded prospectively over 10 years
(Marmot et al. 1984). The main findings of the study were that mortality from CHD
increased with lower employment status, in a gradient manner. Numerous studies have
subsequently confirmed these results, finding a graded association between low socio-
economic status (SES) and high CVD mortality (Alboni et al. 2003; Jeemon and Reddy
2010; Marmot et al. 2008). This can be partly explained by the relations between
unhealthy lifestyle (smoking, fast food diet, etc.) and lower SES (Marmot et al. 1984
and 2008), which, in turn, affects physiological risk factors, such as BP. But even after
adjusting for other risk factors, these socio-economic inequalities cannot be fully
accounted for (Jeemon and Reddy 2010; Marmot et al. 1984 and 2008). In the Whitehall
Study, for instance, the CHD mortality in the group with the lowest employment status
was twice as high as in the group with the highest status after adjusting for other risk
factors (Marmot et al. 1984).
In 1985 a second study of London civil servants was initiated, the Whitehall II Study
(see: www.ucl.ac.uk/whitehallII), including roughly 10 000 men and women (Marmot
and Brunner 2004). The study was led by Michael Marmot. The main findings were that
high job strain and low perceived control at work increased the risk of CHD, as did
demand-reward imbalance, poor support and weak social network (Ferrie 2004).
Multiple studies have since then confirmed the importance of mental stress (in a wide
sense), both acute (Guðjónsdóttir et al. 2011; Wilbert-Lampen et al. 2010) and chronic
(Proietti et al. 2011; Rosengren et al. 2004; Tofler 2011), unpredictability (De Vogli et
al. 2007; Surtees et al. 2007), and social relations (Holt-Lunstad et al. 2010), in the risk
of CVD.
Allostasis and allostatic load
To fully appreciate how stress and other psychosocial factors influence the development
of CVD, one has to seek explanations within the field of stress research and psycho-
neuro-immunology. Allostasis and allostatic load are useful terms in this regard (Epel
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2009; McEwen 1998 i and ii; Sterling and Eyer 1988). Allostasis, coming from Greek,
meaning “stability through change” (McEwen 1998 i and ii), is “defined as a dynamic
regulatory process wherein homeostatic control is maintained by an active process of
adaptation during exposure to physical and behavioural stressors” (McEwen and
Gianaros 2010:191). Thus, homeostasis refers to stability in vital parameters that must
be kept within narrow ranges, such as blood oxygen concentration, pH, etc., while
allostasis refers to the active process maintaining this stability through changes in heart
rate, BP, etc. It is regulated by systems, such as the HPA-axis, the autonomic nervous
system, and the immune system (McEwen 1998 i and ii). Allostatic load is:
defined as the consequence of allodynamic regulatory wear-and-tear on the body and
brain promoting ill health, involving not only the consequences of stressful experiences
themselves, but also the alterations in lifestyle that result from a state of chronic stress
(McEwen and Gianaros 2010:191).
Bruce McEwen, a prominent researcher in the field of stress, defines four situations
associated with allostatic load (McEwen 1998 i and 2010). First, there is frequent stress.
For instance, sudden BP peaks increase the risk of cerebral stroke and MI, and repeated
BP elevations are atherogenic (Kaplan et al. 1991; Muller et al. 1989). Second,
adaptation to repeated stressors of the same type may be inadequate. Thus, instead of
gradually becoming more comfortable with dealing with a particular repeating
challenge, the individual experiences surges of stress as described in the first example.
Third, there may be failure to inactivate the allostatic response after the stressful
situation has passed. For example, recovery of BP may be delayed in some people after
acute stress, such as an arithmetic test (Gerin and Pickering 1995). Also, high
glucocorticoid blood levels (e.g., during a chronic stress response) has some hazardous
effects, including stimulating central accumulation of adipose tissue, and decreasing
insulin sensitivity (Björntorp 1990; Després et al. 1990; Manolopoulos et al. 2010).
Fourth, an inadequate response of an allostatic system to a stressor may cause
compensatory increased activity in another system, in the absence of down regulating
feedback stimuli from the underactive system. E.g., secretion of inflammatory cytokines
increases as a response to stress if the counterregulatory cortisol secretion is attenuated.
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This has, for example, been described among children with atopic dermatitis (Buske-
Kirschbaum et al. 1997). Increased levels of inflammatory cytokines have also been
linked to CVD (Koenig et al. 1999; Libby and Crea 2010; Ridker et al. 1998).
It is apparent that frequent and/or long-lasting stress responses can seriously damage
health, including increasing the risk of CVD. The allostatic response to a stressor
depends on the person's perceived threat of a stressful situation, and the person's general
physical condition (McEwen 1998 i). Thus, an individual's unique biographical
experience, perception, and interpretation are of major importance in the regulation of
allostatic activity. McEwen and Gianaros state:
[W]e will emphasize the brain as the central mediator of stress processes, insofar as
distributed brain networks encode, filter, and store environmental information according
to unique personal histories and life experiences to determine what is threatening and
thus “stressful” to the individual. Moreover, we will emphasize the brain as the
instrumental organ for regulating biological, behavioral, and social responses that are
influenced by short-term (acute) and long-term (chronic) stress processes (McEwen and
Gianaros 2010:191).
One of the major advantages of the “allostasis-model” is that it includes
“psychological” risk factors as well as the traditional “physical” ones. Thus, smoking or
alcohol consumption may lead to a similar allostatic load as a stressful job. I.e., mental
and physical stressors have the same status in the model. In addition, the model
emphasises the individual's experience and interpretation of stressors.
Childhood and foetal origins of cardiovascular disease
Many studies have found associations between childhood experiences and disease
development in adult life. The Adverse Childhood Experiences (ACE) Study (Felitti et
al. 1998), led by Vincent Felitti, was conducted in San Diego in 1995-97 and included
roughly 17 000 adults which answered a detailed questionnaire on adverse childhood
experiences, such as emotional neglect, living with an alcoholic or criminal parent, or
suffering emotional, physical, or sexual abuse. The adverse experiences were
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categorised by the nature of the experience and each participant given a score depending
on the number of event categories ever experienced. The researchers found a dose-
response association between the ACE score and the morbidity in adult life (Felitti et al.
1998). The same association was found with IHD (Dong et al. 2004), and premature
mortality (Brown et al. 2009). Thus, findings of the ACE study suggest adverse
childhood experiences, such as suffering abuse and living in a dysfunctional home, may
seriously affect an individual's health in adult life, possibly through allostatic load. A
childhood of constant fear and instability may mark a person permanently, not only
mentally but also metabolically.
Studies have also found adverse living conditions at even earlier stages in life to be
associated with poor adult health. In the 1970s, Anders Forsdahl found a remarkable
correlation between premature mortality and infant mortality of the same birth cohorts
in Finnmark County, Norway (Forsdahl 1973). His conclusion was that undernutrition
in early life, especially when coupled with affluence in adulthood, rendered individuals
more susceptible to CHD. Similar results have been reported from other studies. The
Helsinki Birth Cohort Study found an association of low weight at birth and during
infancy with CHD in adulthood (Eriksson et al. 2001; Eriksson 2007). Similarly, the
Dutch Famine Birth Cohort Study found people who were exposed as children or even
in utero to the Dutch famine in 1944-45 to exhibit higher mortality and prevalence of
diabetes than controls not exposed to the famine (van Abeelen et al. 2011; Roseboom et
al. 2011). David Barker and co-workers were probably the first to relate undernutrition
in foetal life to CHD (Barker and Osmond 1986; Barker et al. 1989). The Barker
hypothesis (in short) suggests that undernutrition in utero causes some kind of foetal
programming that has long-term effects on the individual's metabolism (Barker 1995).
Metabolic pathways that can be crucial to ensure the vitality of the foetus and infant
may prove to increase the risk of CVD in adult life. To recognise the pioneering work of
Anders Forsdahl, it has been suggested to refer to this as the Forsdahl-Barker hypothesis
(Gram et al. 1995).
45
Epigenetics and telomeres
In recent years epigenetics have given new insights into the Forsdahl-Barker hypothesis.
Even though pre-natal undernutrition and trauma cannot alter the DNA sequence, it can
affect the phenotype through gene transcription. The epigenome is composed of methyl
and actyl groups that are attached to the DNA molecule and result in decreased or
increased transcription of the gene they are attached to (Kuzawa and Sweet 2009;
Petronis 2010). The epigenome is regulated through metabolic signals and has the
potential to change over time. At the same time it is also inherited (Kuzawa and Sweet
2009; Petronis 2010). Thus, undernutrition and other adversities in utero may not only
render an individual more susceptible to diabetes and CVD through foetal epigenetic
programming, but it may also affect the risk of his/her offspring through the inherited
epigenome.
The telomere is another DNA-related phenomenon that has recently been associated
with stress and diseases (Epel 2009; Epel et al. 2010). Telomeres are long DNA
sequences at the ends of the chromosomes, made of nucleotide repetitions. They
function as protective caps on the chromosome ends. While the telomeres are gradually
worn out under cell divisions, they protect the genes from being harmed. Chronic
stressful situations, such as being the caregiver for an Alzheimer's disease patient, have
been found to accelerate telomere wear and tear, and short telomeres have been
associated with cellular aging and morbidity (Epel 2009; Epel et al. 2010; Damjanovic
et al. 2007; Kiecolt-Glaser et al. 2011).
I have presented examples of some of the exciting research on how stress and
psychosocial factors affect the risk of CVD. These examples show how social
deprivation, job strain, childhood abuse, and chronic stress can seriously damage health,
alter the body's metabolism and increase the risk of CVD, even in someone's offspring.
The interaction of the above-mentioned factors may be extremely potent. Thus, the
inherited epigenome may render some people more vulnerable than others to traumatic
childhood experiences and job strain, partly explaining the individual differences in
thresholds for telomere erosion and allostatic load. This is evidence that is generally not
considered when guidelines for CVD prevention are being drafted.
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2.3. Evidence-based guidelines
2.3.1. Evidence-based medicine
Evidence-based medicine (EBM) is a concept that in 20 years has become a central
theme in medicine (Guyatt et al. 2008). This term (and acronym) has achieved dogmatic
status and is vastly overused as a label of excellence. The validity and application of the
phenomenon has been much debated and both too much and too little adherence to the
concept has been widely criticised (Fretheim et al. 2006; GRADE 2011; Grimen and
Terum 2009; Hetlevik et al. 2008; Sackett et al. 1996; Wyller 2011). The main reason
appears to be widespread misunderstanding of the term. Many of those most advocating
the implementation of EBM and criticising non-adherence violate the principles of
EBM themselves. In return, EBM is identified as something it is not (or should not be),
which provokes scepticism and critique. But what is EBM really? And where does it
come from?
The origin of EBM
The EBM movement stems from McMaster University in Hamilton, Canada. In the
1980s a group of clinical epidemiologists, led by David Sackett, taught medical students
and physicians critical appraisal of medical articles and published a series of papers on
the matter (Guyatt et al. 2008). Their ideology “evolved into a philosophy of medical
practice based on knowledge and understanding of the medical literature (...) supporting
each clinical decision” (Guyatt et al. 2008:xix), i.e., basing each clinical decision on the
available evidence rather than tradition. In 1990, Gordon Guyatt, one of the central
actors in the movement, coined the term evidence-based medicine. The term and the
concept became widespread, not least because of the Evidence-Based Medicine
Working Group, led by the McMaster team, which in the 1990s created a series of
articles on EBM in the Journal of the American Medical Association (JAMA).
The definition of EBM has evolved over time. In 1996 Sackett et al. defined EBM in
the following way:
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Evidence based medicine is the conscientious, explicit, and judicious use of current best
evidence in making decisions about the care of individual patients. The practice of
evidence based medicine means integrating individual clinical expertise with the best
available external clinical evidence from systematic research (Sackett et al. 1996:71).
I.e., “EBM” refers to the process of (any given practitioner) conscientiously basing each
clinical decision on the “best available evidence” (identified through a systematic
search) in the light of (one's own) clinical expertise. In the book User's guides to the
medical literature (a doctrine of EBM), Guyatt et al. define two “fundamental principles
of EBM” (Guyatt et al. 2008):
First, EBM posits a hierarchy of evidence to guide clinical decision making. Second,
evidence alone is never sufficient to make a clinical decision. Decision makers must
always trade off the benefits and risks, inconvenience, and costs associated with
alternative management strategies and in doing so, consider their patients' values and
preferences (Guyatt et al. 2008:6).
The hierarchy of evidence
Any empirical observation, collected systematically or not, can be regarded as evidence.
The “quality” or “strength” of the evidence depends on the methods of the study
(observation). “Correct” methodology increases validity of the results, i.e., decreases
potential bias. Thus, the methodological quality of the study decides how trustworthy
the results are as a basis for a clinical decision. For example, results of unsystematic
clinical observations (e.g., case reports) are more prone to bias than well-conducted
RCTs, rendering the RCT results evidence of higher quality (stronger evidence), at
least, when studying intervention effect. However, RCT is not always the best method.
As an example, when studying patients' preferences (e.g., if informed patients find
preventive statin treatment acceptable), qualitative research methods yield stronger
evidence than RCTs, although treatment drop-out (in RCTs) may be regarded as an
important piece of evidence. Thus, every research question has its ideal research
methodology, and EBM posits hierarchies of evidence to facilitate identification of “the
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best available evidence” for different types of questions (treatment effect vs. diagnosis
vs. harm etc.). Where no evidence of high quality (obtained by means of the “ideal
methodology”) is available to answer a given clinical question, evidence of lower levels
in the hierarchy will become “the best available evidence”. Likewise, a poorly
conducted study using a method ranked high in the hierarchy can result in lower quality
evidence than a well-conducted study using a lower ranked method. Large effect sizes,
consistency and precision of results increase the strength of the evidence (Guyatt et al.
2008).
Applicability of study results is another factor requiring careful consideration before
implementation in the individual consultation. Strong evidence of treatment effect may,
for example, have uncertain applicability because of co-morbidities or the age of the
patient (Guyatt et al. 2008).
Values and preferences
The second principle of EBM is that “evidence alone is never sufficient to make a
clinical decision” (Guyatt et al. 2008:6). The values and preferences of the individual
patient (and/or his/her family) have to be considered for every clinical decision. “By
values and preferences, we mean the collection of goals, expectations, predispositions,
and beliefs that individuals have for certain decisions and their potential outcomes”
(Guyatt et al. 2008:10). The implications can be either obvious or unforeseen, so
patients' preferences should not be assumed to be the same as that of the physician or
the majority of the population. Cardiac resuscitation of an elderly or terminally ill
patient is an example of an intervention decision that can differ with values, religion,
etc. Drug treatment for the prevention of CVD is another example, where side-effects,
costs, and inconvenience of the treatment may exceed the potential benefit in some
patients' view but not others. This is a fundamental principle of EBM but often appears
to be forgotten.
Clinical expertise
Each individual evidence-based clinical decision has been described by the McMaster
team to rely on four components: the clinical state and circumstances, patients'
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preferences and actions, research evidence, and clinical expertise (of the physician or
health-care worker) (Haynes et al. 2002). The “clinical state” refers to the symptoms,
disease, or other clinical problem in question and will thus define the relevant evidence,
while “circumstances” refer to the surroundings in which the “clinical state” arises. A
patient with signs of acute myocardial infarction will, for example, not have the same
treatment opportunities if the symptoms arise in a remote, rural area, or in the
neighbourhood of a high-tech hospital. “Patients’ preferences” have been discussed
above. “Patients’ actions” may also need consideration, because they are not always in
aggreement with values and preferences. Lack of treatment adherence may, for
example, stem from forgetfulness or misunderstanding. The “best available research
evidence” will have to be considered in the context of the two previously mentioned
components. “Clinical expertise” refers to the general skills and experience of the
practitioner. It includes the practitioner's ability to identify, interpret, and combine the
best available evidence with the patient's values and preferences in the context of his
clinical state and circumstances in order to reach a clinical decision (Haynes et al.
2002).
To sum up, the essence of EBM is conscientiously basing each clinical decision on the
best available evidence and the patient's values and preferences, in the context of the
given circumstances. To best achieve this goal, clinical expertise is needed. Any
abridgement of this statement cannot be regarded to be in true accord with EBM.
Good doctors use both individual clinical expertise and the best available external
evidence, and neither alone is enough.Without clinical expertise, practice risks
becoming tyrannised by evidence, for even excellent external evidence may be
inapplicable to or inappropriate for an individual patient. Without current best evidence,
practice risks becoming rapidly out of date, to the detriment of patients (Sackett et al.
1996:71).
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2.3.2. Clinical practice guidelines
Traditional guidelines
For decades clinical practice guidelines have been made as an aid to clinicians in their
everyday work. The aim is to summarise the available evidence (and expertise) in the
specific field, to support recommendations aimed at clinicians. Because of the
exponential increase in published research papers in recent decades, it has probably
never been more important to supply clinicians with practical summaries and
recommendations based on the best available evidence. Currently, countless authorities,
organisations, and institutes develop and publish such guidelines for worldwide use
(WHO 2007), regional (Graham et al. 2007; Mancia et al. 2007), national (Cooper et al.
2008; Norheim et al. 2009; National Cholesterol 2002), and even local use in single
hospitals and clinics (Böðvarsson et al. 2011; Digranes et al. 2004). This has not always
been done systematically and explicitly. The typical method has been to establish a
committee of specialists in the field and other stakeholders to a varying degree.
Literature search is often limited, non-systematic, and/or undisclosed. The guideline
committee then reaches a consensus on the recommendations, often in a non-transparent
way. These guidelines have often been of huge assistance to clinicians, offering useful
recommendations based on evidence and expert insights that would otherwise not have
been available to them. However, the validity and applicability of such
recommendations can be hard to evaluate due to a non-transparent production process.
Fortunately, guideline development processes have generally greatly improved.
Some methodological limitations still exist in many guidelines published by prominent
organisations. Guideline authors often have conflicts of interest (Graham et al. 2007;
Mancia et al. 2007; National Cholesterol 2002); relevant stakeholders and targeted users
are not always represented, and the derivation of recommendations is not always
transparent. This opens the door to excessive weight being put on guideline authors'
values and opinions at the cost of evidence and, perhaps, patients' preferences.
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Combined risk algorithms
The method of calculating future risk of CVD events and mortality from combining
information on multiple risk factors was developed by the research team of the
Framingham Study (Anderson et al. 1991). The Framingham algorithm has been used
widely, and many organisations have developed their own algorithms from national or
regional data, based on the Framingham methodology (Conroy et al. 2003; Selmer et al.
2008). The most famous European example is the SCORE algorithm from 2003
(Conroy et al. 2003). The algorithms vary in the risk factors included. Some include
variables, such as BMI (D´Agostino et al. 2011), HDL (Reiner et al. 2011), and
socioeconomic status (Hippisley-Cox et al. 2010), while others do not (Mancia et al.
2007; WHO 2007). Most algorithms do include age, sex, smoking status, BP (SBP), and
(total) cholesterol (De Backer et al. 2003; Graham et al. 2007; Hippisley-Cox et al.
2010; Mancia et al. 2007; Norheim et al. 2009; WHO 2007). While the complete risk
calculators are often available online (D´Agostino et al. 2011; HeartScore 2011; QRISK
2011), guidelines usually present simplified score charts for reference in clinical
practice (De Backer et al. 2003; Norheim et al. 2009; Reiner et al. 2011; WHO 2007).
Most of these algorithms estimate 10-year (absolute) risk of CVD event or CVD
mortality.
Most of these algorithms are derived in the same way. In short (and simplified), a
multiple regression analysis, using Cox or Weibull proportional hazards models, is done
on data from cohort studies with follow-up (of various lengths) on fatal and/or non-fatal
CVD events (or any other given end-point). The regression coefficients derived for each
risk factor are used to estimate the relative risk (hazard ratio) of different combinations
of risk factor levels. Age- and sex-specific incidence rates of the selected end-point in
the given population and information on average levels of the risk factors are combined
with the relative risk calculations to estimate the absolute risk. Thus, BP, smoking, and
cholesterol are each assumed to be of the same relative importance for both sexes and
all ages, and BP and cholesterol are assumed to be linearly associated with CVD events
and death within the combined model (Conroy et al. 2003; Selmer et al. 2008). This
assumption is challenged in section 2.2.2 (regarding cholesterol) and in Paper III and is
discussed in section 4.2.2.
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GRADE
Published guidelines are often touted for being evidence-based and referred to as
representing the gold standard of clinical practice within their specific field. But the
methodology of their production is not always of high standard or in coherence with
EBM. For that reason the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) Working Group was established in 2000 by members of the
McMaster team and collaborators worldwide (health professionals, researchers, and
guideline developers) (Guyatt et al. 2011 i). The aim of the group was to establish a
practical and transparent system to grade the quality of evidence and strength of
recommendations. Their results have been published in a 6-part series of papers in the
British Medical Journal (BMJ) in 2008 and in a 20-part series in the Journal of Clinical
Epidemiology in 2011 (partially still in press) (GRADE 2011). A short overview of how
to develop guidelines using the GRADE system follows below, as a reference for
discussion on the limitations of current guidelines. For further information on GRADE,
see www.gradeworkinggroup.org (see “Publications” for access to published articles).
A summary of how to develop evidence-based guidelines using GRADE (Guyatt et al.
2008 and 2011 ii)
1. Define questions to be addressed
Consider all relevant patient groups, management options, and outcomes
(including morbidity, mortality, quality of life, toxicity and adverse effects,
inconvenience, psychological burden, cost to patient and/or society).
2. Critically appraise available systematic reviews and/or prepare systematic
review(s)
One or more systematic reviews are needed to address all of the relevant patient
groups, management options, and outcomes defined in step 1.
3. Assess the relative importance of outcomes
Ranking the relative importance of the outcomes (defined in step 1) is crucial for
the comparison of management options and for all outcomes to be considered.
Doing this explicitly improves the transparency of recommendations, making
adjustments based on different ranking (values and preferences) easier.
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4. Prepare an evidence profile, including an assessment of the quality of
evidence for each outcome, and a summary of the findings
An “evidence profile” is derived from the systematic review(s) and provides a
simple and systematic summary of:
a. the assessment of the quality of the evidence (considering risk of bias,
inconsistency, indirectness, imprecision, and publication bias) for each
outcome;
b. the findings (absolute and relative risks) for each outcome.
5. Assess the overall quality of evidence and decide on the direction and
strength of the recommendation
The direction (for or against a management option) and the strength (strong or
weak) of the recommendation is based on the quality of the evidence (high
quality evidence can support strong recommendations), the effect (large effect
supports strong recommendations, risk of outcomes decides the direction), and
the balance of desirable vs. undesirable outcomes (the relative importance of
outcomes can be crucial as well as values and preferences). Resource use may
also affect the strength and direction of the recommendation, weighted
according to circumstances.
Additionally, it is important for guidelines to state clearly the clinical question
addressed (health problem and patient group), the targeted guideline users, and who has
developed the guidelines (including information on financial support and conflicts of
interest). Values and preferences underlying recommendations should be explicit (steps
3 and 5). Representatives of targeted users should preferably be involved in the
guideline development. Guideline implementation should preferably be tested in a pilot
project before large scale distribution takes place. Guidelines have to be relevant for and
attainable by the targeted users and the recommendations acceptable for the patients.
The GRADE system has already been adopted by some guideline developers and its use
is likely to increase in upcoming years (GRADE 2011). Strict adherence to the GRADE
system is not a necessary prerequisite for good, evidence-based guidelines, but
considering all the factors described above is mandatory for any guideline to be
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associated with EBM. This overview thus provides a useful framework for identifying
methodological limitations to the validity and relevance of clinical practice guidelines.
2.3.3. Do the guidelines work?
It is a problem that clinical practice guidelines considered to be of adequate
methodological quality and based on high-quality evidence may prove difficult to
implement. In the mid-1990s Irene Hetlevik, one of my mentors, and her co-workers
documented significant discordance between guideline recommendations on
management of BP and diabetes, and the clinical practice in mid-Norway (Hetlevik et
al. 1997 i and ii). Hetlevik et al. conducted an RCT to evaluate the effect of a
multifactorial implementation strategy to improve adherence to clinical guidelines on
CVD prevention. At 12 and 18 months there was no clinically significant difference
between the intervention group and the control group regarding patient outcomes (BP,
BMI, HbA1c, smoking status) (Hetlevik 1999). A decade later another Norwegian RCT,
the Rational Prescribing in Primary Care (RaPP) study (Fretheim et al. 2006), evaluated
an even more extensive, sophisticated, and systematic intervention to support the
implementation of guidelines for the use of antihypertensive and cholesterol-lowering
drugs for primary prevention of CVD. The intervention had very limited effect on
improving guideline adherence in general practice (Fretheim et al. 2006).
Low adherence to authoritative clinical guidelines on CVD prevention among GPs has
been documented widely (Al-Gelban et al. 2011; Bała et al. 2011; Fhärm et al. 2009;
Fretheim et al. 2006; Hetlevik et al. 1997 i and ii; Jaussi et al. 2010; Philips et al. 2001;
Treweek et al. 2005), and there is no reason to assume that this is a phenomenon
isolated to Norway. This suggests the existence of important barriers to guideline
implementation. These barriers may be bound to the point of care (physicians and
patients); to the guideline implementation strategy (the RaPP study suggests this is not
the case); or to the guidelines themselves (quality of evidence and/or development
methodology), i.e., the guideline recommendations may be unattainable. But does it
really matter?
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Does it matter?
Yes, it does matter, and for several reasons. If the guideline recommendations are
unrealistic and unattainable it can cause serious practical and ethical dilemmas in
clinical practice. My three supervisors for this thesis, Linn Getz, Johann Agust
Sigurdsson and Irene Hetlevik, and their co-workers have discussed this issue (Getz et
al. 2004 and 2005; Getz 2006). They estimated that according to the 2003 European
CVD prevention guidelines (SCORE) (De Backer et al. 2003), a majority (76%) of the
adult Norwegian general population had unfavourable risk profiles (Getz et al. 2004 and
2005; Getz 2006). This would cause immense practical problems if the
recommendations were to be followed. Again, the question could be asked: does it
matter? Is individual modification of the guideline recommendations not an option?
The authoritative way in which the recommendations are usually presented and the lack
of transparency (especially regarding values and preferences) makes it rather difficult to
make individual modification in a sensible manner. Besides, the recommendations must
be valid and relevant if the guidelines are intended to be used at all.
Even if the preventive guidelines are not legal documents, they define a certain standard
of care which, if deviated from, might become a basis for malpractice lawsuits when
CVD events occur. But even if strict guideline adherence is not mandatory, such
guidelines are used for quality assessments and as basis for pay-for-performance
systems (Starfield 2011). Physicians thus have economic motives to adhere to
guidelines, potentially at the cost of the patients’ best interest (“person-focused care”),
down-prioritising issues that may be of greater importance to the patient (Starfield
2011).
2.3.4. “Vulgar Cochranism”
The (arguably) most important reason for unrealistic and unattainable guideline
recommendations to matter has to do with the mentality and the culture of the medical
society. These are the greatest limitations to preventive medicine, to technologically
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driven medicine and EBM – the “arrogance of preventive medicine” (Sackett 2002) and
“Vulgar Cochranism” (Wyller 2011).
In 2002, David Sackett wrote about the “arrogance of preventive medicine”:
Preventive medicine displays all 3 elements of arrogance. First, it is aggressively
assertive, pursuing symptomless individuals and telling them what they must do to
remain healthy. (...) Second, preventive medicine is presumptuous, confident that the
interventions it espouses will, on average, do more good than harm to those who accept
and adhere to them. Finally, preventive medicine is overbearing, attacking those who
question the value of its recommendations (Sackett 2002:363).
Sackett's biggest concern was the presumptions; that the assumptions of the validity and
benefit of preventive medical interventions were not based on sound evidence. In 2011
Torgeir Bruun Wyller, a Norwegian geriatrician, coined the term “vulgærcochranisme”
(Norwegian) (Wyller 2011) or Vulgar Cochranism (my translation, which I will use
from here onwards, in lack of a better term) to describe the same abusive arrogance in
relation to EBM. He identified three consequences of overuse and emphasis on “EBM-
evidence” (RCTs and meta-analyses), such as publications of the Cochrane
Collaboration (hence the term, Vulgar Cochranism). First, the available evidence is
applied beyond the range of its validity. The average effect of an intervention in a study
population is assumed to apply to everybody, also the elderly and multimorbid, even if
such patient groups are hardly ever included in RCTs. Wyller also points out that
clinical practice guidelines are often very categorical regarding how (all) patients with
certain medical conditions should be treated in a concrete “evidence-based” way
(Wyller 2011). Others have also pointed out that guidelines focus on specific diseases
and ignore the challenge of multimorbidity (Starfield 2011). Wyller argues that this
indicates inadequate understanding of biology and clinical medicine. Second, excessive
emphasis on the hierarchy of evidence leads to neglect of non-pharmacological
interventions. Many interventions fit poorly to the RCT model and evidence of effect is
therefore regarded as less valid. In addition, it has become difficult to conduct large
clinical trials without the support of the pharmaceutical industry, which leads to biased
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“evidence production” in favour of pharmacological interventions. Third, experience-
based evidence (clinical expertise) is degraded. Pattern recognition, intuition, and
identification of details relevant to the care of the specific patient, i.e., clinical expertise,
is explicitly placed at the bottom of the evidence hierarchy. Wyller points out two
facilitating factors for the rise of Vulgar Cochranism. First, it fits the bureaucratic way
of thinking perfectly, while clinical expertise, on the other hand, is a threat to
bureaucracy, difficult to streamline and hard for policy-makers to count on. Second,
Wyller argues that doctors are trained to learn things by heart, and they like depending
on hard facts and numbers. The Vulgar Cochranism and the hierarchy of evidence is
thus a simple solution to complex problems (Wyller 2011).
Tor-Johan Ekeland, a Norwegian professor in social psychology, has discussed the
limitation of EBM. He addresses the presumptuous nature of EBM and Vulgar
Cochranism (Ekeland does not use this term) simply by the title of the book chapter
“What is the evidence for evidence-based practice?” (Grimen and Terum 2009:145) He
points out that there is no evidence supporting that EBM (as currently practiced) results
in better patient care. Barbara Starfield stated on this issue: “Adoption of guidelines,
particularly those touted as preventive, fails to be consistent with the overwhelming
purpose of medicine, which is the relief of suffering” (Starfield 2011:65).
Like Wyller, Ekeland points out that results of RCTs do not always apply to the
individual patient. He argues that RCTs, and thus EBM, systematically underestimate
and ignore the importance of the clinical context and, therefore, poorly fit the
complexity of clinical reality. Psychotherapy, Ekeland argues, is especially dependent
on the practitioner and the clinical context and should not be standardised to fit the RCT
model. Assuming evidence from RCTs always to be more valid than other evidence (or
even the only valid evidence) introduces bias in favour of pharmacological
interventions. He argues that the absence of (RCT) evidence does not substantiate the
absence of effect. Additionally, because it can be problematic to weigh values vs.
evidence of effect, doing so is generally not considered. EBM, Ekeland states, lacks
critical reflection, and evidence supersedes ethics (Grimen and Terum 2009).
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EBM started out as a quality-improvement project by applying the best available
evidence in everyday clinical practice. This project seems to have evolved (or to be
evolving) into the authoritative Vulgar Cochranism, which demands control over
clinical practice. Ekeland argues that research should be more practice-relevant for
clinical practice to apply the evidence. But Vulgar Cochranism is aggressively assertive.
Facilitated by poor resource management in the healthcare system, health-focused
media and patients’ expanding expectations, an “EBM-label” (e.g., for a certain drug)
automatically becomes an assurance of quality and a justification for resource
allocation. And in that perspective, Ekeland states, criticism of and deviation from
“EBM” may be regarded as unethical and in line with quackery (Grimen and Terum
2009). Thus, Ekeland identifies the element of overbearing in Vulgar Cochranism.
Clinical inertia
The arrogance of preventive medicine and Vulgar Cochranism often presents itself in
discussion of “clinical inertia” (Philips et al. 2001). Clinical inertia is a term introduced
by Philips et al. in 2001, and defined as “failure of health care providers to initiate or
intensify therapy when indicated (Philips et al. 2001:825),” i.e., when indicated by
clinical practice guidelines. Giugliano and Esposito suggested the term also to apply to
“the failure of physicians to stop or reduce therapy no longer needed,” but, they further
state: “Ironically, this neglected side of clinical inertia does not seem to generate as
much concern among physicians or scientific associations” (Giugliano and Esposito
2011:1592). Some imprecision exists regarding the use of the term clinical inertia,
which is sometimes referred to as “therapeutic inertia”, and to varying degrees authors
deem the concept to cover patient non-adherence, but, it generally refers primarily to
physicians (Allen et al. 2009; Faria et al. 2009).
In their article, Philips and colleagues (Philips et al. 2001) focus on clinical inertia in the
management of high BP, dyslipidaemia, and diabetes, and the term appears to be used
most within this field, i.e., the field of CVD prevention. In many guidelines on CVD
prevention, clinical inertia is mentioned, and ways to reduce it are discussed (JNC 2003;
National Cholesterol 2002). Guidelines on CVD prevention are mostly aimed at general
practitioners (GPs), while specialists in cardiology and internal medicine (hospital-
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based) tend to comprise an overwhelming majority of the guideline developing
committees. Guidelines may therefore be regarded authoritative by GPs, and discussion
of clinical inertia (of the GPs) may be regarded as derogatory and insulting, coming
from hospital specialists out of touch with the clinical reality of primary care. As an
example, the 2007 European guidelines on hypertension discuss the importance of the
involvement of WONCA-Europe (European society of GPs) and other professional
societies in the development of guidelines: “This partnership is crucial because general
practitioners are more likely to accept and to use guidelines when these are developed
with the involvement of those known to them” (Mancia et al. 2007:1514). Thus this
implies that WONCA was involved primarily to increase the acceptance among GPs,
rather than for an important input regarding content. About clinical inertia, the JNC 7
hypertension guidelines state:
There is a broad range of clinician commitment to optimal hypertension therapy (…)
Failure to titrate or combine medications and to reinforce lifestyle modifications,
despite knowing that the patient is not at goal BP, represents clinical inertia which must
be overcome [my underlining]. This may be due in part to clinician focus on relieving
symptoms, a lack of familiarity with clinical guidelines, or discomfort in titrating to a
goal (JNC 2003:61).
The guidelines further state: “Clinicians should periodically audit their own patient files
to assess their degree of compliance and success with established goals and treatment
interventions” (JNC 2003:62).
In a report from the US Institute of Medicine, A Population-Based Policy and Systems
Change Approach to Prevent and Control Hypertension (by the Committee on Public
Health Priorities to Reduce and Control Hypertension in the U.S. Population),
hypertension is regarded a “neglected disease” (Institute of Medicine 2010:1) and the
issue of clinical inertia addressed:
Although patient nonadherence to treatment is one reason for lack of hypertension
control, the lack of physician adherence to (…) guidelines (JNC) contributes to the lack
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of awareness, lack of pharmacologic and nonpharmacologic treatment, and lack of
hypertension control in the United States. (…) physicians are not providing treatment
consistent with the guidelines. In particular, physicians are less aggressive in treating
elevated blood pressure in older patients (…) While the reasons for physician
nonadherence to JNC guidelines are unclear, lack of physician awareness and physician
beliefs about the practicality and benefit of treatment may contribute. (…) Numerous
questions remain regarding whether the lack of adherence is related to a lack of
physician agreement with the new treatment guidelines, physician lack of knowledge
regarding the guidelines, inertia based on treating at the previous guideline of 160 mm
Hg/95 mm Hg, or other barriers (Institute of Medicine 2010:12-13).
And a key recommendation is given:
5.1 The committee recommends that the Division for Heart Disease and Stroke
Prevention give high priority to conducting research to better understand the
reasons behind poor physician adherence to current JNC guidelines. Once these
factors are better understood, strategies should be developed to increase the
likelihood that primary providers will screen for and treat hypertension
appropriately, especially in elderly patients (Institute of Medicine 2010:13).
As these examples prove, authoritative parties assert considerable pressure on
physicians (GPs) to follow guidelines, questioning the professional integrity, skills,
knowledge, and commitment of those deviating from the recommendations in their
practice. The tone is often derogatory and guideline non-adherence is not considered
compatible with good patient care. Hence, identifying the reasons for clinical inertia
seems to be considered a step towards ensuring full guideline adherence, and towards
“improvement in clinical practice”, but not towards improvement of the “evidence-
based” guidelines. But according to Sackett et al.:
Evidence based medicine is not “cookbook” medicine. Because it requires a bottom up
approach that integrates the best external evidence with individual clinical expertise and
patients' choice, it cannot result in slavish, cookbook approaches to individual patient
care. External clinical evidence can inform, but can never replace, individual clinical
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expertise, and it is this expertise that decides whether the external evidence applies to
the individual patient at all and, if so, how it should be integrated into a clinical
decision. Similarly, any external guideline must be integrated with individual clinical
expertise in deciding whether and how it matches the patient's clinical state,
predicament, and preferences, and thus whether it should be applied (Sackett et al.
1996:72).
The question then remains whether clinical inertia is just a matter of human error, or
whether GPs have valid reasons for not adhering to guidelines (Giugliano and Esposito
2011; Hetlevik et al. 2008); i.e., whether the guidelines may be erroneous. Are the
guidelines for prevention of CVD valid and relevant to general practice?
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3. THE PRESENT STUDY
3.1. Aims of the study
The objective of this project was to study and discuss the validity and relevance of
international CVD prevention guidelines for general practice. More specifically:
- To document the CVD risk profile of a general population as defined by
selected, authoritative preventive clinical guidelines, by means of modelling
studies.
- To estimate the workload associated with following the recommendations of the
selected guidelines for a well-defined general population in whole.
- To identify potential causes of guidelines' overestimation of risk, focusing on
individual risk factors.
To meet these objectives, four different papers have been written. The aims for each of
these were as follows:
Paper I:
The aim was fourfold: Firstly, to document the prevalence of identified CVD, BP
lowering drug treatment, and five selected risk factors in a well-defined general
population. Secondly, to document the prevalence of high BP as defined by the different
cut-off points given by different guidelines. Thirdly, to identify the proportion of the
population having an “unfavourable risk profile”, i.e. having two or more risk factors.
And, finally, to address the implications of the guidelines' recommendations in the light
of the findings.
Paper II:
Aim: to model the implications of the most recent European guidelines for management
of arterial hypertension (Mancia et al. 2007) in a general population by estimating the
prevalence of unfavourable CVD risk levels according to the guidelines and,
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subsequently, estimating the clinical workload and workforce associated with the
guideline recommendations.
Paper III:
Aim: to document the strenght and validity of total serum cholesterol as a risk factor for
mortality, as defined by current CVD prevention guidelines.
Paper IV:
Aim: to clarify and compare the associations of five anthropometric measures of obesity
and body composition intended for use in clinical councelling of individual patients
(BMI, WHR, WHtR, waist circumference, and hip circumference) with overall
mortality, and specifically with CVD mortality.
3.2. Material and methods
The Nord-Trøndelag Health Study
The work presented in this dissertation is based on the database of The Nord-Trøndelag
Health Study 1995-1997 (HUNT 2). The first large health survey in Nord-Trøndelag
County in Norway (HUNT 1) was conducted in 1984-86 (Holmen et al. 2003). Every
adult (aged 20 years or more) living in the study area was invited to participate in the
HUNT 1 study, and a total of 74 599 (88.1%) of the inhabitants did so. The main
objectives of this survey were to address prevalence rates and quality of health care
provided to individuals with hypertension, diabetes, and tuberculosis (Holmen et al.
2003). The second wave of the HUNT study was conducted in 1995-97. Again, every
adult in Nord-Trøndelag County was invited and 71.2% of the population participated.
This time the scope of the survey was wider, addressing important public health issues
like CVD, diabetes, obstructive lung disease, osteoporosis, and mental health. The
HUNT 2 study has been described in detail by Jostein Holmen and co-workers (Holmen
et al. 2003).
Participation in the HUNT 2 study consisted of a physical examination (including
measurements of BP, height and weight), a non-fasting blood sample, and answering an
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extensive questionnaire on demographic factors (including education and income),
habits (e.g. smoking and physical activity) as well as personal and family medical
histories. Further information on the HUNT studies can be found at:
http://www.ntnu.edu/hunt. Likewise, the questionnaires can be found online at:
http://www.ntnu.edu/hunt/data/que.
The third phase of the HUNT study (HUNT 3) was conducted in 2006-08. Three phases
of a Young-HUNT survey (UngHUNT) have also been conducted, including
participants aged 13-19 years. The HUNT centre holds a high-standard bio-bank with
facilities for advanced bio-material analyses. In addition, the personal identity number
of Norwegian citizens enables linking of HUNT participant data to various registers,
such as the Cause of Death Registry, given approval by the Norwegian Data
Inspectorate.
Ethics statement
Each participant in the HUNT study signed a written consent form regarding the
screening and the use of data for research purposes, including linking to other registers
(subject to the approval of the Norwegian Data Inspectorate). The study was approved
by the Norwegian Data Inspectorate and the Regional Committee for Ethics in Medical
Research.
Study population
The HUNT 2 population is ethnically homogenous, dominated by individuals of Nordic
origin, and has been regarded as fairly representative for the Norwegian nation
regarding demography, socio-economic factors, morbidity, and mortality (Holmen et al.
2003). Overall, 74% of women (34 786) and 65% of men (30 575) chose to participate.
Participation rate was lowest in the youngest and oldest age groups. For both sexes
combined, the participation rates for each decade of age were as follows: 20-29 years,
49%; 30-39 years, 68%; 40-49 years, 77%; 50-59 years, 81%; 60-69 years, 86%; 70-79
years, 80%; 80-89 years, 66%; 90+ years, 53% (Holmen et al. 2003). For more details
on participation rates, see Holmen et al. Norsk Epidemiologi 2003;13:19-32.
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Selective participation evidently has to be considered as a possible source of bias in the
HUNT 2 study, especially in the age groups with the lowest participation rates. A non-
participation study was conducted to identify causes of not attending. Among those
younger than 70 years, the most frequent causes of non-participation reported were lack
of time, having moved out of the county, having forgotten to turn up for the physical
exam, or no special reason (Holmen et al. 2003). For those aged 70+ years the most
frequently given reasons were immobilisation because of disease, regular follow-up by a
physician or hospital, and having moved. A comprehensive non-participation study after
HUNT 1 did not find evidence of selection in health measures in the younger age
groups, but found significantly more morbidity among old non-participants than among
participants of the same age (Holmen et al. 2003).
For the present study, different eligibility criteria were applied in each of the papers,
regarding age, missing data, etc. Details regarding exclusion are to be found in each
paper separately. A summary is presented here in Table 1.
Table 1. Sex-specific number of participants eligible for analysis and inclusion criteria
for each of the paper presented.
Study Men Women Total Inclusion criteria
HUNT 2 30 575 34 786 65 361
Paper I 29 288 32 816 62 104 - Age 20-79 years
Paper II 26 347 24 719 51 066
- Age 20-89 years
- BP ≥120/80 mmHg
- Data available on: BP, smoking,
cholesterol, waist circumference, and
family history of CVD
Paper III 24 235 27 852 52 087
- Age 20-74 years
- Free from CVD at baseline
- Data available on: cholesterol, BP, and
smoking
Paper IV 26 461 30 510 56 971
- Age 20-79 years
- Free from CVD at baseline
- Data available on: weight, height, waist
and hip circumference
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Study variables
In the HUNT 2 study, height and weight were measured with participants wearing light
clothes without shoes; height to the nearest 1.0 cm and weight to the nearest 0.5 kg.
BMI was calculated as weight in kg divided by the squared value of height in meters.
Waist and hip circumferences were measured with a steel band to the nearest 1.0 cm
with the participant standing and with the arms hanging relaxed. The waist
circumference was measured horizontally at the height of the umbilicus, and the hip
circumference was measured likewise at the thickest part of the hip (Holmen et al.
2003). When analysing the anthropometric measures in Paper IV, the aim was to use
clinically recognisable categorisations, rather than percentiles. BMI was categorised
according to WHO definitions (WHO 2000), the waist circumference categories were
defined with 10 cm interval, and the hip circumference categories with 5 cm interval.
The WHR and WHtR were, however, categorised by quintiles. In Papers I and II,
abdominal (waist) obesity was defined as waist circumference >102 cm for men and
>88 cm for women.
In the HUNT 2 survey, total serum cholesterol was measured by an enzymatic
colorimetric cholesterol esterase method (Holmen et al. 2003). The blood pressure of
persons in a seated position was measured by specially trained personnel using
Dinamap 845XT, based on oscillometry. The cuff size was adjusted after measuring the
arm circumference, and blood pressure was recorded as the mean values of the second
and third measurements performed consecutively at the same visit (Holmen et al. 2003).
In Paper II, ”pulse pressure (SBP minus DBP) in the elderly”, as an independent risk
factor, was defined as ≥60 mmHg in people aged >55 years.
Smoking was defined as daily smoking of cigarettes, cigars or a pipe. In Paper IV
smoking status was defined as: unknown, current smoker, former, or never smoker.
Levels of recreational physical activity were defined as self-reported number of hours
spent on hard or light activity during one week: no activity; <3 h light activity; ≥3 h
light activity or <1 h hard activity; ≥1 h hard activity; unknown. Self-reported weekly
alcohol consumption (Paper IV) was categorised as: abstinence, 0-2 glasses (units), 2.1-
5 glasses, 5.1-8 glasses, >8 glasses.
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Established CVD was defined as self-reported angina pectoris, myocardial infarction or
stroke. Likewise, information on BP lowering drug treatment and diagnosed diabetes
was self-reported. Family history of CVD was defined as first-degree relatives (parents
or siblings) with myocardial infarction before the age of 60 or stroke at any age.
Since blood samples were non-fasting, the decision was made not to include
triglycerides, blood glucose, or calculated low-density lipoprotein (LDL) in any of the
analyses included in this thesis (inclusion of postprandial measures might introduce
error).
Follow-up
The personal identity number of Norwegian citizens enables linking of HUNT 2
participant data to the Cause of Death Registry at Statistics Norway (information on
www.ssb.no/english/). For the analysis in Paper III, each participant contributed person-
time from the date of clinical examination (August 1995-June 1997) until ten years of
follow-up had been achieved (until August 2005-June 2007, depending on participation
dates) or until the date of death if this occurred in the follow-up period, making the
oldest participants of the study 84 years of age at the end of the follow-up. The follow-
up time came to a total of 510 297 person-years. For analysis in Paper IV, each
participant contributed person-time from the date of clinical examination until the date
of death or end of follow-up, December 31st 2008. The mean follow-up time was 12.0
years, in total 684 644 person-years. Death from CVD was defined by the International
Classification of Disease code for the primary diagnosis of death (ICD-9: 390-459;
ICD-10: I 00-I 99) as well as death from IHD (ICD-9: 410-414; ICD-10: I 20-I 25).
Guidelines studied
Paper I discusses the implications of applying international clinical preventive
guidelines on the HUNT 2 population, focusing on the prevalence of selected risk
factors and the proportion of the population regarded to be at increased risk. Cut-off
points defining risk factors were based on recommendations of four internationally
renowned clinical preventive guidelines. These were: The 2002 update of the guidelines
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for primary prevention of CVD by the American Heart Association (AHA) (Pearson et
al. 2002); the seventh report of the (USA) Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (JNC 2003) from
2003; the 2006 update of the guidelines on hypertension by the (UK) National Institute
for Clinical Excellence (NICE) (National Institute 2006); and the 2007 European
guidelines on CVD prevention in clinical practice (Graham et al. 2007). The guidelines
were selected as representative samples of the views and recommendations of four
highly regarded associations and institutes from both sides of the Atlantic. Summary of
the recommendations can be found in Table 1 in Paper I.
Paper II models the implementation of the 2007 European guidelines for management
of arterial hypertension (Mancia et al. 2007) on the HUNT 2 population. These
guidelines were chosen on the basis of being the most recent ones on the subject at the
time of the study planning, recommended for use all over Europe. Figure 1 shows the
risk stratification, as presented in the guidelines, as well as the number of recommended
follow-up visits per year for each risk stratum, as interpreted by the study authors.
Figure 2 (Paper II) shows the definitions of the risk factors considered in the study.
Statistical analysis
The SPSS statistical package, version 15.0 (SPSS Inc., Chicago, USA) was used for
frequency analyses in Papers I and II. Stata for Windows (Version 11 StataCorp LP,
TX, USA) was used for analyses of Papers III and IV. A thorough discussion of the
statistical analyses performed in each paper separately follows below.
Paper I
Paper I presents simple descriptive statistics: prevalence of established CVD and risk
factors in absolute numbers and percentages, as well as age standardised prevalence
percentages (Europe and World standard [Waterhouse et al. 1976]) with 95%
confidence intervals (CI). Age standardised prevalences are presented to enable
comparison between countries. The proportions of the population having none of the
risk factors studied, one of them, two, or more than two, as well as the proportion
reporting established disease (CVD, diabetes, or BP treatment) are presented.
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The upper age limit of 79 years was found to be of clinical relevance due to high co-
morbidity and low life expectancy after that point. This coincided with considerably
lower participation rates among the oldest inhabitants in Nord-Trøndelag.
Inclusion of the recently coined risk factor “prehypertension” in the analysis can be
debated. However, differentiation of this factor from hypertension made the relative
importance of prehypertension clearly recognisable.
Paper II
In this paper, we estimated the prevalence within each risk stratum, as defined by the
2007 European hypertension guidelines (Mancia et al. 2007). Age standardised
prevalences were calculated because of inequal participation rates in different age
groups, with the actual age distribution in Nord-Trøndelag (Statistics Norway 2007) as
standard. The total number of recommended follow-up visits per year was calculated by
multiplying the age standardised prevalence numbers with the recommended number of
visits for each risk category. Number of physicians needed to take care of that workload
was calculated by dividing the estimated number of visits by 3 000 – the average
consultation number of a general practitioner at the time (Nossen 2007).
Since the exact number of visits per year for each risk category was not stated by the
2007 guidelines, a subjective interpretation was unavoidable. Individuals in certain risk
categories were recommended to be seen more than twice a year. We interpreted this as
3-4 times a year, and used an average number of 3.5 visits/year (further explained in
Paper II). Sensitivity analyses were also done, exchanging the number 3.5 with 3 and 4,
respectively.
An upper age limit of 89 years was found to be appropriate because of low participation
rate above that age. This cut-off point might be regarded as rather high, but the
guidelines specifically emphasise that preventive treatment should be continued in old
age. Including participants aged 80-89 years might, however, have introduced a
selection bias, favouring the more healthy individuals in that age range. This decision
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was found to be defendable since the effect of such bias would be underestimation of
the workload.
The 2007 European guidelines include a risk stratification chart where the lower cut-off
point for BP is 120/80 mmHg. Individuals with lower BP values are thereby not eligible
for risk evaluation.
Paper III
The first part of the analysis involved making a simple CVD risk estimation chart to be
compared with the charts currently recommended for clinical practice in Norway. The
Systematic Coronary Risk Evaluation (SCORE) chart of the European Society of
Cardiology (Conroy et al. 2003; De Backer et al. 2003), and the nationally adjusted
chart used in the Norwegian National Guidelines (Norheim et al. 2009) were used as a
reference. These charts are intended to depict the 10-year risk of dying from CVD,
given the level of the following risk factors at baseline: sex, age, smoking status,
systolic blood pressure, and total cholesterol. To obtain a meaningful amount of data for
each square of the chart, we based the analysis on three age groups (20-39 years, 40-59
years, and 60-74 years), two levels of systolic blood pressure (<140 mmHg vs. ≥140
mmHg, in accordance with guidelines), smokers vs. non-smokers, and two levels of
total cholesterol. Regarding cholesterol, the levels <5.5 mmol/L vs. ≥5.5 mmol/L were
used (cut-off approximately 215 mg/dL). This cut-off point assigned 40% of
participating males and 43% of females to the “low level” category. Using a cut-off
point of 5.0 mmol/L (which guidelines [De Backer et al. 2003; Graham et al. 2007] state
that cholesterol should be below) would have assigned only 24% of males, and 27% of
females to the lower cholesterol stratum. The median cholesterol level of the
participants was 5.7 mmol/L for both sexes. The observed mortality rates per 1 000
person-years were calculated for each square of the chart.
For the next part of the analysis, Cox proportional hazard models were used to compute
hazard ratios (HRs) for overall mortality, as well as for mortality from CVD and IHD,
associated with different levels of cholesterol at baseline. The precision of the estimated
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associations was assessed by a 95% confidence interval. Departure from the
proportional hazards assumptions was evaluated by Schoenfeld residuals.
Sex-specific HRs were computed for cholesterol as a continuous variable as well as a
variable with four categories (<5.0 mmol/L, 5-5.9 mmol/L, 6.0-6.9 mmol/L, and ≥7.0
mmol/L). The other variables of the aforementioned chart were adjusted for, namely:
age (in the time scale), systolic blood pressure (as a continuous variable), and smoking
status.
An alternative model was also tested, including the same variables, in addition to WHR,
level of physical activity, diabetes mellitus, and family history of CVD. The categorical
cholesterol variable was tested for linear, as well as quadratic trend. Finally, an analysis
of cholesterol as a dichotomous variable with the cut-off point of 5.5 mmol/L was
conducted, stratified by smoking status, and an analysis of the effect of smoking
stratified by the dichotomous cholesterol variable for comparison. Using a finer set of
cholesterol-categories was not deemed to be feasible due to limited statistical power.
The upper age limit of 74 years was identified as a clinically meaningful cut-off for
estimating 10-year risk of death, given the average life-expectancy in Norway (Statistics
Norway 2011).
Paper IV
Associations of five anthropometric measures (BMI, waist circumference, hip
circumference, WHR, and WHtR) with mortality were examined in this study. Each
measure was divided in five categories (see chapter on study variables for details). Cox
proportional hazard models were used to compute hazard ratios for overall mortality and
CVD mortality associated with different levels of each anthropometric measure.
Precision of the estimated associations was assessed by a 95% confidence interval.
Departure from the proportional hazards assumption was evaluated by Schoenfeld
residuals and log-minus-log plots. An interaction term between time and the appropriate
variables was added to the model if the proportional hazards assumption did not hold.
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The HR for participants with BMI below 18.5 kg/m2 (104 men and 314 women) was
analysed for comparison with the other BMI categories but excluded from further
analysis due to the potential of reverse causality (a J-shaped mortality curve)
(Berrington de Gonzalez et al. 2010; Flegal et al. 2007).
Sex specific standard deviation (SD) scores for each of the anthropometric variables
were calculated and the HR associated with an increase of one SD was estimated. The
data were analysed separately for men and women, and all associations were adjusted
for potential confounding effects of age, smoking status and recreational physical
activity. Sensitivity analyses were conducted, involving three additional models (Model
2-4). Model 2 included the same covariates as the main model but excluded participants
with unknown smoking status. Model 3 was adjusted for age, smoking, and physical
activity (as the main model) in addition to diabetes mellitus and weekly alcohol
consumption (abstinence, 0-2 glasses [units], 2.1-5 glasses, 5.1-8 glasses, >8 glasses).
Model 4 was identical to the main model but excluded the first three years of follow-up
to limit the potential reverse causality effect of undiagnosed diseases.
The “relative informativeness” of each anthropometric measure was evaluated by
examining the contributions made to the χ2 likelihood ratio statistic in the Cox
regression model compared with a model that only contained the confounders, as the χ2
statistic can be used as a measure of the improvement of goodness of fit (Prospective
Studies 2002). This was done both in relation to all cause mortality and CVD mortality.
To further compare the predictive properties of the different anthropometric measures
for CVD death, sex-specific net reclassification improvement (NRI) and integrated
discrimination improvement (IDI) were computed when adding each anthropometric
measure to two different prediction models. Model A included age as the only
predictive variable, while Model B included age, smoking status, systolic blood
pressure, and total cholesterol. For each model three different NRI calculations were
done, using two (<5%, ≥5%), three (<1%, 1-9%, ≥10%), and four (<1%, 1-4%, 5-9%,
≥10%) levels of risk of CVD death, respectively.
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In addition, an analysis of the anthropometric measures stratified by age (above and
below 60 years) was conducted. Finally, mutually adjusted analyses were conducted for
waist and hip circumference, as well as for BMI and WHR.
3.3. Results
3.3.1. Synopsis of Papers I-IV
Paper I
Can individuals with a significant risk for cardiovascular disease be adequately
identified by combination of several risk factors? Modelling study based on the
Norwegian HUNT 2 population
Petursson H, Getz L, Sigurdsson JA, Hetlevik I. J Eval Clin Pract 2009;15:103-9
Aims and objectives
Clinicians are generally advised to consider several risk factors (combined risk
estimate) when evaluating patients' CVD risk. The aim was to study whether a
combined assessment of five traditional risk factors might help demarcate a relatively
distinct and manageable group of high-risk individuals in the clinical setting. Five risk
factors were selected and the proportion of a well-defined population with
“unfavourable” levels of at least two of them, as defined by four internationally
renowned guidelines, was estimated. The impact of including so-called
“prehypertension” (BP 120/80-139/89 mmHg) among the risk factors was specifically
addressed. The results are discussed in a wider perspective.
Material and methods
Guideline implementation was modelled on data from the HUNT 2 study comprising 62
104 adults aged 20–79 years (29 288 men and 32 816 women). The risk factors studied
were BP, cholesterol, obesity, smoking, and family history of CVD (1° relatives). Total,
age- and sex-specific point prevalences of each risk factor was calculated, as well as the
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prevalence of having zero, one, two, three or more factors, or having established disease
(diabetes, CVD, BP treatment).
Results
One single CVD risk factor was exhibited by 12.4% of the population (age standardised,
European standard); two factors by 21.5%; and three or more by 49.7%. Established
CVD or diabetes mellitus was reported by 12.5%. In total, 83.7% of the population
exhibited a disease or risk profile with at least two factors, if prehypertension was
included. Table 4 shows the prevalences of individual risk factors.
Conclusions
If authoritative guideline recommendations are literally applied, as many as 84% of
adults in Norway could exhibit two or more CVD risk factors or established disease and
thus be considered in need of individual, clinical attention. This challenges the widely
held presumption that “the net will close” around a manageable group of individuals-at-
risk if several risk factors are jointly considered. As the finding of this study arises in
one of the world’s most long- and healthy-living populations, it raises several practical
as well as ethical questions.
Paper II
Current European guidelines for management of arterial hypertension: Are they
adequate for use in primary care? Modelling study based on the Norwegian HUNT
2 population
Petursson H, Getz L, Sigurdsson JA, Hetlevik I. BMC Fam Pract 2009;10:70
Aims and objectives
Previous studies (including Paper I) indicate that clinical guidelines using combined risk
evaluation for CVD may overestimate risk. The aim of this study was to model and
discuss implementation of the current (2007) hypertension guidelines in a general
Norwegian population, with emphasis on the associated workload.
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Methods
Implementation of the current European Guidelines for the Management of Arterial
Hypertension was modelled on data from the HUNT 2 study, comprising 65 028 adults,
aged 20-89, of whom 51 066 (79%) were eligible for modelling (26 347 men and 24
719 women). Based on the risk estimation chart and recommendations of the guidelines,
the number of recommended follow-up visits per year was calculated, as well as the
number of physicians required for this task.
Results
Among individuals with blood pressure ≥120/80 mmHg, 93% (74% of the total, adult
population [HUNT 2 participants]) would need regular clinical attention and/or drug
treatment, based on their total CVD risk profile. This translates into 296 624 follow-up
visits/100 000 adults/year. In the Norwegian healthcare environment, 99 general
practitioner (GP) positions would be required in the study region for this task alone. The
number of GPs currently serving the adult population in the study area is 87 per 100 000
adults.
Conclusion
The potential workload associated with implementing the 2007 European hypertension
guidelines could destabilise the healthcare system in Norway, one of the world's most
long- and healthy-living nations, by international comparison. Such a large-scale,
preventive medical enterprise can hardly be regarded as scientifically sound and
ethically justifiable, unless issues of practical feasibility and sustainability are
considered in a transparent way.
Paper III
Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid?
Ten years prospective data from the Norwegian HUNT 2 study
Petursson H, Sigurdsson JA, Bengtsson C, Nilsen TIL, Getz L. J Eval Clin Pract
2011;18:159-68.
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Aims and objectives
Many clinical guidelines for CVD prevention contain risk estimation charts/calculators.
These have shown a tendency to overestimate risk, which indicates that there may be
theoretical flaws in the algorithms. Total cholesterol is a frequently used variable in the
risk estimates. Concerns for one's (total) cholesterol value is also widely promoted as
part of a responsible lifestyle, as illustrated by the Norwegian campaign “Under 5” in
2011 (Under 5 2011). Some previous studies, however, indicate that the predictive
properties of cholesterol might not be as straightforward as widely assumed. The aim of
this study was to document the strength and validity of total cholesterol as a risk factor
for mortality in a well-defined, general Norwegian population without known CVD at
baseline.
Methods
The association of total serum cholesterol with total mortality was assessed, as well as
mortality from CVD and IHD specifically, using Cox proportional hazard models. The
study population comprises 52 087 HUNT 2 participants (24 235 men and 27 852
women), aged 20–74, who were followed-up on cause-specific mortality for 10 years
(510 297 person-years in total).
Results
Among women, cholesterol had an inverse association with all-cause mortality (HR
[95% CI]: 0.94 [0.89-0.99] per mmol/L increase) as well as CVD mortality (HR [95%
CI]: 0.97 [0.88-1.07]. The association with IHD mortality (HR [95% CI]: 1.07 [0.92-
1.24]) was not linear but seemed to follow a “U-shaped” curve, with the highest
mortality <5.0 and ≥7.0 mmol/L. Among men, the association of cholesterol with
mortality from CVD (HR [95% CI]: 1.06 [0.98-1.15]) and in total (HR [95% CI]: 0.98
[0.93–1.03]) followed a “U-shaped” pattern.
Conclusion
The study provides an updated epidemiological indication of possible errors in the CVD
risk algorithms of many clinical guidelines. If our findings are generalisable, clinical
and public health recommendations regarding the “dangers” of cholesterol should be
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revised. This is especially true for women, for whom moderately elevated cholesterol
(by current standards) may prove to be not only harmless but even beneficial.
Paper IV
Body configuration as a predictor of mortality: Comparison of five different
anthropometric measures in a 12 year follow-up of the Norwegian HUNT 2 study
Petursson H, Sigurdsson JA, Bengtsson C, Nilsen TIL, Getz L. PloS ONE
2011;6:e26621
Aims and objectives
Distribution of body fat is more important than the amount of fat as a prognostic factor
for life expectancy. Despite that, BMI still holds its status as the most used indicator of
obesity in clinical work. The aim was to study the associations of five anthropometric
indicators of obesity and body composition (BMI, WHR, WHtR, waist circumference,
and hip circumference) with overall mortality, and specifically with CVD mortality.
Methods
We assessed the association of the five different anthropometric measures with
mortality in general and CVD mortality in particular using Cox proportional hazards
models. Predictive properties were compared by computing integrated discrimination
improvement and net reclassification improvement for two different prediction models.
The analyses were conducted on data on 56 971 HUNT 2 participants (26 461 men and
30 510 women) age 20-79 and free from CVD at baseline, followed up for mortality
from 1995-1997 through year 2008 (mean follow-up 12.0 years, 684 644 person-years
in total).
Results
After adjusting for age, smoking and physical activity WHR and WHtR were found to
be the strongest predictors of death. HRs for CVD mortality per increase in WHR of one
standard deviation were 1.23 for men and 1.27 for women. For WHtR, the
corresponding HRs were 1.24 for men and 1.23 for women; for waist circumference,
HRs were 1.19 (men) and 1.22 (women); for BMI, 1.12 (men) and 1.09 (women); and
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finally, for hip circumference, 1.06 (men) and 1.09 (women). WHR offered the greatest
integrated discrimination improvement to the prediction models studied, followed by
WHtR and waist circumference. Hip circumference showed a strong, inverse association
with mortality when adjusting for waist circumference. In all analyses, BMI had weaker
association with mortality than three of the other four measures studied.
Conclusions
The study adds further weight to the evidence that BMI is not the most appropriate
measure of obesity in everyday clinical practice, at least in relation to predicting
mortality. WHR can reliably be measured, is as easy to calculate as BMI, and is
currently a better documented measure than WHtR. It therefore appears reasonable to
recommend WHR as the primary clinical measure of body composition and obesity for
preventive purposes.
Conclusions of Papers I-IV in context
The results of Paper I indicate that prominent preventive clinical guidelines have a
tendency to overestimate CVD risk. At least they fail to identify a clinically manageable
proportion of the population as at “high risk”. Paper II supports this conclusion, adding
that the recommendations of the guidelines studied would introduce an overwhelming
workload to the Norwegian healthcare system. These conclusions raise the question of
where the problem lies. What causes the overestimation? Papers III-IV seek the answer
among individual risk factors – whether flaws in definition (demarcation) of individual
risk factors (we selected cholesterol and obesity for further investigation) could cause
errors in the combined risk estimate. The results of Paper III indicate that the
assumption of a linear association between total cholesterol and CVD mortality, as
presented in most combined risk algorithms, may be erroneous. The results of Paper IV
indicate that WHR and WHtR are more appropriate than BMI for defining “obesity“ for
CVD risk estimation.
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3.3.2. Previously unpublished additional results
In the process of writing a paper presenting quantitative results, numerous potential
tables and figures tend to accumulate. Some of these get published (after alterations to a
varying degree) while others do not. In Appendices I present some tables and figures
that were not included in the published papers I-IV but contain interesting supporting
information. These results will not be discussed in great detail but are summarised in the
context of the papers.
Paper I presents prevalence rates of a few risk factors in absolute numbers as well as age
standardised. Figure A and Figure B (Appendix II) show the prevalence of each risk
factor within each year of age, for men and women, respectively. The prevalence of
most of the risk factors increased with age, most notably for serum cholesterol and
hypertension. Already at age 20 some of the factors were exhibited by a considerable
proportion of the population, which is reflected in Figure 2 (Paper I). An even more
detailed analysis of body configuration is presented in Table A (men) and Table B
(women), which show the prevalence of being overweight or obese, defined by BMI
and waist circumference both separately and combined, in 5-year age groups. It is of
interest to note that in both sexes, prevalence of abdominal obesity increased through all
age groups, while overweight (BMI ≥25.0 kg/m2) plateaued around age 50.
Figure 1 of Paper III depicts the observed ten-year mortality rates per 1 000 person-
years in the HUNT 2 population, according to each level of the risk factors found in the
international SCORE system. Two identical figures were made, presenting all-cause
mortality (Figure C) and IHD mortality (Figure D), respectively. As stated in Paper III,
the results were similar for all three analyses, the models showed a general trend
towards increased mortality for an increase in any of the included risk factors, except
for cholesterol, where no such association was observed.
As can be seen in Table 1 of Paper III, the number of deaths divided by the number of
participants within each of the cholesterol categories yields relative risk ratios quite
different from the adjusted HRs reported. Age-adjustment is the cause of this
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discordance. For further clarification, age-stratified mortality rates for each of the
cholesterol categories are presented in Tables C-E (Appendix I). As the Tables show,
the majority of the deaths occurred among participants aged 60-74 at baseline. A larger
proportion of participants aged 60-74 had total cholesterol above 6 mmol/L than below
6. Therefore, a higher number of deaths in total occurred among those with high
cholesterol levels, compared to those with lower levels. The age-stratified data are more
in accord with the adjusted HRs, showing the highest mortality among the oldest
participants with the lowest cholesterol levels.
Figures E-N (Appendix II) were made in the preparation of Paper IV and are based on
the data on the 56 971 participants included (all free from CVD at inclusion). They
depict the observed sex-specific CVD death rate per 1 000 person-years during the 12
year follow-up for each anthropometric measure separately without any statistical
adjustments. For each measure 20 categories were created for each sex. Each category
included approximately 5% of the population, except the first and last category which
included approximately 1% each. Clinically relevant cut-off points were chosen where
possible. A visual appraisal identifies WHR and WHtR as having the strongest and most
uniform association with mortality, of the measures studied.
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4. DISCUSSION
In theory, clinical practice guidelines on prevention of CVD offer an excellent
opportunity for education and quality improvement in general practice. However, a
range of factors currently appears to limit their validity and relevance. Such limitations
may have important effects on clinical practice and resource allocation, as well as
population health. From another perspective, there seem to be plenty of opportunities
for improvement. While some of the limitations involve easily adjustable technical
details, others are more fundamental and even have historical, social and cultural roots
and implications.
I will first present some methodological considerations regarding Papers I-IV and then
reflect on the scientific and professional development of preventive medicine in general
practice. I will present my reflections as an analysis of the (potential) limitations of
preventive CVD guidelines, which will hopefully result in practical and useful
recommendations regarding guideline improvement.
4.1. Methodological considerations
The main strength of the present study lies in the extensive database of the HUNT 2
study. The HUNT 2 population is large, compared to other population studies, and the
study has good participation rates. All measurements were conducted in a standardised
manner, and the mortality follow-up can be regarded as complete, with virtually the
only potential exception being deaths among individuals who might have emigrated
from the country during the follow-up period.
The wider generalisability of research findings, based on the HUNT studies in general
and the HUNT 2 study in particular, is open to debate. The HUNT 2 population has
been regarded as relatively representative of the Norwegian nation in terms of
demography, socio-economic factors, morbidity, and mortality (Holmen et al. 2003).
The similarities of the Nordic countries, regarding social structure, life-expectancy, etc.
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(Statistics Denmark 2011; Statistics Iceland 2011; Statistics Norway 2011; Statistics
Sweden 2011), suggests a certain transferability of the results, while greater uncertainty
may be associated with application to other different populations. The present study,
however, identified certain limitations to international preventive CVD guidelines that
call for careful consideration in any population targeted for guideline implementation in
the future.
Regarding the papers included in the present study, I have, in hindsight, become aware
of some limitations and issues that might have been addressed. These considerations
will be discussed in the chronological order of the papers.
Paper I
In hindsight, a sensitivity analysis could have been conducted, estimating, e.g., the best
and worst case scenario from the missing data on individual variables. It would even
have been possible to estimate the best and worst case scenario from invited non-
participants living in Nord-Trøndelag County. Also, it would have been of interest to
calculate the ten-year combined risk score for all participants. We refrained from doing
so, mainly due to the complexity of the task, especially when considering more than a
single guideline.
Paper II
The 2007 European guidelines include a risk stratification chart where the lower cut-off
point for BP is 120/80 mmHg. Individuals with lower BP values were thereby not
eligible for risk evaluation. In hindsight, guidelines without such lower BP cut-off
might have been chosen, rendering a larger proportion of HUNT 2 participants eligible
for the analysis.
It might be considered a weakness of the study that the total workload associated with
the guideline recommendations was estimated without taking into account the work
currently spent on BP monitoring, i.e., how much additional workload implementation
of the 2007 guidelines would introduce. This estimation would, however, have been an
extremely complicated. From clinical experience the authors know that much preventive
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work takes place as opportunistic BP measurements and lifestyle recommendations
during consultations initiated for other reasons. Statistics based on the number of visits
with CVD or BP control as the stated reason for contact would probably underestimate
the work actually performed.
Paper III
Preliminary analyses applying the Mantel-Haenszel test focused our interest on further
examining the association of serum cholesterol with mortality. The study was thereby
designed to address this association. It would have been of interest to explore further the
predictive value of cholesterol in a combined risk estimate by means of receiver
operating curves (ROC) or net reclassification improvement analyses, but this was
considered more appropriate for a potential follow-up study.
As mentioned in section 3.3.2, the adjusted HRs presented in Table 1 do not seem to be
in accord with the reported number of deaths, as the number of deaths increase rather
than decrease with higher levels of cholesterol. The explanation for this apparent
paradox lies in the correlation of cholesterol and age. This can be seen from the age-
stratified mortality rates for the different cholesterol categories (Tables C-E in
Appendix I). These data might have been included in Paper III for clarification.
Concerns regarding this matter were raised in a Letter to the Editor of the Journal of
Evaluation in Clinical Practice after publication of Paper III. Table C is included in our
response to that letter. The correspondence will appear in the 2012 January issue of the
journal and is presented in Appendix III.
Figure 1 presents age-stratified mortality rates, but only for a dichotomised cholesterol
variable. A more detailed categorisation might have been preferable. However, that was
not deemed feasible since it would have caused some of the categories (boxes) of Figure
1 to include very few participants. In hindsight, a different cut-off point for
dichotomisation of cholesterol (i.e., 6.0 mmol/L) might have been chosen for more
obvious coherence with the regression analysis.
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A possible explanation for the high mortality observed in the lowest cholesterol
category is reverse causality, i.e., low cholesterol levels at baseline might be due to
undiagnosed diseases that increase the mortality in the group. Thus, excluding, for
instance, the first two years of follow-up may be warranted to reduce this potential bias.
At least this could have been addressed in the form of a sensitivity analysis. The aim of
our study was not to examine the causal relationship between cholesterol and death, but
rather to examine the association as a part of a prediction algorithm. Introducing, as a
decision aid in clinical practice, a prediction algorithm estimating the risk of CVD death
for the next 10 years, whilst immediately excluding the first 2-3 years, would lack
clinical meaning. In the context of the present study, I therefore argue that reverse
causality is not to be considered a cause of bias. Rather, it should be considered part of
the complex, clinical reality.
A recent study by Mørkedal et al., also based on the HUNT 2 population, reported HRs
for the association between total cholesterol and IHD mortality (Mørkedal et al. 2011).
Mørkedal et al. reported the HRs in a supplementary appendix we were not aware of
when Paper III was submitted. These HRs are sex-specific and refer to an increase of 1
SD (men: 1.2 mmol/L; women: 1.3 mmol/L) in total cholesterol. The resulting HRs are
slightly higher than those reported in Paper III: 1.20 for men and 1.14 for women per
increase in total cholesterol of one SD, compared with 1.08 for men and 1.07 for
women per increase in cholesterol of 1.0 mmol/L in Paper III. Closer comparison of the
studies, including a post-publication re-analysis performed jointly by the two author
groups, has shown that the results of the two studies can be fully explained by different
inclusion criteria. These criteria are again linked to the difference in research questions;
Mørkedal et al. present a statistically oriented epidemiological investigation of causal
inferences, whilst Paper III is a practically oriented modelling study of the validity and
relevance of current clinical guidelines. Ideally, the apparent discrepancy between the
two studies should have been addressed in Paper III.
Mørkedal included participants of all ages and excluded only those with incomplete
data on the study variables or a reported history of MI or cerebral stroke, whilst we
additionally excluded those who reported angina pectoris as well as individuals aged 75
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years or older. More than half of the IHD deaths occurred among participants above age
74 and roughly 20% among participants that reported angina pectoris but not MI or
stroke. The exclusion criteria are open to debate. Addressing primary prevention from
the perspective of 10-year mortality predictions has limited clinical relevance in very
old age. The mean life-expectancy in Norway was among the factors informing our
decision on the upper age limit for inclusion. Since we were addressing primary
prevention of CVD, we wanted to be sure not to include the participants who might
already be under secondary preventive surveillance due to histories of MI and/or stroke.
The validity of self-reported MI and stroke in the HUNT 2 study is difficult to evaluate
in the absence of documented information from, for instance, clinical endpoint
registries. To minimise the risk of including patients with established CVD, we also
excluded people with self-reported angina pectoris. Thereby, some participants at high
risk of CVD and truly eligible for targeted prevention (which they might in fact not
have sought) could have been excluded. This would result in underestimating the true
effect of high cholesterol if these participants had higher cholesterol levels than the
mean for their age. However, we believe that Norwegian patients reporting angina
pectoris are likely to have undergone a medical work-up and be under surveillance and
receiving relevant prophylactic treatment. Thus, the direction of any possible bias
related to inclusion/exclusion of self-reported angina pectoris is not obvious. A
sensitivity analysis with inclusion of participants who reported angina pectoris could
have shed further light on this issue.
Paper IV
It could have been of interest to seek out the cut-off points yielding the highest NRI
estimates, thus identifying a risk stratification model with the best predictive properties.
This was, however, considered to be outside the study aims. It would also be relevant to
compare the predictive ability of the anthropometric measures as dichotomous
variables, because preventive guidelines often refer to BMI and waist circumference in
that manner. However, an international consensus has not been reached regarding WHR
and WHtR cut-offs for obesity, in contrast to BMI and waist circumference (WHO 2011
ii). Before settling on such cut-off points, it must be specified whether they are intended
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to identify high body fat percentage or, alternatively, high risk of morbidity/mortality.
This question is addressed in Paper IV.
4.2. Possible limitations to guideline validity and relevance
I have presented evidence indicating that international clinical guidelines on prevention
of CVD may have limited validity and relevance for general practice, at least in
Norway. The guidelines appear to overestimate CVD risk and fail to correctly identify a
manageable proportion of the population as “high-risk individuals”, for whom
individual preventive strategies would be effective and beneficial. Thus, current
guidelines seem to introduce inadequate thresholds for individual-based high risk
preventive strategies as an alternative (or complement) to population-based mass
strategies (Buetow et al. 2007; Rose 1985). The strategy of targeting individuals at risk
(“high-risk strategy”) ends up being recommended at the level of mass strategy, which
can hardly be regarded as sustainable or responsible.
If one takes for granted that the guidelines are not followed, that the recommendations
do not translate into practice, the obvious question will be asked: Are the guidelines
“good enough”. Here “good enough” asks whether the guidelines are of high
methodological standard, based on the best available evidence, and whether the
available evidence is sufficient to support efficient, cost-effective, and realistic
(obtainable) preventive strategies. To guide the reader through my analysis, a flowchart
of the arguments is presented in Figure 1, below.
4.2.1. “Prevention in practice” inadequate
If it is taken for granted that the existing clinical preventive guidelines are “good
enough”, i.e., of good methodological quality and based on sound and sufficient
evidence, potential limitations must be found where the recommendations are put into
practice - meaning that the guidelines are not followed correctly or not well enough. I
have identified four possible “barriers”: the physicians, the number of physicians, the
organisation, and the patients.
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Figure 1. Potential limitations to guideline validity and relevance.
Physicians not “good enough”
Physicians may not be familiar with the current guidelines or may disagree with the
recommendations; they may not have the experience and/or knowledge to adequately
reach treatment goals (such as lowering BP below 140/90 mmHg); or they may not feel
committed to identifying patients “at risk” and treating them to guideline-recommended
“Pharmaceutical bias”
“Vulgar Cochranism”
Surrogate end-points
Evidence gap in important areas
Are the guidelines “good enough”?
Yes “Prevention in practice” inadequate
Physicians not “good enough”
Physicians not many enough
Organisation not “good enough”
Patients not “good enough”
Validity of  risk factor definitions
Validity of combined risk estimates
Validity/relevance of included risk factors
Validity/relevance of excluded risk factors
Non-adherance to EBM principles
No Guidelines not “well enough” made
Evidence not “good enough”
Combining fragmented knowledge
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goals. This has been described as clinical inertia, the “failure of health care providers to
initiate or intensify therapy when indicated” (Philips et al. 2001:825). Clinical inertia is
discussed in chapter 2.3.4. Although clinical inertia may contribute to guideline non-
adherence, I regard researchers/thinkers pointing to professional inadequacy as the main
barrier for preventive guideline implementation as relatively arrogant and inadequately
informed. The guidelines are in most instances aimed at practicing physicians, and GPs
are primarily involved and responsible for primary prevention of CVD. Thus, discussion
of clinical inertia can soon become an expression of distrust toward GPs. In my opinion,
clinical inertia should generally be addressed in a wider context of other possible
reasons for non-adherence, including organisational workload and time constraints;
patient-related issues, such as “patient preferences”, and competing health issues (co-
and multimorbidity). The physician and his patient may find it necessary to prioritise
other important issues, leading to deviation from guideline recommendations (Hetlevik
et al. 2008).
Physicians not many enough
Paper II indicated that the GPs currently practicing in Nord-Trøndelag are not many
enough to handle the workload associated with the guideline recommendations. A
possible solution would be to increase the number of GPs. Intuitively this is, however,
not a realistic option on a large scale. The investment demanded for educating and
employing these additional physicians is likely to exceed the possible gain from lower
CVD incidence. These investments of manpower and resources would have to be
thoroughly evaluated in a larger context with other possible (preventive) societal
projects worthy of investment (i.e., opportunity cost), such as maternal and neonatal
care and the educational system. Also, it has to be borne in mind that CVD prevention
does not seem to be the only field of medicine where disease-specific guidelines
recommend allocation of unavailable resources. Clearly, the number of physicians
cannot be increased to meet every potential demand. The law of diminishing returns
(Fisher and Welch 1999) will eventually deem further investment in medical activity
non-beneficial. Some increase in the number of physicians may be considered as part of
a multifactorial solution but can hardly be regarded as the primary strategy.
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Organisation not “good enough”
In Norway, individual GP consultations account for most person-based CVD primary
prevention. Perhaps this organisation of preventive work might be made more efficient
and cost-effective. Instead of meeting the GP 2-4 times a year for BP controls as
recommended by guidelines (Mancia et al. 2007), the patient might be seen by assisting
health-care personnel, giving protocol-based care including BP measurements, blood
tests, lifestyle advice etc. Patients without special aberrations in test results or BP
readings would meet their GP, for example, once every five years for a re-evaluation of
the treatment and the treatment goals. Although such reorganisation of preventive work
would decrease GPs' workload this would only mean an increased investment in other
positions – an investment that would demand a thorough cost-benefit evaluation.
Patients not “good enough”
Patient adherence to treatment and willingness (motivation and capability) to follow a
physician's advice can explain some of the deviation from guideline recommendations
and treatment goals. These “obstacles” to guideline-adherence may be present on the
individual as well as societal level. A society with high-stress levels and unreasonable
work demands will not only have poor CVD risk profiles (De Vogli et al. 2007; Ferrie
2004), but might also feature decreased opportunities for leisure-time physical activity
and other health-promoting activities. A society of great social inequity may limit the
preventive opportunities for the lower classes. A consumption-focused market society
may nurture materialism, dependence on luxuries, delicacies (high-calorie diet,
overeating, alcohol and tobacco consumption), and simple solutions (drugs and surgery
to lose weight), possibly making the citizens adverse to healthy living and physical
exercise (Fugelli 2003 and 2008; Grimen and Terum 2009). Although such societal
factors may be seen as potential targets for improvement, it can hardly be regarded as
relevant to guidelines. Recommendations on motivation and how to improve individual
adherence to treatment might, however, be addressed. Anyway, for guidelines to be
valid and relevant they must be aimed at the population of interest, not at an ideal or
utopic population. The guidelines must provide useful recommendations for the
population in question. Thus, a discussion of patients not being “good enough” for
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optimal guideline-adherence (though interesting) is of little relevance to guideline
evaluation.
4.2.2. Guidelines not “well enough” made
If we look for limitations outside the “point of delivery” of health care, two obvious
targets must be identified – the guidelines themselves, and the evidence they are based
on. Factors underlying guidelines not being “well enough made” refer to
methodological flaws, misinterpretation of evidence, and failure to translate relevant
evidence into recommendations.
Validity of risk factor definitions
The risk evaluation, the treatment, and the follow-up on patients depend on valid
definitions of specific risk factors, and when relevant, combinations of these (multi-
factorial risk estimates). Errors in definitions and assumptions regarding any of the risk
factors are bound to result in errors or imprecision in the resulting risk estimates. This
will again decrease the value of follow-up measurements by over- or underestimating
treatment effects, with reference to patient-important outcomes (e.g., risk of death).
Paper IV addresses this error, as well as Paper III to a certain degree: The results of
Paper IV indicate that defining obesity / adiposity / body configuration / body
composition as a risk factor according to BMI levels will introduce an error which can
be reduced by using WHR or WHtR instead – at least when considering the ability to
predict patient-important outcomes. Likewise, according to Paper III, defining the risk
factor dyslipidaemia in terms of total cholesterol may turn out to be invalid, but this
problem may possibly be correctable by substituting some other lipid particle(s) for
total cholesterol.
In recent decades there has been a constant trend of lowering cut-offs defining risk
factors, such as BP (see section 2.2.1). Even though the lowering of cut-off points has
been based on the available evidence at the time of redefinition, it inevitably increases
the prevalence of the risk factor and the proportion of the population defined as “at
risk”. Since the association of most risk factors with CVD is not an on-off phenomenon
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but rather a gradient one, it is possible to demonstrate an increase in relative risk to very
low levels of a risk factor if there is a sufficient number of study participants
(Prospective Studies 2002). Theoretically this risk inflation can label the majority of a
population as “at risk” even if the absolute risk is low and, as a result, “normal”
becomes abnormal. I.e., the academic “normal” or ideal becomes rare, and what is
normal or common in the population becomes undesirable (unacceptable) and not good
enough. As an example of this, the risk estimation chart of the 2007 European
hypertension guidelines (Mancia et al. 2007) identifies the lowest risk category
(prehypertension and no other risk factors) as “average risk” and all the other categories
(BP ≥140/90 mmHg and/or coexisting risk factors) as variably “added risk”, without
even defining BP levels below 120/80 mmHg as “low risk”. In a wider perspective, this
phenomenon is further augmented with the simultaneous risk inflation of several risk
factors for various other diseases.
The question remains whether such risk inflation affects the validity of the risk factors
as such. The answer depends on the circumstances. When a continuous variable, such as
BP, is treated as dichotomous (hypertension vs. normal BP), lowering the cut-off point
will increase the sensitivity of the risk factor and decrease the specificity. Thus, the
ability to adequately identify “high risk” individuals is likely to decrease.
Validity/relevance of included risk factors
Defining the risk factors “correctly” is not always enough. It is of fundamental
importance that the risk factors included in risk estimates, discussed in guidelines, and
recommended as targets for medical intervention are in fact valid and relevant - valid as
risk factors for the disease in question and relevant as treatment targets. Paper III
discusses the validity of total cholesterol as a risk factor for CVD.
For any factor to be valid for inclusion in a combined risk estimate, it has to improve
the predictive ability of the prediction model. It does not necessarily have to be a “true
risk factor” in the sense of a causal factor. Statin use may, for example, be useful in a
model applied to the general population to predict CHD events, even though statin use
is not a causal factor, because statins are primarily used among individuals at
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considerably higher risk of CHD than the general public. The results of Paper III
indicate that total cholesterol may not be valid as it is currently used in most combined
risk estimates. The possibility arises that total cholesterol is merely a risk marker rather
than a risk factor.
For risk factors (or markers) to be valid as targets of intervention, an effective treatment
to lower the risk factor levels has to be available, and the effect has to be reflected in
decreasing incidence in patient-important outcomes. Statins are the only treatment
option demonstrated decisively to lower both total cholesterol and mortality (see section
2.2.2). Lowering cholesterol to a certain level with statins is more effective, regarding
patient-important outcomes, than reaching the same cholesterol level with any other
drug. The fact that statins have a range of documented effects, other than lowering
cholesterol (Meng 2005; Vaughan et al. 1996), inhibiting atherosclerosis and
atherothrombosis supports the hypothesis that cholesterol lowering in itself might be of
little causal importance. Thus, total cholesterol may not be valid as a target of therapy
and might perhaps be abandoned as such in the future. Replacing it with a different lipid
particle (such as LDL or ApoB) might be a relevant step.
Current guidelines of CVD prevention lump together a number of clinical outcomes
related to coronary circulation as well as the peripheral circulatory system. Emerging
evidence suggests that the impact of cholesterol as a risk factor/marker might not be the
same for IHD and cerebral stroke (Hamer et al. 2011; Prospective Studies 2007). There
is indeed a possibility that cholesterol will in the near future be proven to have partially
different roles in (or related to) the pathogenetic processes of heart and brain vascular
diseases. If this is so, clinical advice related to preventing one outcome (IHD) may not
have the same validity for the other and, to many people, even more threatening clinical
outcome (cerebral stroke).
Validity/relevance of excluded risk factors
As discussed in section 2.2.4 there is much evidence available on various risk factors
that are discussed in the guidelines only to a small degree or not at all, not to mention
their inclusion in the risk estimates. Some of these are of limited relevance for practical
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reasons, e.g., “risk genes” with low prevalence and/or penetrance (Levely et al. 2011),
and markers that are difficult or expensive to measure, such as apolipoproteins
(Sniderman et al. 2003) and air-pollution (Zhang et al. 2011). However, there are some
risk factors that guideline authors tend to exclude that might be relevant. These factors
may be deemed irrelevant or impractical for recommendations, or the authors might
simply not be aware of their significance. Low socioeconomic status has been shown to
be an important risk factor for CVD (Marmot et al. 1984 and 2008) but is hardly ever
included in risk calculators and rarely discussed in guidelines. Recommendations on
interventions for improving SES (or inequity in a society) would of course be beyond
the scope of guidelines on CVD prevention, but information on SES is likely to improve
the risk estimate (Hippisley-Cox et al. 2010).
Substantial discussion of psychosocial factors is hard to come by in the guidelines. The
2007 European hypertension guidelines (Mancia et al. 2007) studied in Paper II are a
good example of this. The reference list of the guidelines includes 825 references, none
of which discuss psychosocial risk factors. The discussion is often limited to
recommending that depression and anxiety disorders might affect risk and should be
treated. Such recommendations often get lost in these reports, which tend to be of
considerable length. The importance of stress and existential trauma is rarely addressed,
and the 1962 WHO recommendations of “common-sense psychotherapy” for essential
hypertension (WHO 1962) are long forgotten. This is, however, not always the case,
and I see signs that the situation is improving. The Norwegian CVD prevention
guidelines, for example, explicitly state that psychosocial factors such as low SES, poor
social network, existential trauma, and high stress levels increase the risk of CVD (as
depicted by the risk estimation chart), and recommend interventions where appropriate
(Norheim et al. 2009).
Co- and multimorbidity is another important aspect seldom addressed by guidelines'
authors, apart from that of existing renal disease and diabetes (Boyd et al. 2005;
Starfield 2011). Multimorbidity is a growing problem in the aging Western populations
that needs to be considered in therapeutic management of patients (Boyd and Fortin
2010; Parekh and Barton 2010). Addressing multimorbidity specifically in the CVD
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prevention guidelines may lead to recommendations on a more aggressive therapeutic
approach to a patient with multiple comorbidities because the comorbidities may
potentially increase the risk of CVD. Alternatively, less aggressive medical intervention
may be recommended due to the risk of polypharmacy and adverse effects. Parekh and
Barton state:
The tremendous efforts in the fight against chronic disease have inadvertently created
individual disease “silos,” which are reinforced by specialty organizations, advocacy
groups, disease management organizations, and government at all levels.
Transformation from a single chronic condition approach to a multiple chronic
conditions approach is needed (Parekh and Barton 2010:1304).
The “silo” approach strikes me as an excellent metaphor for describing the scope of
most preventive, clinical guidelines and recommendations. Disease specific mortality
and morbidity is consistently emphasised, while all-cause mortality is hardly ever
mentioned. To GPs and patients, however, the statistical endpoint death, irrespective of
cause, may be a good starting point for a nuanced discussion of potential medical
interventions. The “silo-vision” may easily lead to dilemmas when multiple guidelines
targeting multiple diseases in a single individual are not easily combined because of, for
instance, drug interactions. The situation is further enhanced by specialists, patient
organisations and other stakeholders who compete to draw attention to “their” disease.
In its ultimate consequence, the “silos” may come to overshadow the individual
persons’ unique situation and needs. Important factors might become excluded from
consideration by one silo specialist because they are dealt with in guidelines which
pertain to another disease silo.
Validity of combined risk estimates
The combined risk estimate, originally developed by the Framingham research team, is
an intuitively appealing idea which is currently recommended in most CVD guidelines.
However, current international risk algorithms appear to have limited validity and
relevance for general practice, at least in Norway and possibly in many other countries
as well, if the results of Papers I-II are generalisable to similar contexts. These risk
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algorithms appear to offer good sensitivity for the high-risk individuals but poor
specificity. For a risk algorithm to be valid for use in a specific population it has to be
based on representative data. The data has to be considered in the context of time and
geographical origin, reflecting factors such as mortality rates, economy, pollution, and
quality of health care systems – i.e., factors confounding the associations of traditional
biological risk factors with CVD incidence/mortality on a population basis. The
European SCORE risk algorithm (Conroy et al. 2003) is, for example, based on 76
cohorts from 12 countries and data gathered in the 1970s and 1980s. This seriously
affects the validity of the algorithm in any population 30-40 years later.
National algorithms based on local data may possess considerably better predictive
properties but, as discussed in Papers III-IV and in the paragraphs here above, these
algorithms might also have significant, correctable, inherent errors. Careful critical
appraisal of the current risk factor definitions (including cut-offs), and the validity and
relevance of the risk factors included as well as those not included might raise the
predictive value of the algorithms to higher standards. Action levels (risk levels where
intervention is recommended) also have to be carefully evaluated in association with the
workload likely to result.
A recent systematic review (Liew et al. 2011) reported some additional limitations of 21
CVD risk scores studied. The risk scores differed considerably in terms of population,
predictors and outcomes, making them non-interchangeable. Some of the algorithms
were based on cohorts with missing data on specific risk factors for substantial
proportions of individuals, sometimes over 60% (Liew et al. 2011). And, thirdly, effect
of treatment (i.e., treatment at baseline or treatment “drop-in”) was not considered fully
by any of the algorithms, which might cause an underestimation of risk, especially in
the high risk category.
In a wider perspective, alternatives to the combined risk estimate approach have been
suggested. In 2003, Wald and Law suggested an approach to CVD prevention more
resembling a mass strategy than a high-risk approach (Wald and Law 2003). They
suggested the development of “the polypill”, which would combine six active
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components (statin, thiazide, β-blocker, ACE-inhibitor, folic acid, and aspirin) in one
pill and could lower the individual CVD risk considerably. They suggested the polypill
be recommended for every adult above age 55 and younger people with symptoms of
occlusive arterial disease. No measurements of BP or cholesterol would take place,
either before treatment initiation, or for monitoring the treatment. This way the CVD
burden of the population as a whole would be significantly decreased, and more so than
by focusing specifically on high-risk individuals. At the same time, resources would be
saved by dropping the usual screenings and follow-ups, making this approach more
cost-effective on the whole than the usual approach. The main problem with this
method is that for some individuals the risk of adverse effects of the intervention would
be higher than the potential benefit, which would violate the primum non nocere
principle. According to Wald and Law, this would be rare (Wald and Law 2003).
Identifying those unlikely to benefit from the polypill (i.e., those with low CVD risk)
might be suggested, but that brings us right back to the starting point with screening for
high-risk individuals.
Although the polypill strategy has some important flaws and currently seems an
unlikely or inappropriate option, it is thought-provoking and challenges the current
standards; such challenges are necessary for progress in the field. Age is by far the most
important risk factor and adding more and more risk factors to a statistical prediction
model already including age, no matter how good the model is, cannot improve the
prediction (discrimination) more than a few percent (Cook 2007; Wald and Law 2003).
CVD risk algorithms have an (unidentified) upper limit of positive and negative
predictive value, and it does not seem to be very close to 100%. It will always be a
judgement call whether the improvement in prediction, obtained by measuring risk
factors, is worth the resources invested.
Non-adherence to EBM principles
Although clinical guidelines are often touted as “EBM-documents”, significant
deviations from the principles discussed in section 2.3 are often to be found. Guidelines
on prevention of CVD vary considerably in this regard. The 5-step summary of how to
97
develop EBM-guidelines provided in section 2.3.2 can act as a simple guideline-
evaluation tool.
1. Define questions to be addressed
The defined clinical question is not always clear enough regarding the relevant patient
groups, all relevant management options, and all relevant outcomes. Guidelines on
primary prevention of CVD usually do not exempt patients with comorbidities (other
than CVD) but rarely address practical considerations such as frailty and polypharmacy,
the exception being pregnant women and patients with diabetes or renal disease
(Graham et al. 2007; JNC 2003; Mancia et al. 2007; Norheim et al. 2009). Treatment of
the elderly is usually discussed without considering comorbidities (Boyd et al. 2005).
Discussion of psychosocial risk factors and appropriate management options tends to be
minimal or none at all (JNC 2003; Mancia et al. 2007) although this is not always the
case (see, e.g., the 2009 Norwegian guidelines (Norheim et al. 2009)). Regarding
outcomes, guidelines tend to address the adverse effects of preventive treatment (see
chapter 4.3) only to a very limited degree (including inconvenience and psychological
burden), at least not in a transparent manner.
2. Critically appraise available systematic reviews and/or prepare new ones
Discussion of systematic reviews is often inadequate which makes it difficult to
evaluate how extensive the literature search has been, and whether all relevant issues
have been addressed (see, for instance, Graham et al. 2007; Mancia et al. 2007).
3. Assess the relative importance of outcomes
Assessment of the relative importance of outcomes depends on (all) the relevant
outcomes being clearly and explicitly defined in the first place, which is usually not the
case. Thus, this assessment is rarely transparent.
4. Prepare an evidence profile
Clear, schematic evidence profiles are extremely rare in CVD prevention guidelines.
Invariably the guidelines present a narrative (and/or schematic) summary of the
evidence supporting specific recommendations. This presentation often lacks
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information on absolute risk (reduction). The guidelines depend on various systems for
grading the evidence and information on limitations (of the evidence presented) is often
lacking.
5. Assess the quality of evidence and decide on the direction and strength of
recommendations
Since evidence profiles are usually incomplete or not presented at all, the assessment of
the quality of the evidence is not transparent, and decisions on the direction and strength
of recommendations become difficult to evaluate. The evaluation becomes even more
difficult since guideline authors rarely adequately state the relative importance of
outcomes and the values and preferences on which the recommendations are based.
Additionally, discussion on the resource use associated with the implementation of the
guidelines is often scarce (Graham et al. 2007; JNC 2003; Mancia et al. 2007) or
underestimated (Getz et al. 2004 and 2005). This is especially important when certain
recommendations seem to be based on expert (guideline authors') opinion to a large
extent, rather than objective evidence. An example of this is the recommendations on
the rate of follow-up visits given in the 2007 European hypertension guidelines (Mancia
et al. 2007) where no references are cited on this matter. While issues of resource
allocation do not receive much attention, guideline authors rely rather on predictions of
cost-effectiveness, which are usually of debatable validity (Järvinen et al. 2011).
4.2.3. Evidence not “good enough”
The third potential source of limitations of the guidelines is the available evidence they
rely on. The evidence may be inadequate to support the recommendations of the
guidelines; an evidence-gap may exist in important areas, and the current mainstream
interpretation of the available evidence may not be adequate to serve the task of
prevention as well as possible.
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“Pharmaceutical bias”
The pharmaceutical industry has broad-based influence on medical research and
practice. It is widely documented that industry-sponsored drug trials tend to yield more
positive results for the drug and the pharmaceutical companies involved (i.e., show
more effect) than trials with independent sponsors (Lexchin et al. 2003; Schott et al.
2010). Pharmaceutical companies have been found to deliberately avoid publishing
negative results and making the data unavailable for analysis by independent
researchers (Ghaemi et al. 2008). Further impact on practice is gained by advertising
campaigns directed at doctors and patients (HEART UK 2011; Under 5 2011), and
direct (financial) incentives to doctors, guideline authors, and policy-makers (Moynihan
2006 and 2010; Neuman et al. 2011). In addition, the pharmaceutical industry, as well
as providers of other medical supplies and technology, is a major contributor to medical
research. Obviously the industry will focus on trials for advertising and justifying use of
their products, reflected in study designs and research fields. The synergy of all these
factors causes an enormous pharmaceutical bias in research and practice. The result is
more evidence production in profitable research areas, compared with less profitable
ones (non-pharmacological treatment); bias of the available evidence in favour of drug
treatment; influential actors (politicians, guideline authors, etc.) have conflicting
interests (Moynihan 2006 and 2010; Neuman et al. 2011); patient organisations demand
“the best” (new and/or expensive) treatment options and tests available; and physicians
are bombarded with selective information (HEART UK 2011; Moynihan 2010; Under 5
2011).
Like any manufacturer of any other product, a pharmaceutical company benefits from
increasing the number of its customers. This can be done by increasing the company's
share of the existing market (marketing campaigns, etc.) or by enlarging the market. By
widening the definitions of a disease or a risk factor (wider indications for drug use), the
potential market can expand enormously. This has happened in many areas, such as BP-
and cholesterol-lowering treatment. The JUPITER trial (Ridker et al. 2008) is a good
example of this kind of a marketing strategy. Thus, the pharmaceutical industry can
affect the definitions of risk factors (Moynihan 2006), diseases, and “pre-diseases”
(Moynihan 2010). This is a form of medicalisation and disease mongering.
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Surrogate end-points
Trials of preventive interventions are often designed to document drug effects on
surrogate end-points, since (statistically significant) effect on mortality may take many
years to document, while effect on, e.g., BP may take only weeks to detect. Popular
surrogate markers are, e.g., BP, cholesterol, and carotid intima-media thickness (on
ultrasound). While this decreases the time and costs necessary to conduct a trial, it also
decreases the validity of the results. Although LDL, for example, is a documented risk
factor for CVD and mortality, and many drugs have been shown to lower LDL, only
statins have been shown to decisively reduce mortality (see section 2.2.2). Thus, an
effective reduction in a risk factor does not necessarily translate into reduction in
mortality. Basing guideline recommendations on evidence of risk factor lowering but
not effect on mortality or CVD events can introduce bias.
Combining fragmented knowledge
It is obviously beneficial to minimise potential confounding effects in any research.
When studying the effects of a certain drug on a specific risk factor or mortality, it can
be beneficial to “isolate” the effects of the drug in question, e.g., by including only
healthy participants not using any other drugs. However, such results can only be
generalised to similar populations of healthy individuals. But clinical reality is far more
complex (Strand et al. 2004). Inevitably, many patients evaluated for CVD prevention
will have other chronic conditions with associated drug treatment, such as asthma,
osteoporosis, arthritis, pain syndromes and depression. The guidelines recommend the
same BP and cholesterol lowering treatment for everyone. Prescriptions that are
initiated or recommended by different disease specialists (or guidelines) can, however,
result in polypharmacy, which may prove suboptimal or even harmful with respect to
some patients' overall health and safety (Boyd et al. 2005; Schuler et al. 2008). This
problem is seldom addressed and documented in clinical trials. Of course, an RCT
cannot be conducted for every combination of drugs and diseases, but great caution
should generally be shown when “lumping together” disease-specific drug regimens in
individuals with co- and multimorbidities. Polypharmacy, as widely practiced today, is
not in accordance with the standards and principles of EBM.
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Polypharmacy is just one of the problems associated with combining pieces of evidence
obtained from narrowly focused research. The mainstream biomedical research method
is to defragment the human being in a Cartesian way (Getz 2006) and combine again the
pieces of evidence obtained. Although regarded methodologically correct, this may not
lead to the right conclusions. The lipid-lowering drug ezetimibe can be taken as an
example. Even if ezetimibe has beneficial effects on the lipid profile, it does not mean
that it will have a beneficial effect on CVD development in a specific individual in his
context of social surroundings, risk factors, diseases, and drugs.
Combined risk estimates can be regarded as another example. Linear relationships
between risk factors and disease are assumed, without studying the possibility of, for
instance, U-curve phenomena, and the risk factors combined in a mathematical
prediction model. Even though the details of the models are correct, from a certain
perspective, the predictive ability of the model has to be checked thoroughly for
validation in the target population. Such validation analyses do not always precede the
implementation of the risk estimates.
Cost effectiveness analyses are important for supporting recommendations of the use of
therapeutic interventions – i.e., comparison of the cost of the treatment versus the direct
and indirect gain, such as decreased mortality, morbidity, and hospitalisation. The
majority of the available cost effectiveness analyses are, however, subject to
considerable bias. Usually these are statistical cost prediction models based on the
results of RCTs (with selective inclusion criteria, etc.), not representing the clinical
reality of general practice (Järvinen et al. 2011). Such cost effectiveness analyses are
thus likely to overestimate the benefit of the treatment, which may affect the validity of
recommendations.
Evidence gaps in important areas
There appears to be an evidence gap regarding certain aspects of CVD and prevention.
This is especially the case in non-pharmacologic intervention and the humanistic
aspects of cardiovascular illness aetiology. Section 2.2.4 discusses themes where an
abundance of research opportunities seems to exist. Interventions for allostatic-
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overload, for violated integrity and traumatic life-events have only to a small degree
been addressed in the context of CVD. Perhaps it is time for a serious evaluation of the
role of narrative-based medicine and “common-sense psychotherapy” (WHO 1962) in
CVD prevention. These interventions are, however, not immediately suited for RCTs,
and they do not attract much interest from industrial sponsors.
“Vulgar Cochranism”
The recently introduced concept Vulgar Cochranism has been discussed in detail in
section 2.3.4. Vulgar Cochranism does not refer to inadequate evidence as such, but
rather to presumptuous and erroneous use of evidence. First, available evidence may be
applied beyond the range of its validity (combining fragmented knowledge, see above).
Second, there is excessive emphasis on RCTs and pharmaceutically biased evidence,
downgrading non-pharmacological interventions and evidence involving structural,
societal phenomena and psychosocial risk factors. The evidence gap discussed above is
exaggerated and ignored at the same time by overlooking the available evidence in the
field as well as the research opportunities. Third, the role of clinical expertise of
(general) practitioners (for whom the guidelines are intended) is devaluated and, with
aggressive assertiveness, attempts to adjust the guidelines to clinical reality are met with
labels such as clinical inertia. Vulgar Cochranism is overbearing, and criticism of
guidelines' shortcomings is not well tolerated.
4.3. Adverse effects of prevention
It is a common view that prevention is better than cure. This is often true, but not in a
general sense at any cost. CVD prevention can be expensive – for the individual, the
health care system, and society, both in terms of money and other resources, such as
physicians' consultation time (see Paper II). For interventions to be recommended by
guidelines, they preferably have to be estimated as cost-effective. However, health care
systems do not have unlimited resources, and choices have to be made regarding which
projects to invest in and to what degree. It seems obvious that to increase the resources
invested in CVD prevention, cuts have to be made in other areas, even if the prevention
is highly cost-effective. Before criticising physicians for clinical inertia and demanding
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better guideline adherence, policy makers and guideline authors should perhaps suggest
activities in general practice that can be decreased or abandoned.
In addition to direct pharmacological side-effects and drug interactions, preventive drug
prescription exposes individuals to another potential health hazard which has not
received much attention: the nocebo effect of being labelled as “a patient”, as well as of
consuming tablets, possibly without any obvious subjective (or objective) benefit
(Barsky et al. 2002; Hahn 1997; Haynes et al. 1978; McCormick 1998; Olshansky 2007;
Sångren et al. 2009).
The exponential increase in papers published on risk in recent decades, and the
accompanying increase in defined risk factors, has been called “the risk epidemic”
(Skolbekken 1995). Due to the epidemic of inflating risk factors, fuelled by enthusiastic
biomedical reductionism and Vulgar Cochranism, everybody seems to becoming at risk
of being diagnosed as at risk. It can hardly be practical to label the majority of the
population “at increased risk”, and ethically doing so is highly questionable. Mass
stigmatisation is hardly a good preventive strategy. In the end “life itself is a universally
fatal sexually transmitted disease” (McCormick 1998:166), and the risk of death and
disease cannot be reduced to naught. A responsible and sustainable preventive strategy
has to allow for a realistic level of acceptable risk. “The Zero-vision” is harmful to
preventive medicine and harmful to the health of the population (Fugelli 2003 and
2006).
Those practicing Vulgar Cochranism usually do not take these adverse effects into
account when estimating cost-effectiveness and demanding implementation of
“evidence-based treatment”.
The harmful effects of preventive interventions and their excessive use have raised
voices of concern (Starfield et al. 2008). An emerging concept called quaternary
prevention has even been defined as an important task of GPs (Kuehlein et al. 2010).
Referring to the dangers of excessive medical activity, quaternary prevention is defined
as: “an action taken to identify a patient at risk of over-medicalization, to protect him
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from new medical invasion, and to suggest to him interventions which are ethically
acceptable” (Bentzen 2003). The World Organization of Family Doctors (WONCA) has
identified excessive implementation of interventions for therapeutic and preventive
purposes, often with little or uncertain effect, as a real threat to the health of patients and
populations that needs to be addressed and considered in clinical practice (Kuehlein et
al. 2010; Starfield et al. 2008).
4.4 Conclusion
In theory, clinical practice guidelines on prevention of CVD offer an excellent
opportunity for education and quality improvement in general practice. However, there
currently appears to be a range of factors limiting the validity and relevance of such
guidelines, at least in Norway. Such limitations may have important effects on clinical
practice and resource allocation, as well as population health. The guidelines appear to
overestimate CVD risk and fail to correctly identify a manageable proportion of the
population as “high-risk individuals”, for whom individual preventive strategies would
be effective and beneficial. The strategy of targeting individuals at risk (“high-risk
strategy”) ends up being recommended at the level of mass strategy, which can hardly
be regarded as sustainable or responsible.
Many factors limit the validity and relevance of current guidelines for prevention of
CVD in general practice. The factors I deem most important can be summarised in three
terms: Vulgar Cochranism, silo-vision, and zero-vision. Vulgar Cochranism refers to the
presumptuous use of evidence, applying trial results and conclusions outside their range
of validity, as well as arrogance and aggressive assertiveness leading to an almost
unconditional justification of recommendations based on evidence that has been
selectively defined as the most (or only) valid evidence. Subsequently, adherence to
these recommendations may be regarded as morally and even legally mandatory, and
non-adherence is harshly criticised. Silo-vision further adds to the problems of Vulgar
Cochranism, with its narrow focus on a specific disease or a group of diseases (such as
CVD) without addressing the person as a whole, ignoring important factors such as
multimorbidity and polypharmacy. Silo-vision can lead to the exclusion of significant
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factors, such as mental stress and social circumstances, based on subjective
interpretation and preferences (of guideline authors) alone. Finally, zero-vision may
lead to unattainable goals being set. For instance, the elimination of premature CVD
mortality, say, death before age 70 in Norway, may sound like an appealing goal, but it
is hardly realistic when resource allocation is considered.
Vulgar Cochranism, silo-vision, and zero-vision are factors involving mentality and
culture and are, therefore, not easily altered. However, many factors have been
addressed in this thesis that may prove less resistant to improvement efforts. These
include, e.g., considering psychosocial risk factors in combined risk estimates,
depending on evidence of patient-important outcomes rather than surrogate end-points,
and re-assessing the validity of risk factor definitions, such as defining obesity with
measures of central adiposity rather than with BMI.
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5. WAYS TO IMPROVEMENT - A PROPOSAL
I see considerable room for improvement when it comes to clinical guidelines on CVD
prevention in general practice. Some aspects might be significantly improved by
relatively simple (yet potentially controversial) manoeuvres, including altering cut-off
points to diminish the at-risk groups. Other aspects would require more fundamental
change in thinking about the problem of CVD as a whole.
I regard eliminating Vulgar Cochranism to be of highest priority, not only to ameliorate
clinical guidelines as such but also to safeguard the academic integrity of medicine in
general. Vulgar Cochranism is, by definition, not in accord with good academic
practice. Selectively down-grading or even excluding certain types of evidence and
research fields is ethically unjustifiable and cannot be practical in the long run.
Likewise, aggressively asserting favoured evidence, stigmatising colleagues as
“clinically inert” and attempting to tyrannise professionals who raise critical voices is
not consistent with academic openness and debate.
General improvement in the understanding of what evidence-based medicine really is
and is not is needed among many professionals and policy-makers. It is also time for
researchers and practitioners to raise their awareness above narrow silo perspectives on
diseases and risks. I certainly acknowledge that silo-vision may be helpful, or even
necessary, in many situations, particularly in organ-specialised hospital wards. But in
primary health care silo-vision cannot be defended as a general approach. All
stakeholders in the healthcare system must respect this fact. Furthermore, the silo
approach is inadequate as a main approach in scientific medicine; since it is not
compatible with real patients' lives, too much reliance on the approach is logically
bound to limit advancement in the field. For optimal treatment of a person's health
profile (illness, risk and disease pattern), understanding the whole person in his or her
context is necessary. This comprehensive view includes the person's biological status,
past and current life stressors, and social and cultural surroundings. New evidence is
currently emerging which facilitates a much deeper understanding of the
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interdependency of all these factors. Research in epigenetics and stress physiology
(including the concept allostatic load and research on the dynamics of the chromosomes'
telomeres) offers an unprecedented possibility to understand, for instance, how mental
stress and/or integrity violations fuel the development of diseases in general and CVD
in particular. This new evidence may also contribute considerably to explaining the
fundamental and general relationship between social inequity and health. In the 2001
Harveian Oration, Iona Heath asks:
The socio-political construction of health inequality has become undeniable (Holtz et al.
2006). As society becomes ever more economically polarised, health is systematically
damaged by the structural violence this entails and yet governments still appear to
believe that health inequality can be tackled in isolation from the socioeconomic
inequality that drives it. Doctors have seemed content to collude in this offloading of
responsibility through the rhetoric of ‘lifestyle medicine’ (Porter 2006), a sophisticated
variant of the age-old game of victim-blaming. Paul Farmer argues that the central
contributions of medicine and public health to ‘future progress in human rights will be
linked to the equitable distribution of the fruits of scientific advancement’ (Farmer
1999). How can we ensure that this is taken to apply to scientific advances in the
biology of biography just as much as to advances in biotechnology? (Heath 2011:18-19)
Continued adherence to the silo-vision would typically lead to focusing on
pharmaceutical interventions to counteract telomere erosion, instead of increasing
human support to care-givers of chronically ill patients, whose telomeres statistically
tend to erode faster than “normal” (Heath 2011).
The zero-vision is in line with Vulgar Cochranism and silo-vision. It fits poorly with
true EBM and person-focused care. With a change in the approach to CVD (and other
chronic diseases), where issues like quality-adjusted life-years, resource allocation, and
opportunity cost would become more important than ICD codes for causes of death, the
zero-vision would  be bound to fade.
Significant improvement regarding the above-mentioned factors would depend on
fundamental change in the mentality of mainstream medicine: the overall focus needs to
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be shifted away from the biotechnological approach to the “average body”, to a more
holistic approach to the unique person. If I am challenged to present recommendations
on a more immediate and practical level, directly related to improvement of the validity
and relevance of CVD prevention guidelines for general practice, I suggest the
following set of relatively demarcated issues:
1. Transparency is crucial at all levels of guideline development, regarding the
authors' conflicts of interest, the methods of guideline development, the critical
appraisal of evidence, the values and preferences behind the recommendations,
etc.
2. Adherence to a comprehensive, structured, and explicit system of guideline
development, such as the GRADE system, may offer considerable advantages
and decrease the likelihood of important issues being ignored. Such adherence
includes:
a. a well-defined question should be addressed covering all relevant patient
groups (including the elderly and multimorbid), all relevant interventions
(including non-pharmacological), and all relevant patient-important
outcomes (including all-cause mortality, morbidity, and adverse effects);
b. conducting a systematic review (or relying on an existing one);
c. quality assessment of the available evidence;
d. transparent assessment of all the relevant harms and benefits of
interventions that the recommendations cover.
3. Adverse effects of interventions should be explicitly considered, including the
harm of labelling subjectively healthy individuals as patients “at risk”.
4. Efforts should be made to limit “pharmaceutical bias”, by identifying and
highlighting non-pharmacological intervention strategies and minimising
conflicts of interest among guideline authors.
5. Evidence of effects on surrogate markers should not be regarded as equivalent to
(or likely to be equivalent to) effects on patient-important outcomes.
6. Re-assessment may be needed of the validity of definitions of certain risk
factors, such as the use of BMI levels to define obesity.
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7. Re-assessment of the validity and relevance of risk factors addressed in the
guidelines is warranted; the use of total cholesterol is a good example.
8. An extensive assessment should take place of the validity and relevance of risk
factors that tend to be excluded from the guidelines, including mental stress and
low SES.
9. Combined risk estimates should be validated in any given population before
recommended for implementation.
10. Resource use has to be thoroughly addressed. Preferably, resource use should be
discussed in relation to issues such as disease burden, quality-adjusted life-years,
all-cause mortality, and opportunity cost.
This is not an exhaustive list but my recommendations on possible ways to improve the
validity and relevance of guidelines on prevention of CVD for general practice.
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Abstract
Rationale, aims and objectives Clinicians are generally advised to consider several risk
factors when evaluating patients’ cardiovascular disease (CVD) risk. Our aim was to study
whether combined assessment of ﬁve traditional risk factors might help doctors demarcate
a relatively distinct and manageable group of high-risk individuals. We selected ﬁve
modiﬁable risk factors and estimated the proportion of a well-deﬁned population with
‘unfavourable’ levels of at least two of them, as deﬁned by four internationally renowned
guidelines. The impact of including so-called ‘prehypertension’ among the risk factors was
speciﬁcally addressed, and the results are discussed in a wider perspective.
Material and methods Guideline implementation was modelled on data from a cross-
sectional Norwegian population study comprising 62 104 adults aged 20–79 years (The
Nord-Tröndelag Health Study 1995–7). Total, age- and gender-speciﬁc point prevalences of
individuals with zero, one, two, three or more factors, in addition to established disease,
were calculated.
Results One single CVD risk factor was exhibited by 12.4% of the population; two factors
by 21.5%; and three or more by 49.7%. Established CVD or diabetes mellitus was reported
by 12.5%. In total, 83.7% of the population exhibited a risk or disease proﬁle with at least
two factors, if prehypertension was included.
Conclusions If guideline recommendations are literally applied, as many as 84% of adults
in Norway could exhibit two or more CVD or risk factors and thus be considered in need
of individual, clinical attention. This challenges the widely held presumption that ‘the net
will close’ around a manageable group of individuals-at-risk if several risk factors are
jointly considered. As the ﬁnding of this study arises in one of the world’s most long- and
healthy-living populations, it raises several practical as well as ethical questions.
Introduction
Cardiovascular disease (CVD) is currently the major cause of
death in the Western world, including Europe (see e.g. http://
www.heartcharter.eu). Mortality from CVD has, however,
declined substantially since the 1970s [1], and many Western
populations appear to be undergoing the resolution phase of a
so-called 20th-century epidemic of CVD. This epidemic report-
edly began in the 1930s and peaked in the 1950s and 1960s. The
epidemic’s impact on medical thought and practice has been pro-
found, but still, the reasons behind the rise and fall of CVD in the
20th-century are far from clear [2]. In view of the new ‘epidemics’
of obesity and diabetes, there is a widespread concern that the
burden of CVD will start to rise again.
Large-scale medical searches for factors that could predict
future heart disease began shortly after World War II with the
Journal of Evaluation in Clinical Practice ISSN 1356-1294
© 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd, Journal of Evaluation in Clinical Practice 15 (2009) 103–109 103
establishment of the US Framingham study. Around 1960, hyper-
tension, hypercholesterolemia and smoking were singled out as the
three most apparent risk factors for ischaemic heart disease. Since
then, increasingly detailed knowledge regarding the impact of
numerous measurable and potentially modiﬁable biological risk
factors and risk markers has been published [2]. Development and
marketing of tolerable and presumably safe antihypertensive and
lipid lowering drugs have contributed much to the immense inter-
est in CVD prevention among researchers and clinicians.
In 1962, the World Health Organization published the ﬁrst inter-
national report on the importance of blood pressure control [3].
After this milestone publication, subsequent generations of clini-
cal recommendations and guidelines regarding blood pressure as
well as a steadily increasing number of other measurable risk
factors have been released on both sides of the Atlantic [4–13].
With time, the thresholds for clinical intervention on the basis of
single risk factors have been lowered several times. Redeﬁnition of
a risk factor cut-off point inevitably leads to a corresponding
change in the number of individuals that will be categorized as ‘at
risk’ and in need of clinical attention [14,15]. In 2004, our research
group documented that implementation of the 2003 European
guidelines on CVD prevention could label as much as 76% of a
general Norwegian population aged 20 years and older, and 90%
of individuals aged 50 years and older, as having unfavourably
high cholesterol and/or blood pressure levels [15]. Arising in the
context of one of the world’s longest-living and healthiest-living
populations [16], this ﬁnding was highlighted in an editorial in the
British Medical Journal [17]. A heated debate followed on the
BMJ website [17]. Key authors of the European guidelines entered
the debate and stated that the focus on single risk factors repre-
sented a startling lack of understanding, and argued that the Euro-
pean guidelines would not lead to medicalization of whole
populations since CVD risk should in practice be evaluated on the
basis of a combined risk factor estimate. This advice was (and still
is) in line with mainstream clinical recommendations for good
practice [7,9,13]. The crucial question, however, is how well-
combined risk evaluation strategies actually work in practice. Will
they, as intended, aid clinicians to deﬁne a relatively well-
demarcated and manageable high-risk group who can be targeted
for further follow-up?
Formal, combined risk calculators
From the viewpoint of the practicing clinician, there are in prin-
ciple two ways of performing a combined CVD risk evaluation.
The ﬁrst method involves a formal ‘risk prediction algorithm’ or
‘calculator’ developed on the basis of epidemiological outcome
data. The level of a given individual’s conventional risk factors
(modiﬁable, such as blood pressure, cholesterol and smoking; and
unmodiﬁable, i.e. age and gender) will be fed into the algorithm
and result in a computed estimate of risk (for disease events or
mortality). The ﬁrst algorithm of this kind was based on the US
Framingham study [18]. The Framingham model has later been
updated and adjusted for use both in the United States and in
Europe. In 2003, a European risk system called SCORE (System-
atic Coronary Risk Evaluation) was launched, based on data from
12 European cohort studies recruited from the 1970s on [9,19,20].
In 2003 and 2007, European guidelines on CVD prevention based
on the SCORE system have been published [9,12].
Although a combined risk approach may often represent an
adequate, general approach to CVD risk evaluation, the clinical
implementation of combined CVD risk algorithms has encoun-
tered problems. It has been well documented in a variety of
settings that both the US Framingham and the European SCORE
models may lead to signiﬁcant overestimation of risk [9,12,21–
23]. In 2005, our research group went on to document that imple-
mentation of the SCORE risk system, as outlined in the 2003
European guidelines on CVD prevention, could also label a major-
ity of the above-mentioned Norwegian population as in need of
‘maximal clinical attention’ due to high combined risk [21].
The main reason for the risk calculators’ tendency to statisti-
cally overestimate risk is most likely the previously mentioned
epidemiological decline in CVD incidence leading to a so-called
‘retrospective risk bias’ [12,21]. To tackle this dilemma, guideline
authors recommend that risk calculators be calibrated against
national data. But even in the presence of mathematically valid
risk calculators, the size of the high-risk group might still be so
large as to represent a major challenge.
Consideration of multiple risk factors
Clinicians who do not have access to a calibrated and validated
risk calculator for use in their local setting are likely to apply a
more straightforward approach to combined risk evaluation. The
typical case would involve an otherwise healthy person who pre-
sents with a moderately increased blood pressure, or a moderately
increased cholesterol. In this situation, the doctor may or should,
according to guidelines, consider the level of other risk factors
before deciding on further action. The presence of more than one
elevated risk factor (beyond the currently recommended cut-off
point) would strengthen the argument for clinical intervention,
while absence of additional risk factors might justify a more
expectant approach.
The aim of the present study was to examine the practical
usefulness of the latter CVD risk evaluation method from a clinical
viewpoint. We selected ﬁve modiﬁable risk factors, and with ref-
erence to recommended cut-off points in four internationally
renowned guidelines, studied what proportions of a given Norwe-
gian population would exhibit ‘unfavourable’ levels of at least two
of them. In our analysis, we speciﬁcally addressed the emerging
risk (or literally pre-risk) factor called ‘prehypertension’ (120–139/
80–89 mmHg) which has been included in some guidelines since
2003 [8]. Other more recent guidelines avoid using this ambigu-
ous, medical term. They label a blood pressure level of 120–129/
80–84 mmHg as ‘normal’, but indicate that it is not optimal. The
level 130–139/85–89 mmHg is termed ‘high normal’ [9,11,13].
Whatever terminology used, blood pressure in the ranges 120–
139/80–89 have attracted increasing attention as a risk factor for
CVD among researchers and clinicians in the ﬁeld of CVD
prevention [24–26].
Materials and methods
Based on data from a large and well-organized Norwegian popu-
lation study: the Nord-Tröndelag Health Study 1995–7 (HUNT 2
study) [27], we estimated the proportions of the population who
would exhibit unfavourable combinations of risk factors, if evalu-
ated according to the following CVD prevention recommenda-
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tions: The guidelines from theAmerican Heart Association (AHA)
[7], the European Society of Cardiology [9,12], the UK National
Institute for Clinical Excellence [10] and the US Joint National
Committee (seventh report, JNC 7) [8], respectively. The guide-
lines’ recommended cut-off points are listed in Table 1.
When modelling the implementation of guidelines, we started
by identifying individuals with self-reported myocardial infarc-
tion, stroke, angina pectoris or on-going antihypertensive treat-
ment. Patients with diabetes mellitus (both types I and II) were
also included here, as current guidelines recommend close CVD
surveillance for these patients. We categorized these people as
having ‘established disease’ and thus as eligible for clinical atten-
tion irrespective of current risk factor levels. Subsequently, all
remaining individuals were categorized as ‘below’ or ‘above’ the
recommended limits for the following measured and calculated
CVD risk variables: blood pressure, total serum cholesterol, waist
circumference and body mass index (BMI), and daily smoking. A
family history of premature CVD was also considered as a risk
factor.
The HUNT 2 population study
The HUNT 2 study was designed to investigate the signiﬁcance of
biomedical risk factors. Its design and methods have been
described in detail elsewhere [27]. The overall participation rate
in HUNT 2 was 76% among women and 67% among men (for
both sexes combined 20–29 years: 49%; 30–39 years: 68%;
40–49 years: 77%; 50–59 years: 81%; 60–69 years: 86%). The
present study is based on data from all participants aged
20–79 years (in total 62 104 individuals, 29 288 males and 32 816
females; see Table 2). The HUNT 2 population has been consid-
ered relatively representative for the total Norwegian population
regarding demography, socioeconomic factors, morbidity and
mortality [27].
In the HUNT 2 survey, blood pressure was measured on persons
in seated position by specially trained personnel using a Dinamap
845XT based on oscillometry. Cuff size was adjusted after mea-
suring the arm circumference, and blood pressure was recorded as
the mean values of the second and third of three measurements
performed consecutively at the same visit. Total cholesterol was
measured by an enzymatic colorimetric cholesterolesterase
method [27]. Height was measured to the nearest 1.0 cm and
weight to the nearest 0.5 kg and BMI was calculated as kg m-2.
In the present analysis, smoking was deﬁned as daily smoking
of cigarettes, cigars or pipe. Family history of CVD was deﬁned as
ﬁrst-degree relatives (parents or siblings) with myocardial infarc-
tion before the age of 60 or stroke at any age.
For international comparison, prevalence rates were also calcu-
lated according to the European and World age standardization
(Table 3) [28].
The spss statistical package, version 15.0 (SPSS Inc., Chicago,
IL, USA), was used for statistical frequency analyses. All surveys
in HUNT 2 were approved by the Norwegian Data Inspectorate
and the Regional Committee for Ethics in Medical Research.
Results
The prevalence numbers for each separate risk factor is shown in
Table 4. Unfavourably, high blood pressure (including both hyper-
tension and prehypertension) is the single most prevalent risk
factor for which medical attention would be recommended, fol-
lowed by total cholesterol. In many instances, the prevalence of the
risk factors varied signiﬁcantly when calculated according to the
European and World age standardization.
About 98% of the population had at least one of the risk factors
(or established disease conditions) in question. If ‘prehyperten-
sion’ was excluded, and only hypertension was considered, this
number remained almost unchanged, or 95% (Table 4).
Figure 1 illustrates the potential impact of different blood pres-
sure deﬁnitions according to the guidelines studied. Even the
Table 1 Overview of the selected risk factors’ cut-off points in four
clinical guidelines on CVD: the American Heart Association (AHA), Euro-
pean guidelines on CVD prevention in clinical practice (EUR), National
Institute of Clinical Excellence (NICE) and the Seventh Report of the
Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (JNC 7)
Guideline
Regular assessment by
health care providers
Medical treatment or
follow-up by health care
providers
AHA BP  130/80 mmHg BP  140/90 mmHg
BMI  25.0 kg m-2
Waist circumference
Men >102 cm
Women >88 cm
Smoking
Family history of CVD
EUR Cholesterol  5 mmol L-1 BP  140/90 mmHg
BMI  25.0 kg m-2 Cholesterol > 8 mmol L-1
Waist circumference
Men >102 cm
Women >88 cm
Smoking
Family history of CVD
NICE BP > 140/90 mmHg BP  160/100 mmHg
Smoking
JNC 7 BP  120/80 mmHg BP  140/90 mmHg
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease.
Table 2 Participants in the HUNT 2 (1995–7) study according to age and
gender
Age groups Men Women Total
20–24 1 761 2 156 3 917
25–29 2 163 2 561 4 724
30–34 2 579 2 917 5 496
35–39 2 820 3 207 6 027
40–44 3 161 3 478 6 639
45–49 3 334 3 566 6 900
50–54 3 064 3 314 6 378
55–59 2 333 2 461 4 794
60–64 2 113 2 292 4 405
65–69 2 232 2 418 4 650
70–74 2 134 2 382 4 516
75–79 1 594 2 064 3 658
Total 29 288 32 816 62 104
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minimal difference between applying a hypertension deﬁnitions of
>140/90 mmHg versus 140/90 mmHg would affect 0.8–2.5%
of the people within each age group. It is evident that prehyper-
tension is present in a considerable proportion of the population.
The currently recommended blood pressure cut-off points 130/
80 mmHg (by the AHA guidelines) and 120/80 mmHg (by the
JNC 7 guidelines) would have the greatest consequences among
people younger than 50 years.
Figure 2 shows the point prevalence of people at different ages
who are identiﬁed with established CVD, or with three or more,
two, one, or zero of the CVD risk factors in question. After age
standardization (Europe), it turned out that only 3.9% of the total
population would be labelled as free, from both disease and all the
above-mentioned risk factors. One single risk factor was exhibited
by 12.4% of the population; two risk factors by 21.5%; and three
or more factors by 49.7%. Established CVD or diabetes mellitus
was reported by 12.5%. In total, 83.7% of the population exhibited
a risk or disease proﬁle which involved at least two cardiovascular
risk factors.
Discussion
More than eight of 10 Norwegians may exhibit two or more CVD
risk factors – or established disease – and thus be eligible for
targeted clinical attention, if current recommendations are inter-
preted literally. Rather than aiding practicing clinicians to demar-
cate a reasonable large and manageable high-risk group with
respect to further evaluation and follow-up, combination of risk
factors appears to inﬂate the population at risk.
As can be seen from Table 4, prehypertension has a substantial
impact on the population at risk, as long as blood pressure is
considered in isolation. However, this effect almost vanishes when
all ﬁve factors are considered jointly. This means that most people
with prehypertension also exhibit one or more other risk factors,
such as an unfavourably high level of cholesterol.
Table 3 Standardized age distribution of inhabitants in Europe and the
world, as well as age distribution of the Norwegian population in 2005
Age groups European standard World standard Norway
0–4 8 000 12 000 6 277
5–9 7 000 10 000 6 663
10–14 7 000 9 000 6 800
15–19 7 000 9 000 6 275
20–24 7 000 8 000 5 946
25–29 7 000 8 000 6 301
30–34 7 000 6 000 7 411
35–39 7 000 6 000 7 710
40–44 7 000 6 000 7 135
45–49 7 000 6 000 6 896
50–54 7 000 5 000 6 494
55–59 6 000 4 000 6 524
60–64 5 000 4 000 4 855
65–69 4 000 3 000 3 712
70–74 3 000 2 000 3 320
75–79 2 000 1 000 3 053
80–84 1 000 500 2 589
85+ 1 000 500 2 038
Total 100 000 100 000 100 000
The shadowed area refers to the age groups in our study.
Table 4 Prevalence and 95% CIs of CVD and selected CVD risk factors in the HUNT 2 (1995–7) study as well as calculated prevalence according to
the European and World age standardizations
Risk factors and diseases
Prevalence percentage
(absolute numers)
Age standardized prevalence percentage
Number
missingEurope 95% CI World 95% CI
Hypertension* 43.2 (26 687/61 844) 38.6 38.2–38.9 35.2 34.8–35.6 260
Prehypertension† 37.8 (23 390/61 871) 40.3 40.0–40.7 42.1 41.7–42.5 233
Cholesterol  5 mmol L-1 75.8 (46 935/61 929) 72.1 71.7–72.5 68.7 68.4–69.1 175
Body fat
BMI = 25.0–29.9 43.3 (26 718/61 667) 42.2 41.8–42.6 41.1 40.7–41.5 437
BMI  30.0 16.6 (10 217/61 667) 15.6 15.3–15.9 14.8 14.5–15.1 437
Waist obesity‡ 18.4 (11 291/61 320) 16.6 16.4–16.9 15.4 15.1–15.7 784
Smoking 33.7 (18 288/54 244) 33.6 33.2–34.0 33.5 33.1–33.9 7860
Close relatives§ with CVD 32.7 (17 797/54 437) 30.3 29.9–30.6 28.1 27.7–28.5 7667
Established disease and/or on preventive treatment 15.8 (9 754/61 769) 12.5 12.3–12.8 10.5 10.3–10.8 335
Myocardial infarction 2.9 (1 781/61 847) 2.2 2.1–2.3 1.8 1.7–1.9 257
Stroke 1.6 (1 006/61 804) 1.2 1.1–1.3 1.0 0.9–1.1 300
Angina pectoris 4.4 (2 702/61 801) 3.2 3.1–3.3 2.6 2.5–2.7 303
Diabetes 2.7 (1 653/61 863) 2.1 2.0–2.3 1.8 1.7–2.0 241
Antihypertensive treatment 10.4 (6 421/61 845) 8.3 8.1–8.5 7.0 6.8–7.2 259
One or more of the above 97.6 (60 051/61 522) 97.0 96.9–97.1 96.5 96.3–96.6 582
One or more of the above except prehypertension 94.8 (57 727/60 872) 93.3 93.1–93.5 92.0 91.8–92.2 1232
*Hypertensinon deﬁned as 140/90 mmHg or on antihypertensive treatment.
†Prehypertension deﬁned as blood pressure 120/80–139/89 mmHg without antihypertensive treatment.
‡Waist circumference: men >102 cm, women >88 cm.
§First-degree relatives with a family history of myocardial infarction before the age of 60 or stroke at any time.
BMI, body mass index; CI, conﬁdence interval; CVD, cardiovascular disease.
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Technical strengths and limitations of the
present analysis
The HUNT 2 study population is well deﬁned, with high partici-
pation rates, and considered fairly representative for Norway as a
whole. Compared with other European regions, including regions
involved in the MONICA project (third phase, 1992–4) [29], it did
not differ signiﬁcantly with respect to cholesterol levels and
smoking habits at the time of data collection. Blood pressure levels
were somewhat higher in the HUNT 2 population than in most
comparable countries, yet lower than in Finland. We acknowledge
that since the data collection in 1995–7, changes may have taken
place, both regarding lifestyle and in the distribution of biological
disease risk factors in the Norwegian population [30]. We may
thereby, like many other investigators in the ﬁeld of CVD, be
introducing a certain retrospective risk bias as we apply population
data collected 10 years ago.
With respect to family risk for CVD, the HUNT 2 study enabled
us to identify individuals who reported ﬁrst-degree relative(s) with
premature myocardial infarction. Stroke in close relatives,
however, was in the HUNT 2 study reported without reference to
age. As can be seen from Table 4, this potential source of overes-
timation has only a minor impact on the resulting risk population.
In this paper, we have deliberately chosen to outline the poten-
tial scenario of complete guideline adherence in the area of indi-
vidual CVD risk assessment. We also chose to include medical
surveillance for ‘prehypertension’ in Figs 1 and 2. It can be
argued that most guidelines do not go that far in their recommen-
dations as yet. On the other hand, opinion leaders in the medical
community appear to be on the brink of accepting the idea, not
only of actively monitoring prehypertension, but even to treat
it with drugs [24,25]. As an illustration of the increasing focus
on the subject, one may note that papers with the words
‘prehypertension’/‘prehypertension’ in the title appeared only
sporadically in PubMed until the year 2003 when it suddenly
appeared in the title of four papers. In 2004, the number of pub-
lications rose to 14; in 2006, 41; and 2007 is likely to see a further
increase. It can also be mentioned that Norwegian health authori-
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ties in 2003 issued a fee-for-service lifestyle advice scheme ‘Green
prescription’ where advice and individual follow-up were indi-
cated even for people with blood pressure in the ‘prehypertensive’
range. It later turned out that the Green prescriptions had low
legitimacy among Norwegian general practitioners [31]. One of
the reasons may be that the target group was so vast. It has been
calculated that literal adherence to the Green prescription initiative
could in fact consume half of all consultations in Norwegian
primary health care [32].
A medical ‘vision zero’?
Disease prevention and health promotion are, and should remain,
central goals of medicine. It is, however, a major challenge to ﬁnd
a reasonable balance between – on the one hand – biological,
speciﬁc and risk-oriented approaches to improving health, and –
on the other – more general and ‘salutogenetic’ approaches [2].
Deﬁnition of relevant and clinically meaningful cut-off levels for
individual risk intervention is crucial in this connection. We
believe that it can be demoralizing and alienating for primary
health care professionals to feel obliged to inform a large majority
of the individuals they serve that their current cardiovascular
health is not ‘good enough’ according to biomedical standards
[32]. The prospect of thus ‘medicalizing’ a large majority of an
adult population such as the one in Norway, with one of the
world’s longest-living and healthy-living populations according to
WHO statistics [1,16], evokes several epistemological and ethical
challenges [15]. Resource allocation and workload are also among
issues that need careful consideration before authoritative clinical
recommendations are launched [2,15,21].
We believe the present study serves as a vivid illustration of a
piecemeal biomedical empirism that may have become both too
good and at the same time not good enough [33–35]. By ‘too
good’, we mean that the statistical impact of traditional, biological
risk factors for CVD has now been investigated so extensively that
almost every citizen can ﬁnd empirical arguments for concern
related to his or her bodily risk proﬁle. By ‘not good enough’, we
mean that a narrow and reductive biological perspective which
labels almost every citizen as in need of personalized, medical
care, may divert both clinicians’ and politicians’ attention away
from more comprehensive, adequate and sustainable scientiﬁc
approaches to population health and disease [2].
As primary health care doctors and researchers in two of the
richest countries in the Western world, we see it as a duty of
the medical community not only to care for the health status of the
local individuals we serve, but also to consider our chosen aims and
means from a global perspective. We are not convinced that the
current trend in direction of an authoritative ‘vision zero’ in the area
of CVD prevention represents realistic and sound medicine [2].
Peter Kosso, philosopher of science, has argued that ‘good’ science
which really brings humankind forwards tends to have a distinct
aesthetical quality to it [35]. If the ‘ethos’ of scientiﬁcally based
medicine becomes too dominated by surveillance and control of
individual’s isolated biological factors, down to the lowest levels of
risk, it may lose its appeal as an impressive, human endeavour.
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Abstract
Background: Previous studies indicate that clinical guidelines using combined risk evaluation for
cardiovascular diseases (CVD) may overestimate risk. The aim of this study was to model and
discuss implementation of the current (2007) hypertension guidelines in a general Norwegian
population.
Methods: Implementation of the current European Guidelines for the Management of Arterial
Hypertension was modelled on data from a cross-sectional, representative Norwegian population
study (The Nord-Trøndelag Health Study 1995-97), comprising 65,028 adults, aged 20-89, of whom
51,066 (79%) were eligible for modelling.
Results: Among individuals with blood pressure t120/80 mmHg, 93% (74% of the total, adult
population) would need regular clinical attention and/or drug treatment, based on their total CVD
risk profile. This translates into 296,624 follow-up visits/100,000 adults/year. In the Norwegian
healthcare environment, 99 general practitioner (GP) positions would be required in the study
region for this task alone. The number of GPs currently serving the adult population in the study
area is 87 per 100,000 adults.
Conclusion: The potential workload associated with the European hypertension guidelines could
destabilise the healthcare system in Norway, one of the world's most long- and healthy-living
nations, by international comparison. Large-scale, preventive medical enterprises can hardly be
regarded as scientifically sound and ethically justifiable, unless issues of practical feasibility,
sustainability and social determinants of health are considered.
Background
The interest in preventive measures for cardiovascular dis-
eases (CVD) has escalated in the last decades [1]. Apart
from smoking and elevated cholesterol, hypertension has
for the last fifty years been considered the most predictive
CVD risk factor. The first international report highlighting
the importance of blood pressure control was published
in 1962 by the World Health Organisation (WHO) [2].
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After this milestone publication several generations of
clinical hypertension guidelines have followed on both
sides of the Atlantic [3-13]. In 2003, the European Society
of Hypertension (ESH) and the European Society of Car-
diology (ESC) published their own guidelines on hyper-
tension treatment, having until then endorsed the
guidelines issued by the WHO and the International Soci-
ety of Hypertension (ISH) [9]. The 2003 hypertension
guidelines became the most quoted paper in the medical
literature [13], and the guidelines were updated in 2007
[13].
For the last decade, combined CVD risk evaluation instru-
ments have gained an important role in CVD prevention
guidelines [8,12,14-16]. First prominent in the 1999
guidelines from the WHO/ISH [4], and followed by the
2003 [9] and 2007 [13] publications by the ESH/ESC,
such estimates have also become central in hypertension
guidelines. During the same time period, however, the
threshold for intervention in relation to individual risk
factors has also been lowered. The 2007 ESH/ESC guide-
lines also present a new risk factor, high pulse pressure
(systolic minus diastolic blood pressure) in the elderly, in
its combined risk model.
To be implementable in the everyday clinical setting, it is
essential that guidelines harmonise with clinical and prac-
tical realities. Both the number of patients in need of treat-
ment and the treatment goals should appear reasonable,
both from a societal and a local clinical perspective. When
the approach of guidelines to CVD risk identification and
stratification changes, it is hard to foresee the conse-
quences in terms of the population-at-risk and the clinical
workload. One way to address this important topic would
be to conduct modelling studies as an integral part of
guideline development. Empirical modelling studies of
clinical guidelines, however, are surprisingly rare. Some
recent papers [17-20], including studies from our own
group [21] have shown that the 2003 European Guide-
lines on CVD Prevention [8] significantly overestimated
CVD risk in several European regions. Consequently,
there is a strong argument for assessing the potential
impact of new clinical guidelines.
The aim of the present study was to model the implica-
tions of the most recent European guidelines for the man-
agement of arterial hypertension [13] in a general
Norwegian population. We primarily estimated the prev-
alence of individuals with unfavourable CVD risk levels
according to the guidelines. Subsequently, the potential
clinical workload and workforce associated with reaching
recommended treatment goals in this group were calcu-
lated. We finally reflect upon the implications of our find-
ings.
Methods
Data from a large and renowned population study (the
HUNT 2 Study, see http://www.ntnu.no/hunt/english)
[22] allowed us to calculate the proportion of the popula-
tion with an unfavourable combination of risk factors, as
defined by the 2007 guidelines [13]. Based on these fig-
ures, we estimated the number of follow-up visits needed
to achieve the guidelines' recommended treatment goals.
This number was again translated into the number of gen-
eral practitioners (GP) potentially needed to carry out this
work.
Norway is a country with a solid primary healthcare sys-
tem, and every citizen is listed with a GP. Care is mostly
delivered by the GPs and rarely by other trained staff, such
as nurse practitioners. Our model was designed to fit into
this context. In the following, we will present some essen-
tial details about the HUNT 2 data and our modelling of
the clinical workload associated with the 2007 guidelines.
The HUNT 2 population data
The Nord-Trøndelag Health Study 1995-97 (HUNT 2) has
been described in detail elsewhere [22]. The overall partic-
ipation rate in HUNT 2 was 76% among women and 67%
among men. The HUNT 2 population has been consid-
ered representative of the total Norwegian population
regarding demography, socio-economic factors, morbid-
ity and mortality, including mortality from CVD [22].
Our model is based on data from all HUNT 2 participants
aged 20-89 years, in total 65,028 individuals (30,447
males and 34,581 females), see Table 1.
Of these, 12,139 individuals (3,085 men and 9,054
women) had to be excluded because they had blood pres-
sure levels below 120/80 mmHg (the 2007 guidelines do
not address this group). Additionally, 1,015 men and 808
women had missing data regarding blood pressure or
other factors of the six risk factors considered. In total, this
rendered 51,066 HUNT 2 participants (79%) eligible for
our modelling procedure. Among the 13,962 excluded
participants, however, 788 (5.6%) did report established
CVD, diabetes or receiving blood-pressure-lowering treat-
ment. Our study thus underestimates the population-in-
need-of-attention and associated workload at this point.
The participation rates in the HUNT 2 study were different
in different age groups, with lower rates among the
younger participants. When estimating the annual
number of follow-up visits, this unequal participation rate
was corrected for by age-standardising the HUNT 2 data
with the 2007 age distribution in Nord-Trøndelag, which
is similar to Norway in general [23,24]. This gives the
younger age-groups, and hence the lower risk levels,
increased weight in our calculations.
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Variables studied
The basis for our model is the definition and classification
of blood pressure levels, as defined by the guidelines, see
Figure 1. The determination of an individuals' risk level
however also depends on the presence of other relevant
risk factors. Figure 2 gives an overview of these, including
the cut-off points applied in our modelling procedure.
In the present dataset, smoking was defined as daily
smoking of cigarettes, cigars or a pipe. Family history of
CVD was defined as 1st-degree relatives (parents, brothers
and/or sisters) with myocardial infarction before age 60 or
stroke at any age. Established CVD was defined as self-
reported myocardial infarction, stroke or angina pectoris.
Methods for measurement of blood pressure and body
composition are described elsewhere [22].
Some risk factors listed in the guidelines had to be omit-
ted from our model as they were not assessed in the
HUNT 2 study. These were: abnormal glucose tolerance
test, fasting plasma glucose, LDL-cholesterol and triglycer-
ide levels (HUNT 2 participants were not fasting). People
with renal disease and/or subclinical organ damage were
not accounted for separately.
The 2007 guidelines give no details regarding the cut-off
points for 'levels of pulse pressure (in the elderly)'. After
reviewing the literature, we defined 'elderly' as above 55
years of age (the same definition as the guidelines used for
age as an independent risk factor in men) and 'high' pulse
pressure level as t60 mmHg [25-35].
Estimation of clinical workload
Our estimates of the clinical workload related to each
CVD risk category have been inserted in Figure 1. The
number of follow-up visits are based on the guidelines'
specific recommendations [13], when possible. As the fol-
low-up frequency is not always accurately specified, we
needed to make some interpretations, which we justify in
detail below.
- Individuals at the lowest risk level (called 'average
risk') are said to need no blood pressure intervention,
and therefore we set the number of yearly visits to zero
for this category.
- The guidelines' Box 22 ('Patients' follow-up', p.
1513) states that "Patients at low risk or with grade 1
hypertension may be seen every 6 months...". We
therefore use 2 visits per year for these categories.
- The guidelines subsequently state that "Visits should
be more frequent in high or very high risk patients.
This is the case also in patients under non-pharmaco-
logical treatment alone due to the variable antihyper-
tensive response and the low compliance with this
intervention". We defined the term "more frequent"
(than 2 visits per year) to mean 3-4 visits per year.
Based on the above quote, we allocated an average of
3.5 visits per year for the categories 'high added risk,'
'very high added risk' and individuals with 'low added
risk' who exhibit BP <140/90 under non-pharmaco-
logical surveillance due to the presence of other risk
factors.
Since the choice of 3.5 visits per year on average for the
most demanding follow-up categories can be discussed,
we analysed our model's sensitivity to changes regarding
this number. Alternative analyses based on 3.0 and 4.0
visits per year are also presented.
Table 1: Participants in the study
Age groups Participants in HUNT-2 Eligible
Men Women Total Men Women Total
20-24 1761 2156 3917 1293 1085 2378
25-29 2163 2561 4724 1703 1202 2905
30-34 2579 2917 5496 2085 1362 3447
35-39 2820 3207 6027 2315 1645 3960
40-44 3161 3478 6639 2670 2140 4810
45-49 3334 3566 6900 2920 2520 5440
50-54 3064 3314 6378 2748 2631 5379
55-59 2333 2461 4794 2121 2086 4207
60-64 2113 2292 4405 1934 2057 3991
65-69 2232 2418 4650 2095 2249 4344
70-74 2134 2382 4516 1980 2240 4220
75-79 1594 2064 3658 1474 1942 3416
80-84 820 1231 2051 726 1127 1853
85-89 339 534 873 283 433 716
Total 30447 34581 65028 26347 24719 51066
Participants in the HUNT-2 (1995-7) study and those eligible for modelling in the present study according to age and gender.
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The guidelines recommend that "patients should be seen
often (e.g., every 2 to 4 weeks)" [13] during the blood
pressure drug titration phase. Our model however does
not include visits needed to formally diagnose hyperten-
sion, nor the series of visits associated with initial drug
titration. As we include only follow-up visits beyond that
point, our model will underestimate workload.
As mentioned, the guidelines only address individuals
with blood pressure levels of at least 120/80 mmHg, and
people with lower blood pressure are excluded from this
model, regardless of their medical history.
Estimating the necessary primary care workforce
The prevalence of individuals assigned to each of the risk
categories outlined in Figure 2 was calculated as a basis for
analysis of clinical workforce needed.
In 2007 (January 1st), the Nord-Trøndelag County had
129,069 inhabitants. The population aged 20-89 accounts
for about 72% of the total [23]. Nord-Trøndelag County
was served by 112 GPs in 2007 [36]. This translates into
87 GPs per 100,000 inhabitants. This GP density is quite
comparable to Norway as a whole (90 GPs per 100,000
inhabitants). We estimated the same number of GPs (87)
to take care of every 100,000 adults (i.e., individuals eligi-
ble for our study). When calculating the medical work-
force needed, we assumed that each GP in Nord-
Trøndelag would conduct an average of 3000 consulta-
tions per year, which is equal to the Norwegian average
[36].
Statistics
The SPSS statistical package, version 15.0, was used for
statistical frequency analyses.
Ethical approval
The HUNT 2 survey in the Nord-Trøndelag health study
was approved by the Norwegian Data Inspectorate and
the regional committee for ethics in medical research.
Cardiovascular risk stratification chart with recommended follow-up frequency for each categoryFigure 1
Cardiovascular risk stratification chart with recommended follow-up frequency for each category. A reconstruc-
tion of Figure 1 from the 2007 Guidelines for Management of Arterial Hypertension [13], with inserted recommendations 
regarding the number of follow-up visits per year in each risk category. Low, moderate, high and very high risk refer to the 10-
year risk of a CV fatal or non-fatal event. The term 'added' indicates in all categories that risk is greater than average. The risk 
factors referred to in the left column are: age, smoking, dyslipidaemia, elevated fasting plasma glucose, abnormal glucose toler-
ance test, abdominal obesity, a family history of premature CVD and 'high pulse pressure in the elderly'. Abbreviations: SBP: 
systolic blood pressure; DBP: diastolic blood pressure; HT: hypertension. OD: subclinical organ damage; MS: metabolic syn-
drome.
Blood pressure (mmHg) 
Other risk factors, 
OD or disease 
Normal 
SBP 120-129 
or DBP 80-84 
High normal 
SBP 130-139 
or DBP 85-89
Grade 1 HT 
SBP 140-159 
or DBP 90-99
Grade 2 HT 
SBP 160-179 or 
DBP 100-109
Grade 3 HT 
SBP ≥180 
or DBP ≥110
Risk level Average risk Average risk Low 
added risk 
Moderate 
added risk 
High 
added risk No other  
risk factor Follow up 
visits /year 0 0 2 2 3.5 
Risk level Low 
added risk 
Low 
added risk 
Moderate 
added risk 
Moderate 
added risk 
Very high 
added risk 1-2 risk 
factors Follow up 
visits /year 3.5 3.5 2 2 3.5 
Risk level Moderate 
added risk 
High 
added risk 
High 
added risk 
High 
added risk 
Very high 
added risk 
3 or more  
risk factors, 
MS, OD or 
Diabetes 
Follow up 
visits /year 3.5 3.5 3.5 3.5 3.5 
Risk level Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk 
Very high 
added risk Established 
CV or renal 
disease Follow up 
visits /year 3.5 3.5 3.5 3.5 3.5 
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Results
The 2007 European Guidelines for Management of Arte-
rial Hypertension [13] covered 79% of the total HUNT 2
population, aged 20-89. Figure 3 shows age-standardised
prevalence (percentage and absolute numbers) in each
risk category, as well as the associated number of follow-
up visits recommended per 100,000 adults per year.
As shown in Figure 3, only 6.6% of all individuals with a
blood pressure of t120/80 mmHg were classified as "aver-
age risk". The rest, or 93.4% (i.e., 74% of the total, adult
population), were classified as eligible for regular clinical
attention and/or drug treatment in the near future, based
on their total CVD risk profile, according to guideline rec-
ommendations. In the subgroup aged 50-64, the propor-
tion eligible for clinical attention reached 99%.
Implementing the aforementioned model of clinical fol-
low-up visits to our population of 65,028 adults, we
found that 296,624 visits per 100,000 adults would be
needed per year (Figure 3). This means that 99 GPs per
100,000 adults would be needed in Nord-Trøndelag
County to implement these hypertension guidelines. This
figure can be compared with the estimated number of 87
GPs per 100,000 adults, who in 2007 served the adult
population in the county for all contact reasons.
If individuals in the higher risk categories and those under
specific lifestyle supervision were to be seen 3.0 times or
alternatively 4.0 times yearly instead of 3.5 times, as pre-
viously discussed, the total number of visits would be
260,035 or alternatively 333,212 visits per year. This cor-
responds to 87 or 111 GP positions, respectively.
Figure 4 shows the proportion of individuals at different
risk levels by age and gender. As expected, the proportion
of individuals at higher risk increases with age for both
men and women.
Discussion
Modelling the implementation of current European
guidelines on arterial hypertension [13] on a general pop-
ulation of Norwegian adults, aged 20-89, we found that
93.4% of all individuals with blood pressure of t120/80
mmHg (i.e., 74% of the total, adult population) would be
eligible for regular clinical attention and/or drug treat-
ment, based on their total CVD risk profile. In terms of the
primary care workforce, a larger number of GPs would be
needed for the sole purpose of implementing the hyper-
tension guidelines, than the number of doctors who cur-
rently serve all primary care needs of this population -
which is affluent as well as long-lived and healthy-living,
by international comparison. These findings raise impor-
tant questions related to the scientific validity, clinical sus-
tainability and social responsibility of the guidelines.
Some limitations and other methodological considera-
tions related to our implementation model have to be
taken into consideration. Compared with other European
regions, including regions involved in the MONICA
project (third phase, 1992-94) [37], HUNT 2 did not dif-
fer significantly with respect to cholesterol levels and
smoking habits at the time of data collection. The blood
pressure levels, however, were somewhat higher in the
HUNT 2 population than in most comparable countries,
yet lower than in Finland [37,38].
Our sensitivity analysis of 3.0 and 4.0 follow-up visits
instead of 3.5 for those in the higher risk levels and those
with lifestyle changes shows that our concerns remain
valid, even if the conservative estimate is chosen.
It would obviously have been of interest to qualify the
total workload in terms of 'additional preventive meas-
ures' as opposed to 'already established workload related
to clinical disease'. Our data are however not suited to
make valid and transparent calculations of these sub-cate-
gories of workload. For instance, we know that a good
deal of blood pressure follow-up in Norway takes place in
consultations taking place for other contact reasons.
It may be argued that follow-up of known CVD risk
patients may demand less, or alternatively more, than the
average consultation time. The guideline authors empha-
sise that blood pressure control is a demanding, clinical
task: "Indeed, health providers sometimes wrongly con-
Risk factors and cut-off pointsF gure 2
Risk factors and cut-off points. The risk factors and the 
cut-off points used in the present study, based on the 2007 
Guidelines for the Management of Arterial Hypertension 
[13]. Abbreviations: M: men; W: women; TC: total choles-
terol; MI: myocardial infarction.
Risk factors Cut-off points 
Pulse pressure in the elderly ≥ 60 mmHg in people > 55 years of age 
Age M > 55 years W > 65 years 
Smoking Daily smoking of cigarettes, 
cigars or pipe 
Dyslipidaemia TC > 5.0 mmol/l or  HDL < 1.0 mmol/l 
Abdominal obesity Waist circumference > 102 
cm (M), > 88 cm (W) 
Family history of premature 
cardiovascular disease 
Having a 1st-degree relative 
with MI before age 60 or 
stroke at any age 
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sider the management of hypertension as the matter of
few minute visits and reimburse doctors accordingly"
[13]. In the presence of doubt, we chose to base our calcu-
lations on the average Norwegian GP patient turnover
rate. These calculations are however transparent and can
easily be adapted to fit healthcare models with higher GP
turnover rates or, alternatively, more contact with auxil-
iary staff and fewer doctor visits.
The aforementioned adjustments made to accommodate
the nature of the HUNT 2 data as well as the exclusion of
visits related to initial diagnosis and drug titration, will all
tend to underestimate the population-at-risk and clinical
workload. This, however, does not mean that our final
results represent an underestimate. As said, the average
blood pressure in the HUNT 2 population was slightly
higher than in comparable countries, and the use of ten-
year-old population data in our model may also imply a
tendency to overestimation as blood pressure levels in the
Norwegian population may have decreased since 1995-7.
Such trends have at least been observed in some other
European regions [39,40]. But even if our model were to
overestimate the population-at-risk somewhat, important
theoretical, practical and ethical issues need to be
addressed.
One crucial question that is hard to answer, and which is
not specific for the 2007 hypertension guidelines, is
whether the guideline's recommended approach would
prove clinically effective if implemented in the general
population, just as recommended. We have previously
demonstrated how the 2003 European CVD prevention
guidelines inflated the high-risk group, most likely due to
a phenomenon called retrospective risk bias
[17,20,21,24,41], resulting from the fact that mortality
from CVD has decreased steadily in Western Europe dur-
ing recent decades [42]. The reasons for this decline are
Age-standardised prevalence of individuals in each risk category and associated number of follow-up visitsFigure 3
Age-standardised prevalence of individuals in each risk category and associated number of follow-up visits. Age-
standardised prevalence for each risk category in relation to blood pressure levels (absolute numbers within brackets) as well 
as the calculated number of follow-up visits needed each year according to the 2007 Guidelines for the Management of Arterial 
Hypertension [13] per 100,000 adults, aged 20 to 89 in the HUNT 2 Study, Norway. Abbreviations: OD: subclinical organ dam-
age; HT: hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; MS: metabolic syndrome; CV: cardiovascu-
lar disease.
Blood pressure (mmHg) 
Other risk factors, 
OD or Disease 
Normal 
SBP 120-129 
or DBP 80-84 
High normal 
SBP 130-139 
or DBP 85-89
Grade 1 HT 
SBP 140-159 
or DBP 90-99
Grade 2 HT 
SBP 160-179 or 
DBP 100-109
Grade 3 HT 
SBP ≥180 
or DBP ≥110
Standardized 
prevalence 
3.8% 
(3 772) 
2.8% 
(2 799) 
1.6% 
(1 645) 
0.2% 
(162) 
0.0% 
(22) No other 
risk factor Follow up 
visits /year 0 0 3 291 324 76 
Standardized 
prevalence 
17.2% 
(17 189) 
16.4% 
(16 366) 
15.1% 
(15 117) 
3.3% 
(3 326) 
0.9% 
(904) 1-2 risk 
factors Follow up 
visits /year 60 161 57 282 30 235 6 652 3 164 
Standardized 
prevalence 
3.6% 
(3 577) 
5.0% 
(5 025) 
10.9% 
(10 925) 
7.2% 
(7 217) 
4.2% 
(4 190) 3 or more risk factors, 
MS, OD or 
Diabetes 
Follow up 
visits /year 12 520 17 587 38 238 25 259 14 665 
Standardized 
prevalence 
0.9% 
(904) 
1.3% 
(1 347) 
2.6% 
(2 642) 
1.9% 
(1 854) 
1.0% 
(1 016) Established 
CV or renal 
disease Follow up 
visits /year 3 163 4 715 9 248 6 490 3 556 
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complex and cannot be accounted for by changes in con-
ventional risk factors and medical interventions alone.
Recently, a prestigious, Norwegian study was conducted
on evidence-based implementation of a CVD preventive
guideline in general practice [43,44]. It turned out that
even motivated GPs receiving tailored information,
prompting and feedback showed surprisingly low con-
cordance with the recommendations. This finding accords
well with previous studies in national and international
settings [45,46]. The lack of adherence, as is usually the
case, was interpreted as proof that practicing clinicians are
not 'good enough'. This interpretation may however be
unsatisfactory. An alternative, or additional, interpreta-
tion is that contemporary CVD prevention guidelines are
not good enough, in the sense that they are not in reason-
able concordance with human nature and the realities of
clinical practice [47].
The 2007 guideline's evidence-base contains 825 refer-
ences. None of these discuss how medical professionals
may address societal, political, work-related and rela-
tional factors, which have all been documented to play
significant roles in CVD aetiology and prognosis [47,48].
Gender-specific proportions of individuals within 5-year age groups, labelled at different risk levelsFigure 4
Gender-specific proportions of individuals within 5-year age groups, labelled at different risk levels. Gender-spe-
cific proportions of individuals within 5-year age groups, labelled at different risk levels according to the 2007 Guidelines for 
the Management of Arterial Hypertension [13]: average risk (purple), low added risk (green), moderate added risk (yellow), 
high added risk (orange), and very high added risk (red).
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We realise that it would be a challenging task to accom-
modate such perspectives in clinical guidelines, but ignor-
ing evidence because it fits poorly with the mainstream,
established biomedical understanding of hypertension is
neither scientifically nor morally defendable.
Conclusion
Our findings indicate that the 2007 European blood pres-
sure guidelines have an inherent potential to destabilise
the healthcare system in Norway, one of the world's most
long- and healthy-living nations, by international com-
parison. In our view, such a large-scale, preventive medi-
cal enterprise can only be regarded as scientifically sound
and truly evidence-based, as long as issues of practical fea-
sibility and sustainability are made transparent and dis-
cussed [45].
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Abstract
Rationale, aims and objectives Many clinical guidelines for cardiovascular disease
(CVD) prevention contain risk estimation charts/calculators. These have shown a tendency
to overestimate risk, which indicates that there might be theoretical ﬂaws in the algorithms.
Total cholesterol is a frequently used variable in the risk estimates. Some studies indicate
that the predictive properties of cholesterol might not be as straightforward as widely
assumed. Our aim was to document the strength and validity of total cholesterol as a risk
factor for mortality in a well-deﬁned, general Norwegian population without known CVD
at baseline.
Methods We assessed the association of total serum cholesterol with total mortality, as
well as mortality from CVD and ischaemic heart disease (IHD), using Cox proportional
hazard models. The study population comprises 52 087 Norwegians, aged 20–74, who
participated in the Nord-Trøndelag Health Study (HUNT 2, 1995–1997) and were
followed-up on cause-speciﬁc mortality for 10 years (510 297 person-years in total).
Results Among women, cholesterol had an inverse association with all-cause mortality
[hazard ratio (HR): 0.94; 95% conﬁdence interval (CI): 0.89–0.99 per 1.0 mmol L-1
increase] as well as CVD mortality (HR: 0.97; 95% CI: 0.88–1.07). The association with
IHD mortality (HR: 1.07; 95% CI: 0.92–1.24) was not linear but seemed to follow a
‘U-shaped’ curve, with the highest mortality <5.0 and 7.0 mmol L-1. Among men, the
association of cholesterol with mortality from CVD (HR: 1.06; 95% CI: 0.98–1.15) and in
total (HR: 0.98; 95% CI: 0.93–1.03) followed a ‘U-shaped’ pattern.
Conclusion Our study provides an updated epidemiological indication of possible errors
in the CVD risk algorithms of many clinical guidelines. If our ﬁndings are generalizable,
clinical and public health recommendations regarding the ‘dangers’ of cholesterol should
be revised. This is especially true for women, for whom moderately elevated cholesterol
(by current standards) may prove to be not only harmless but even beneﬁcial.
Introduction
It has long been considered ‘common knowledge’ that total serum
cholesterol is an important and strong, independent risk factor for
cardiovascular disease (CVD) [1–4]. This association has been
deemed to be linear, meaning ‘the lower the total cholesterol level,
the better’. During the last decades, CVD prevention has been
marked by a trend of gradually lowering thresholds of risk deﬁni-
tions regarding cholesterol levels [2,5–8], in parallel with other
CVD risk factors such as hypertension and blood sugar [5,7,9–12].
Campaigns aimed at the general public have underlined the risks
associated with total cholesterol above 5.0 mmol L-1 (see, for
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instance, the 2011 Norwegian campaign ‘Under 5’ at http://www.
under5.no).
In recent years, a ‘combined estimate’ [2,7,8,13–17] has
become the most widespread method for CVD risk evaluation, as
it is believed to have better predictive properties than the single
risk factor approach. Most combined estimates include the risk
factors of age, sex, smoking, blood pressure and serum cholesterol.
Additionally, the algorithms include, to a varying degree, other
factors such as diabetes, obesity, family history and cholesterol
subfractions [low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) cholesterol] [2,5,7,8,12–17].
Some studies [18–22], including papers from our research
group [23,24], have problematized overestimation of CVD risk
in authoritative, preventive clinical guidelines. Both single risk
factors [24,25] and combined risk estimates have been addressed
[23,26]. We have shown that according to authoritative CVD
guidelines, 75% of the adult Norwegian population would be
deemed at risk for CVD and in need of clinical attention (advice
and supervision) [25,26]. Consequently, we have questioned the
theoretical basis of the guidelines. In the present study, we look
speciﬁcally at the validity of guidelines’ risk estimations involving
cholesterol. In particular, we challenge the widespread assumption
of a linear relationship between total cholesterol levels and disease
development (expressed as mortality in our analysis).
We are well aware of evidence indicating that cholesterol sub-
particles, including various lipoproteins, may have stronger asso-
ciations with CVD development than total cholesterol [27–34].
However, the emphasis on total cholesterol (as both a single risk
factor and an element in multiple risk estimates) still prevails in
many authoritative, clinical guidelines [1,7,17]. For instance, both
the 2003 and the 2007 European Guidelines on CVD prevention
state that ‘in general, total plasma cholesterol should be below 5,’
[2,16] and the risk charts in the same guidelines include total
cholesterol.
In the past decades, a number of studies have found a strong and
graded association between serum cholesterol and mortality from
ischaemic heart disease (IHD) [14,35–48]. Regarding total mor-
tality, however, the association has not been clear. Some studies
have found no association, and others have even suggested an
inverse relationship [38–41,43,49–61]. Some studies have shown
an inverse or a U-shaped association between cholesterol and
death from causes other than CVD, such as cancer [52,56,62,63].
The phrase ‘U-shaped association’ (alternatively ‘J-shaped’) indi-
cates that higher mortality (or incidences) can be observed both in
individuals with low and high levels of cholesterol compared with
individuals with levels in between. It is important to note, however,
that the phrase ‘U-shaped’ does not necessarily indicate that both
arms of the ‘U’ are equal in terms of mortality rates or the propor-
tion of the population belonging to each arm.
Regarding the association between cholesterol and overall CVD
mortality, some studies have found no association or a U-shaped
or even an inverse association [37,58,61,64–67]. This has been
explained by an association with cerebral strokes (primarily haem-
orrhagic strokes), as opposed to heart disease [34,46,67–72]. Inter-
estingly, some studies have also found an inverse [55,67,73] or a
U-shaped [61,74–78] association with IHD incidence and mortal-
ity, primarily among individuals, aged 60 years and older.
The incidence, prevalence and mortality from CVD have
decreased substantially throughout the Western world in recent
decades [79,80]. There are also signiﬁcant time trend changes
regarding various risk factors for CVD [81–83]. Changes have
occurred, both regarding risk factors frequently included in com-
bined risk estimates [83–85] and for factors such as societal struc-
ture [86,87], pollution [88], television viewing [89] and dietary
habits [90,91]. These on-going changes are likely to alter the
predictive value of risk algorithms based on observational data
collected years or even decades ago (retrospective risk bias). As
cholesterol has become an essential part of lay-people’s basic
understanding of their health, and the prevalence of slightly
‘elevated’ cholesterol levels is so high, we believe that it is impor-
tant to re-examine old assumptions regarding cholesterol as a risk
factor.
The aim of the present study was to document the strength and
validity of total serum cholesterol as a risk factor for mortality, as
deﬁned by current CVD prevention guidelines. For this purpose,
we used data from a well-deﬁned, general Norwegian population
without known CVD at baseline. We focused on deaths from
cardiovascular disease, IHD and death from all causes (total
mortality) within a follow-up period of 10 years.
Methods
Study population
All adults, aged 20 years or older and living in Nord-Trøndelag
County in Norway in 1995–1997, were invited to participate in the
second wave of the Nord-Trøndelag Health Study (HUNT 2).
Overall, 74% of women (34 786) and 65% of men (30 575) chose
to participate. The HUNT 2 population is ethnically homogeneous
(dominated by individuals of Nordic origin) and has been consid-
ered fairly representative of the total Norwegian population with
respect to demography, socio-economic factors, morbidity and
mortality, including mortality from CVD [92]. The HUNT 2 study
has been described in detail elsewhere (see http://www.ntnu.no/
hunt/english) [92].
For the purpose of the present analysis, the following HUNT 2
participants were excluded: 6780 individuals aged 75 years or
more at baseline (2815 men and 3965 women); 3430 individuals
(2207 men and 1223 women) with established CVD at baseline
(self-reported myocardial infarction, stroke or angina pectoris);
and 3064 persons with missing data on one or more of the follow-
ing variables: serum cholesterol, systolic blood pressure and
smoking status. Our calculations are thereby based on information
from 52 087 individuals (24 235 men and 27 852 women) aged
20–74 years and free from known CVD at baseline.
Study variables
In the HUNT 2 survey, total serum cholesterol was measured by
an enzymatic colorimetric cholesterol esterase method [92]. The
blood pressure of persons in a seated position was measured by a
specially trained personnel using Dinamap 845XT, based on oscil-
lometry. The cuff size was adjusted after measuring the arm cir-
cumference, and blood pressure was recorded as the mean values
of the second and third measurements performed consecutively at
the same visit. Smoking was deﬁned as daily smoking of ciga-
rettes, cigars or a pipe.
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Follow-up
The personal identity number of Norwegian citizens enabled
linking of HUNT 2 participant data to the Cause of Death Registry
at Statistics Norway (information on http://www.ssb.no/english/).
For the present analysis, each participant contributed person–time
from the date of clinical examination (August 1995–June 1997)
until 10 years of follow-up had been achieved (until August 2005–
June 2007, depending on participation dates) or until the date of
death if this occurred in the follow-up period, making the oldest
participants of the study 84 years of age at the end of the follow-
up. The follow-up time came to a total of 510 297 person-years.
Death from CVD was deﬁned by the International Classiﬁcation of
Disease code for the primary diagnosis of death (ICD-9: 390-459;
ICD-10: I 00-I 99) as well as death from IHD (ICD-9: 410-414;
ICD-10: I 20-I 25).
Statistical analysis
The ﬁrst part of our analysis involved making a simple CVD risk
estimation chart to compare with the charts currently recom-
mended for clinical practice in Norway. We used the Systematic
Coronary Risk Evaluation (SCORE) chart of the European Society
of Cardiology [2,15] and the nationally adjusted chart used in the
Norwegian National Guidelines [17] as a reference. These charts
are intended to depict the 10-year risk of dying from CVD, given
the level of risk factors at baseline: sex, age, smoking status,
systolic blood pressure and total cholesterol. To have a meaningful
amount of data for each square of our chart, we based it on three
age groups (20–39, 40–59 and 60–74 years), two levels of systolic
blood pressure (<140 mm Hg vs. 140 mm Hg, in accordance
with guidelines), smokers vs. non-smokers, and two levels of total
cholesterol. Regarding cholesterol, the levels <5.5 mmol L-1 vs.
5.5 mmol L-1 were used (cut-off approximately 215 mg dL-1).
This cut-off point assigns 40% of participating males and 43% of
females to the ‘low level’ category. Using a cut-off point of
5.0 mmol L-1 (which guidelines [2,16] state that cholesterol
should be below) would have assigned only 24% of males and
27% of females to the lower cholesterol stratum. The median
cholesterol level of the participants was 5.7 mmol L-1 for both
genders. The observed mortality rates per 1000 person-years were
calculated for each square of the chart.
For the next part of our analysis, we used Cox proportional
hazard models to compute hazard ratios (HRs) for overall mortal-
ity and mortality from CVD and IHD, associated with different
levels of cholesterol at baseline. The precision of the estimated
associations was assessed by a 95% conﬁdence interval (CI).
Departure from the proportional hazard assumptions was evalu-
ated by Schoenfeld residuals.
We computed sex-speciﬁc HRs for cholesterol as a continuous
variable as well as a variable with four categories (<5.0, 5–5.9,
6.0–6.9 and 7.0 mmol L-1). We adjusted for the other variables
of the aforementioned chart, namely age (in the timescale), sys-
tolic blood pressure (as a continuous variable) and smoking status.
We also ran an alternative model including the same variables,
in addition to waist-to-hip ratio (WHR), level of physical activity,
self-reported diabetes mellitus and family history of CVD. The
categorical cholesterol variable was tested for linear as well as
quadratic trend. Finally, we conducted an analysis of cholesterol
as a dichotomous variable with the cut-off point of 5.5 mmol L-1,
stratiﬁed by smoking status, and an analysis of the effect of
smoking stratiﬁed by the dichotomous cholesterol variable for
comparison.
All statistical tests were two-sided and all analyses were
performed using Stata for Windows (version 11; StataCorp LP,
TX, USA).
Ethics statement
Each participant in the HUNT study signed a written consent
regarding the screening and the use of data for research purposes
as well as linking their data to other registers (subject to the
approval of the Norwegian Data Inspectorate). The study was
approved by the Norwegian Data Inspectorate and the Regional
Committee for Ethics in Medical Research.
Results
Figure 1 shows CVD mortality for the HUNT 2 population during
the 10-year follow-up period (mortality rates per 1000 person-
years), according to each level of the risk factors found in the
international SCORE system. This model showed a general trend
towards increased mortality for an increase in any of the included
risk factors, except for cholesterol, where no such association was
observed. The results were similar regarding all-cause mortality
and IHD mortality (data not shown).
Table 1 shows the sex-speciﬁc associations of different levels
of serum cholesterol with mortality, both total mortality and CVD
and IHD mortality. Among women, serum cholesterol had an
inverse association with all-cause mortality as well as CVD mor-
tality (although not reaching statistical signiﬁcance) (Table 1). The
association with IHD mortality appeared to follow a U-shaped
curve. Test for quadratic trend did not support the existence of a
U-shaped curve (P = 0.16).
Among men, cholesterol did not seem to be linearly associated
with mortality but rather the association followed a U-shaped
pattern, with the lowest mortality appearing in the second
cholesterol category (5.0–5.9 mmol L-1). This was apparent in
all mortality categories. Consequently, cholesterol analysed as a
continuous variable did not show a statistically signiﬁcant
linear association with mortality. Test for quadratic trend yielded
P = 0.01 for all-cause mortality (indicating a true U-curve), P =
0.055 for CVD (approaching statistical signiﬁcance) and P = 0.80
for IHD (practically excluding a U-curve). The associations
between cholesterol and mortality are visualized in Figs 2–4.
A sensitivity analysis adjusting for four additional risk factors
(WHR, physical activity and family history) revealed results of
no considerable difference from the ﬁrst model (adjusting for age,
smoking and systolic blood pressure) for either sex.
The association of a dichotomous cholesterol variable with
mortality, stratiﬁed by smoking status, is shown in Table 2.
The HRs relate to the risk of dying among individuals with high
serum cholesterol (5.5 mmol L-1) compared with those with
lower levels (<5.5 mmol L-1). Having cholesterol levels above
5.5 mmol L-1 was not associated with increased mortality, either
among smokers or among non-smokers.
Smoking, on the other hand, was strongly associated with
increased mortality in all mortality categories among both sexes
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(Table 3). Among women, the association was somewhat stronger
for those with cholesterol below 5.5 mmol L-1.
Discussion
In this validation study of current guidelines for CVD prevention,
which is based on new epidemiological data from a large and
representative Norwegian population, we found total cholesterol
to be an overestimated risk factor.
Regarding the association between total cholesterol and mortal-
ity, our results generally indicated U-shaped or inverse linear
curves for total and CVD mortality. Only the association with
IHD among men could be interpreted as suggesting a positive,
linear trend.
Our results contradict the guidelines’ well-established demar-
cation line (5 mmol L-1) between ‘good’ and ‘too high’ levels
of cholesterol. They also contradict the popularized idea of a
positive, linear relationship between cholesterol and fatal disease.
Guideline-based advice regarding CVD prevention may thus
be outdated and misleading, particularly regarding many women
who have cholesterol levels in the range of 5–7 mmol L-1 and are
currently encouraged to take better care of their health.
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Figure 1 Ten-year incidence of fatal cardio-
vascular disease per 1000 person-years in the
population of Nord-Trøndelag (HUNT 2 study).
Table 1 Risk of death from all causes, cardiovascular disease and ischaemic heart disease among individuals aged 20–74; associations of total
cholesterol with mortality
Cholesterol
(mmol L-1)
No. of
persons
All causes Cardiovascular disease Ischaemic heart disease
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
Men
<5.0 5 918 208 1.00 (Reference) 58 1.00 (Reference) 24 1.00 (Reference)
5.0–5.9 8 021 410 0.77 (0.65–0.92) 132 0.80 (0.59–1.09) 65 0.94 (0.59–1.50)
6.0–6.9 6 658 500 0.84 (0.71–0.99) 168 0.87 (0.64–1.18) 85 1.06 (0.67–1.67)
7.0 3 638 329 0.89 (0.74–1.06) 0.90 128 1.05 (0.76–1.44) 0.25 57 1.12 (0.69–1.81) 0.39
per unit increase 24 235 1447 0.98 (0.93–1.03) 0.35 486 1.06 (0.98–1.15) 0.17 231 1.08 (0.96–1.22) 0.18
Women
<5.0 7 613 98 1.00 (Reference) 19 1.00 (Reference) 9 1.00 (Reference)
5.0–5.9 8 565 243 0.92 (0.72–1.17) 59 0.90 (0.53–1.52) 19 0.61 (0.27–1.38)
6.0–6.9 6 404 327 0.84 (0.66–1.06) 91 0.81 (0.49–1.35) 32 0.60 (0.28–1.30)
7.0 5 270 375 0.72 (0.57–0.92) 0.001 121 0.74 (0.44–1.22) 0.13 56 0.72 (0.34–1.51) 1.00
per unit increase 27 852 1043 0.94 (0.89–0.99) 0.02 290 0.97 (0.88–1.07) 0.53 116 1.07 (0.92–1.24) 0.37
*Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure (continuous).
CI, conﬁdence interval; HR, hazard ratio.
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Our ﬁnding of signiﬁcant discrepancies between epidemiologi-
cal data and clinical guidelines [2,16,17], suggesting a linear rela-
tion between total cholesterol and mortality from CVD is in accord
with other studies [61,66,67].
The main strengths of our study are the prospective and com-
prehensive nature of the HUNT 2 survey, its good participation
rates, and representativeness of the entire Norwegian population
of similar, i.e. Nordic, origin. A corresponding weakness is the
lack of immediate generalizability to Norwegians with other
ethnic backgrounds.Another potential weakness of our study is the
lack of information about cholesterol-lowering drug treatment
among the participants. However, this is unlikely to be an impor-
tant source of bias as our population was free from CVD at base-
line, and cholesterol-lowering drugs were not recommended for
primary prevention in the study period.
It is possible that the Norwegian HUNT 2 population differs
somewhat from earlier study populations in levels of CVD risk
factors and mortality, and that this may affect (or confound) the
association of cholesterol with mortality. Norway is an afﬂuent
country, and Norwegians are currently one of the longest lived
people in the world [93]. The rate of smoking among men is
relatively low, by international comparison [93]. The stable
social structure could also play a part, including a well-functioning
health care system with good access and coverage for all.
Various studies have shown cholesterol, smoking and high
blood pressure to have a multiplicative effect on IHD risk rather
than an additive effect [94–97]. It may be that cholesterol acts
differently as a risk factor for IHD than previously believed,
at least in certain risk factor combinations and/or under certain
Hazard
ratio
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0.80
0.60
<5.0 5.0–5.9
Total cholesterol (mmol L−1)
6.0–6.9 ≥7.0
Figure 2 Risk of death (all causes) associated with different levels
of total cholesterol. Hazard ratios and 95% conﬁdence intervals for
men (blue box) and women (red diamond) separately. Adjusted for
age, smoking and systolic blood pressure.
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Figure 3 Risk of death from cardiovascular disease associated with
different levels of total cholesterol. Hazard ratios and 95% conﬁdence
intervals for men (blue box) and women (red diamond). Adjusted for
age, smoking and systolic blood pressure.
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Figure 4 Risk of death from ischaemic heart disease associated with
different levels of total cholesterol. Hazard ratios and 95% conﬁdence
intervals for men (blue box) and women (red diamond). Adjusted for
age, smoking and systolic blood pressure.
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developmental and contextual circumstances, such as those men-
tioned earlier. At least in some settings, cholesterol may represent
a risk marker and/or a weak risk factor rather than an important
one. More valid risk factors might be found by further investiga-
tion of lipoproteins and/or other subparticles of cholesterol, but
the same dilemmas may arise in relation to those entities. What
appears evident, however, is that more updated and complex
disease prediction models are needed.
Regarding the immediate future of guidelines and combined
risk estimates for CVD, we envisage three options: ﬁrst, IHD
Table 2 Risk of death from all causes, cardiovascular disease and ischaemic heart disease depending on smoking status for individuals 20–74 years
old; hazard ratios for high* total cholesterol compared with low cholesterol levels
Cause of
death
Level of
cholesterol*
Men Women
No. of
persons
No. of
deaths
Adjusted† HR
(95% CI)
No. of
persons
No. of
deaths
Adjusted† HR
(95% CI)
All causes
Smokers High 4726 476 0.87 (0.73–1.03) 5 406 339 1.00 (0.77–1.31)
Low 2680 180 1.00 (Reference) 3 795 75 1.00 (Reference)
Non-smokers High 9724 573 0.94 (0.80–1.10) 10 485 503 0.74 (0.60–0.91)
Low 7105 218 1.00 (Reference) 8 166 126 1.00 (Reference)
CVD
Smokers High 4726 181 0.92 (0.68–1.24) 5 406 94 1.09 (0.60–2.00)
Low 2680 58 1.00 (Reference) 3 795 13 1.00 (Reference)
Non-smokers High 9724 182 0.91 (0.68–1.21) 10 485 160 1.00 (0.63–1.57)
Low 7105 65 1.00 (Reference) 8 166 23 1.00 (Reference)
IHD
Smokers High 4726 89 1.03 (0.66–1.59) 5 406 46 1.19 (0.48–2.93)
Low 2680 26 1.00 (Reference) 3 795 6 1.00 (Reference)
Non-smokers High 9724 88 1.00 (0.65–1.53) 10 485 56 0.96 (0.45–2.06)
Low 7105 28 1.00 (Reference) 8 166 8 1.00 (Reference)
*Comparison of high (5.5 mmol L-1) vs. low (<5.5 mmol L-1) total cholesterol.
†Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure.
CVD, cardiovascular disease; CI, conﬁdence interval; HR, hazard ratio; IHD, ischaemic heart disease.
Table 3 Risk of death from all causes, cardiovascular disease and ischaemic heart disease depending on levels of total cholesterol for individuals
20–74 years old; hazard ratios for smoking compared with non-smoking
Cause of death Smoking status
Men Women
No. of
persons
No. of
deaths
Adjusted* HR
(95% CI)
No. of
persons
No. of
deaths
Adjusted* HR
(95% CI)
All causes
High† cholesterol Smoking 4726 476 2.09 (1.71–2.55) 5 406 339 1.72 (1.29–2.30)
Non-smoking 2680 180 1.00 (Reference) 3 795 75 1.00 (Reference)
Low‡ cholesterol Smoking 9724 573 1.99 (1.76–2.24) 10 485 503 2.16 (1.87–2.48)
Non-smoking 7105 218 1.00 (Reference) 8 166 126 1.00 (Reference)
CVD
High cholesterol Smoking 4726 181 2.30 (1.61–3.29) 5 406 94 1.82 (0.91–3.64)
Non-smoking 2680 58 1.00 (Reference) 3 795 13 1.00 (Reference)
Low cholesterol Smoking 9724 182 2.44 (1.98–3.00) 10 485 160 2.24 (1.73–2.91)
Non-smoking 7105 65 1.00 (Reference) 8 166 23 1.00 (Reference)
IHD
High cholesterol Smoking 4726 89 2.28 (1.34–3.90) 5 406 46 2.35 (0.80–6.95)
Non-smoking 2680 26 1.00 (Reference) 3 795 6 1.00 (Reference)
Low cholesterol Smoking 9724 88 2.42 (1.80–3.25) 10 485 56 3.08 (2.07–4.58)
Non-smoking 7105 28 1.00 (Reference) 8 166 8 1.00 (Reference)
*Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure.
†High total cholesterol 5.5 mmol L-1.
‡Low total cholesterol <5.5 mmol L-1.
CVD, cardiovascular disease; CI, conﬁdence interval; HR, hazard ratio; IHD, ischaemic heart disease.
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mortality (and not overall CVD mortality) might be considered an
appropriate end point for the current risk estimates. However, our
results (Table 1) indicate that even such a limited focus would be
problematic, at least for women. Alternatively, total cholesterol
could be excluded from the risk estimates, potentially being
replaced either by nothing or by some different subparticle(s) of
cholesterol with better predictive properties, such as HDL or HDL/
total cholesterol [2,8,16]. Finally, future risk estimates may be
based on more nuanced statistical models, allowing for gender-
and age-speciﬁc associations between cholesterol and disease
development (mortality).
The Norwegian guidelines for prevention of CVD [17] include
a risk estimation model developed on the basis of Norwegian
population data [21]. This model assumes a linear association of
cholesterol with CVD mortality, and the authors do not indicate
that any evaluation of the linearity of the association has taken
place, i.e. an evaluation of a possible U-shaped association. Selmer
et al. included participants, aged 20–67, in their study, while we
included people up to 74 years old, and the U-shaped association
has been most prominent in studies, including participants over
age 60. This difference should, however, be minimized by the
statistical adjustments made for the effects of age. Besides the
included age groups, there is no reason to believe that the Norwe-
gian population data underlying the Norwegian guidelines differ
considerably from the HUNT 2 population.
To address the question of whether the U-shaped association
was age-dependent in the HUNT population, we performed an
age-stratiﬁed Cox-regression analysis post-hoc. The results indi-
cated a U-shaped association of cholesterol with CVD mortality
among men aged 40–74, and an inverse association among women
aged 60–74. Because of limited statistical power, we refrain from
emphasizing these results. Seen in the light of previous studies
[37,55,58,61,64–66,73–77], it is possible that a U-shaped associa-
tion is primarily a phenomenon related to people aged 60 years
and older.
Our smoking-stratiﬁed analysis (Table 2) indicated that the
U-shaped association can possibly be found among both smokers
and non-smokers, as no considerable difference was observed
between these two strata. Analysis with more categories of cho-
lesterol levels would have been preferable here, but due to limited
statistical power, we refrain from further analyses post-hoc.
In contrast to cholesterol, the detrimental effect of smoking was
clearly evident even after stratifying for cholesterol levels
(Table 3). This emphasizes the importance of smoking as a CVD
risk factor compared with cholesterol.
Conclusions
Based on epidemiological analysis of updated and comprehensive
population data, we found that the underlying assumptions regard-
ing cholesterol in clinical guidelines for CVD prevention might be
ﬂawed: cholesterol emerged as an overestimated risk factor in our
study, indicating that guideline information might be misleading,
particularly for women with ‘moderately elevated’ cholesterol
levels in the range of 5–7 mmol L-1. Our ﬁndings are in good
accord with some previous studies. A potential explanation of the
lack of accord between clinical guidelines and recent population
data, including ours, is time trend changes for CVD/IHD and
underlying causal (risk) factors.
‘Know your numbers’ (a concept pertaining to medical risk
factor levels, including cholesterol) is currently considered part of
responsible citizenship, as well as an essential element of preven-
tive medical care. Many individuals who could otherwise call
themselves healthy struggle conscientiously to push their choles-
terol under the presumed ‘danger’ limit (i.e. the recommended
cut-off point of 5 mmol L-1), coached by health personnel, per-
sonal trainers and caring family members. Massive commercial
interests are linked to drugs and other remedies marketed for this
purpose. It is therefore of immediate and wide interest to ﬁnd out
whether our results are generalizable to other populations.
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Abstract
Background: Distribution of body fat is more important than the amount of fat as a prognostic factor for life expectancy.
Despite that, body mass index (BMI) still holds its status as the most used indicator of obesity in clinical work.
Methods: We assessed the association of five different anthropometric measures with mortality in general and
cardiovascular disease (CVD) mortality in particular using Cox proportional hazards models. Predictive properties were
compared by computing integrated discrimination improvement and net reclassification improvement for two different
prediction models. The measures studied were BMI, waist circumference, hip circumference, waist-to-hip ratio (WHR), and
waist-to-height ratio (WHtR). The study population was a prospective cohort of 62,223 Norwegians, age 20–79, followed up
for mortality from 1995–1997 to the end of 2008 (mean follow-up 12.0 years) in the Nord-Trøndelag Health Study (HUNT 2).
Results: After adjusting for age, smoking and physical activity WHR and WHtR were found to be the strongest predictors of
death. Hazard ratios (HRs) for CVD mortality per increase in WHR of one standard deviation were 1.23 for men and 1.27 for
women. For WHtR, these HRs were 1.24 for men and 1.23 for women. WHR offered the greatest integrated discrimination
improvement to the prediction models studied, followed by WHtR and waist circumference. Hip circumference was in
strong inverse association with mortality when adjusting for waist circumference. In all analyses, BMI had weaker association
with mortality than three of the other four measures studied.
Conclusions: Our study adds further knowledge to the evidence that BMI is not the most appropriate measure of obesity in
everyday clinical practice. WHR can reliably be measured and is as easy to calculate as BMI and is currently better
documented than WHtR. It appears reasonable to recommend WHR as the primary measure of body composition and
obesity.
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Introduction
It is well documented that distribution of body fat is more
important than the amount of fat as a prognostic factor for
metabolic disturbance, cardiovascular diseases (CVD) and life
expectancy [1–6]. Central or abdominal fat has been associated
with the highest risk [7], with visceral fat being of special
importance [8,9]. Increased waist-to-hip ratio (WHR) as a risk
factor for CVD and mortality was first reported from the Swedish
population studies in Gothenburg in 1984 where WHR was shown
to be a stronger prognostic factor than body mass index (BMI)
[3,4]. These results have repeatedly been confirmed since [10–14].
The specific protective effect of increased peripheral (lower body)
fat in the form of hip and thigh [15] circumference in contrast to
waist girth has also been reported [9], both for men [13,16] and
women [17,18]. The more recent measure waist-to-height ratio
(waist circumference divided by height [WHtR]) disregards the
peripheral fat but takes the height into account. Some researchers
have found WHtR to be an even stronger predictor of death, CVD
[19–22] and CVD risk factors [23,24] than the above mentioned
measures. Others have suggested the difference of these anthro-
pometric measures to be insignificant or none at all, regarding
predictive ability for CVD [25,26].
In recent years an increasing amount of knowledge has been
gathered regarding the metabolic basis for the special importance of
central fat distribution. Various metabolic, endocrine and neural
factors appear to influence where the body fat accumulates and how
this affects the individual’s physiology and disease risk [5,8,9,27].
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In the wake of the increasing prevalence of obesity in most parts
of the world [28–32], there has been a debate about which
anthropometric measures are best suited to define and monitor
obesity for medical purposes. Despite the evidence of abdominal
obesity being far more important than body weight regarding
mortality and CVD, definitions of overweight and obesity based
on BMI continue to be the most widely used measures in
publications, including clinical guidelines designed for individual,
preventive or therapeutic counselling [28,33–35]. Many guidelines
mention WHR and/or waist circumference as interchangeable
with BMI although the correlation is questionable [10,11,21,23].
This practical approximation decreases the specificity of the
obesity definition and undermines the predictive precision of CVD
risk estimates.
The aim of this study was to further clarify the associations of
anthropometric indicators of obesity and body composition (BMI,
WHR, WHtR, waist circumference, and hip circumference) with
overall mortality, and specifically with CVD mortality.
Methods
Study population
All adults aged 20 years or older and living in Nord-Trøndelag
County in Norway were in 1995 to 1997 invited to participate at
the second wave of the Nord-Trøndelag Health Study (HUNT 2).
Overall, 74% of women (34,786) and 65% of men (30,575) chose
to participate. The HUNT 2 population is ethnically homogenous
(dominated by individuals of Nordic origin) and has been
considered representative of the total Norwegian population
regarding demography, socio-economic factors, morbidity and
mortality, including mortality from CVD [36]. The HUNT 2
study has been described in detail elsewhere [36] (see www.ntnu.
no/hunt/english).
For the purpose of the present analysis, 3,138 participants aged
80 years or more at baseline (1,231 men and 1,907 women) were
excluded. Individuals with established CVD at baseline (self-
reported myocardial infarction, stroke or angina pectoris) were
excluded, 4,571 in total (2,780 men and 1,791 women), as well as
681 person with missing data on one or more of the following
variables: height, weight, waist circumference, and hip circumfer-
ence. Our calculations are thus based on information from 56,971
individuals (26,461 men and 30,510 women) aged 20–79 years
who were without any known CVD at baseline. Baseline
characteristics are depicted in the supporting information (Table
S1).
Study variables
In the HUNT 2 study, height and weight were measured with
participants wearing light clothes without shoes; height to the
nearest 1.0 cm and weight to the nearest 0.5 kg. Based on these
measures we calculated BMI as weight in kg divided by the
squared value of height in meters. Waist and hip circumferences
were measured with a steel band to the nearest 1.0 cm with the
participant standing and with the arms hanging relaxed. The waist
circumference was measured horizontally at the height of the
umbilicus, and the hip circumference was measured likewise at the
thickest part of the hip [36]. When analysing the anthropometric
measures, we aimed at using clinically recognisable categorisa-
tions, rather than percentiles. BMI was categorised according to
WHO definitions [28], the waist circumference categories were
defined with 10 cm interval, and the hip circumference categories
with 5 cm interval. The WHR and WHtR were, however,
categorised by quintiles.
In the present analysis smoking was defined as daily smoking of
cigarettes, cigars or a pipe. Smoking status was defined as
unknown, current smoker, former, or never smoker. Levels of
recreational physical activity were defined as self-reported number
of hours spent on hard or light activity during one week: no
activity; ,3 h light activity; $3 h light activity or ,1 h hard
activity; $1 h hard activity; unknown.
Follow-up
The personal identity number of Norwegian citizens enabled
linkage of HUNT 2 participant data to the Cause of Death
Registry at Statistics Norway (information on www.ssb.no/
english/). For the present analysis, each participant contributed
person-time from the date of clinical examination (August 1995–
June 1997) until the date of death or end of follow-up (December
31st 2008). The mean follow-up time was 12.0 years, in total
684,644 person-years. Death from CVD was defined by the
International Classification of Disease code for the primary
diagnosis of death (ICD-9: 390–459; ICD-10: I 00-I 99).
Ethics statement
Each participant in the HUNT study signed a written consent
regarding the screening and the use of data for research purposes
as well as to linking their data to other registers (subject to
approval of the Norwegian Data Inspectorate). The study was
approved by the Norwegian Data Inspectorate and by the
Regional Committee for Ethics in Medical Research.
Statistical analysis
We used Cox proportional hazard models to compute hazard
ratios (HRs) for overall mortality and CVD mortality associated
with different levels of each anthropometric measure. Precision of
the estimated associations was assessed by a 95% confidence
interval. Departure from the proportional hazards assumption was
evaluated by Schoenfeld residuals and log-minus-log plots. An
interaction term between time and the appropriate variables was
added to the model if the proportional hazards assumption did not
hold.
We analysed the HR for participants with BMI below 18.5 kg/
m2 (104 men and 314 women) for comparison with the other BMI
categories but excluded them from further analysis due to the
potential of reverse causality (a J-shaped mortality curve) [37,38].
We calculated sex specific standard deviation (SD) scores for
each of the anthropometric variables and estimated the HR
associated with an increase of one SD.
We analysed the data separately for men and women, and all
associations were adjusted for potential confounding effects of age,
smoking status and recreational physical activity. We conducted
sensitivity analyses involving three additional models (Model 2–4).
Model 2 included the same covariates as the main model but
excluded participants with unknown smoking status. Model 3 was
adjusted for age, smoking, and physical activity (as our main
model) in addition to self-reported diabetes mellitus and weekly
alcohol consumption (abstinence, 0–2 glasses [units], 2.1–5 glasses,
5.1–8 glasses, .8 glasses). Model 4 was identical to our main
model but excluded the first three years of follow-up to limit the
reverse causality effect of undiagnosed diseases.
The ‘‘relative informativeness’’ of each anthropometric measure
was evaluated by examining the contributions made to the x2
likelihood ratio statistic in the Cox regression model compared
with a model that only contained the confounders, as the x2
statistic can be used as a measure of the improvement of goodness
of fit [39]. This was done both in relation with all cause and CVD
mortality, respectively.
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To further compare the predictive properties of the different
anthropometric measures for CVD death, sex-specific net
reclassification improvement (NRI) and integrated discrimination
improvement (IDI) were computed when adding each anthropo-
metric measure to two different prediction models. Model A
included age as the only predictive variable, while Model B
included age, smoking status, systolic blood pressure, and total
cholesterol. For each model three different NRI calculations were
done, using two (,5%, $5%), three (,1%, 1–9%, $10%), and
four (,1%, 1–4%, 5–9%, $10%) levels of risk of CVD death,
respectively.
In addition, we conducted an analysis of the anthropometric
measures stratified by age (above and below 60 years). Finally,
mutually adjusted analyses were conducted for waist and hip
circumference, as well as for BMI and WHR.
All statistical tests were two-sided and all analyses were
performed using Stata for Windows (Version 11 StataCorp LP,
TX, USA).
Results
We present the risk of death from all causes and from CVD
among men and women aged 20–79 (Tables 1 and 2) with
absolute numbers and HRs in association with each of the
anthropometric measures studied, after adjusting for age, smoking
and physical activity. For men, WHR and WHtR had the highest
(and similar) predictive power, both regarding mortality from
CVD and from all causes, followed by waist circumference
(Table 1). BMI had considerably weaker association, with HRs
only reaching statistical significance for death from CVD but not
overall mortality.
All cause mortality was for both sexes statistically significantly
lower in the BMI range 25.0–29.9 compared to the reference
group (BMI 18.5–24.9), given the above adjustments.
Overall the results were similar for both sexes except for WHR
appearing as a somewhat stronger predictor among women, as
compared to men, while HRs for WHtR seemed more comparable
with that of waist circumference than WHR (Table 2). This was
apparent in both mortality categories.
The sensitivity analyses did not deviate considerably from the
primary results. Among men, the HRs per one SD increase in
anthropometric measures never differed more than 0.02 from the
main model (Table S2). Among women, adjustment for self-
reported diabetes and alcohol consumption resulted in a slight
decrease in all HRs (Table S3). The decrease was in the range of
0.04–0.06 for CVD mortality and 0.03–0.04 for total mortality.
Less deviation from the main model was seen in other parts of the
analysis.
Table 3 shows the x2 likelihood ratio statistic for each measure.
Within brackets the informativeness is given in percentage relative
to WHR which was the most informative measure. The table
shows results from analysis of the anthropometric measures as
continuous variables. Our sensitivity analysis, examining the
measures as categorical variables, gave similar results (data not
shown).
The results from our analysis of reclassification and discrimi-
nation improvement are shown in Table 4 and Table 5. Among
men (Table 4), WHtR offered most improvement to the prediction
models studied, judging from the IDI, followed closely by WHR.
Among women (Table 5), most improvement was associated with
WHR, followed by WHtR and waist circumference. BMI and hip
circumference seemed to add little or no information to the
prediction models. Waist circumference, WHR and WHtR
alternately produced the highest NRI, depending on the model
and cut-points used. Some discordance between NRI and IDI
estimates were noted.
Risk of death from CVD associated with the measures studied
stratified by age is shown in Table 6. HRs are given both for men
and women, aged 20–59 years versus 60–79 at baseline, for each
of the measures. The strongest association was between CVD
mortality and WHtR for men and WHR for women. For all
measures the HRs were somewhat higher for the younger
stratum.
The results for CVD mortality from the mutual adjustment
analysis of hip and waist circumferences are shown in Table 7.
Adjusting for hip circumference strengthened the association of
waist girth with CVD mortality considerably for both sexes.
Increasing hip circumference, on the other hand, seemed to be
protective when adjusting for the waist. The results were similar
for all cause mortality (not shown in table). The results from a
corresponding analysis of BMI and WHR, mutually adjusted, are
shown in Table 8. Adjusting BMI for WHR attenuated the
association of BMI with mortality significantly, while adjusting
WHR for BMI had no significant effect on the association.
Discussion
Of the five anthropometric measures studied, WHR and WHtR
were most strongly associated with mortality, after adjusting for
confounding factors. This was true both regarding overall
mortality and death from CVD specifically. In accordance with
other studies, our results show that BMI is a poorer predictor of
death than the other measures [2–7,10–13,40]. These results
underscore the advantage of assessing body configuration rather
than body weight when estimating mortality risk. Furthermore,
when controlling for waist circumference, increasing hip circum-
ference appears to be protective in both genders. In our study,
obesity emerged as a more important risk factor among young
people, in comparison to older. This is in coherence with earlier
studies [41].
In all parts of our analysis, BMI showed weaker associations
with both all cause mortality and CVD mortality, when
compared to waist circumference, WHR and WHtR. Further-
more, BMI was the only among these four measures which failed
to show a statistically significant association with all cause
mortality. BMI also contributed less additional information to the
prediction models studied (Tables 4 and 5), and offered poorer
fitting models (Table 3). Hence, BMI seems to be a poorer
indicator of disease risk than the other measures studied, being
superior only to hip circumference. When adjusting for WHR,
BMI seemed even less predictive, while adjusting for BMI had no
effect on WHR mortality associations. This emphasises the
superiority of the alternative measures over BMI as indicators of
CVD risk.
Waist circumference proved to be a statistically significant risk
factor in all analyses, but still showed weaker associations with
mortality than both WHR and WHtR. In particular, it emerged as
a strong risk factor when adjusting for hip circumference. This
underlines the significance of considering body configuration
rather than the abdominal girth alone.
Hip circumference showed a weak positive association with
mortality. However, when adjusting for waist circumference, it
proved to be inversely related to CVD mortality in both genders.
This finding is in accordance with previous research [9,13,16–18].
Both in the presence (Table 6) and absence of age stratification
(Tables 1 and 2), WHR turned out to be a stronger risk factor than
WHtR among women, whilst the two measures had similar
predictive power among men. This gender difference favoured the
Body Configuration as a Predictor of Mortality
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use of WHtR among younger men. In any case, our results show
that WHR and WHtR are superior to the other measures in
relation to prediction of mortality.
Based on the IDIs (Tables 4 and 5), WHR and WHtR offered
the greatest improvement to our prediction models, followed
closely by waist circumference for women. The improvement
Table 1. Risk of death from all causes and from cardiovascular disease among men aged 20–79; associations with anthropometric
measures.
All causes Cardiovascular disease
Anthropometric measures
No. of
persons
No. of
deaths
Adjusteda
HR (95% CI) Ptrend
No. of
deaths
Adjusteda
HR (95% CI) Ptrend
Body mass index (kg/m2)
,18.5b 104 31 2.48 (1.73–3.54) 9 2.23 (1.15–4.33)
18.5–24.9 9,575 970 1.00 (Reference) 300 1.00 (Reference)
25.0–29.9 13,138 1,320 0.86 (0.79–0.93) 492 1.04 (0.90–1.21)
30.0–34.9 3,154 445 1.10 (0.98–1.23) 175 1.42 (1.17–1.71)
$35.0 490 70 1.34 (1.05–1.72) 0.16 28 1.78 (1.20–2.64) ,0.001
per 5 kg/m2 26,357 2,805 1.04 (0.98–1.10) 0.21 995 1.19 (1.08–1.30) ,0.001
per SD (3.4 kg/m2) 26,357 2,805 1.02 (0.99–1.06) 0.21 995 1.12 (1.06–1.20) ,0.001
Waist circumference (cm)
,80 1,882 116 1.17 (0.96–1.42) 33 1.06 (0.74–1.53)
80–89 9,466 723 1.00 (Reference) 233 1.00 (Reference)
90–99 10,378 1,134 1.01 (0.92–1.11) 404 1.10 (0.93–1.29)
100–109 3,625 588 1.11 (0.99–1.24) 226 1.27 (1.05–1.53)
$110 1,006 244 1.64 (1.41–1.90) ,0.001 99 1.99 (1.56–2.53) ,0.001
per 10 cm 26,357 2,805 1.11 (1.07–1.16) ,0.001 995 1.21 (1.13–1.29) ,0.001
per SD (9.1 cm) 26,357 2,805 1.10 (1.06–1.14) ,0.001 995 1.19 (1.12–1.26) ,0.001
Hip circumference (cm)
,95 2,360 275 1.18 (1.02–1.36) 80 0.96 (0.75–1.25)
95–99 6,158 639 1.00 (Reference) 225 1.00 (Reference)
100–104 9,203 925 0.89 (0.80–0.99) 335 0.92 (0.77–1.09)
105–109 5,471 546 0.86 (0.76–0.96) 200 0.89 (0.73–1.08)
$110 3,165 420 1.17 (1.03–1.33) 0.52 155 1.23 (1.00–1.51) 0.24
per 10 cm 26,357 2,805 1.01 (0.95–1.07) 0.76 995 1.11 (1.00–1.23) 0.05
per SD (6.2 cm) 26,357 2,805 1.01 (0.97–1.05) 0.76 995 1.06 (1.00–1.13) 0.05
Waist-to-hip ratio
,0.85 5,301 254 1.07 (0.90–1.26) 75 1.11 (0.82–1.50)
0.86–0.87 5,126 328 1.00 (Reference) 97 1.00 (Reference)
0.88–0.89 5,287 493 1.12 (0.97–1.29) 167 1.25 (0.97–1.60)
0.90–0.93 5,367 646 1.14 (0.99–1.30) 233 1.33 (1.05–1.69)
$0.94 5,276 1,084 1.38 (1.21–1.56) ,0.001 423 1.70 (1.36–2.13) ,0.001
per 0.1 unit 26,357 2,805 1.28 (1.20–1.36) ,0.001 995 1.43 (1.29–1.59) ,0.001
per SD (0.06) 26,357 2,805 1.15 (1.11–1.19) ,0.001 995 1.23 (1.16–1.30) ,0.001
Waist-to-height ratio
,0.47 5,286 239 1.10 (0.93–1.30) 63 1.09 (0.79–1.50)
0.48–0.49 5,219 334 1.00 (Reference) 94 1.00 (Reference)
0.50–0.51 5,360 501 1.11 (0.96–1.27) 173 1.34 (1.04–1.72)
0.52–0.54 5,264 663 1.07 (0.94–1.23) 238 1.31 (1.03–1.67)
$0.55 5,228 1,068 1.24 (1.09–1.40) 0.005 427 1.65 (1.32–2.08) ,0.001
per 0.1 unit 26,357 2,805 1.24 (1.15–1.33) ,0.001 995 1.50 (1.33–1.68) ,0.001
per SD (0.05) 26,357 2,805 1.12 (1.08–1.16) ,0.001 995 1.24 (1.16–1.31) ,0.001
Abbreviations: HR = hazard ratio, CI = confidence interval, SD = standard deviation.
aAdjusted for age (in the time scale), smoking (never, former, current, unknown) and physical activity per week (no, ,3 hours light, $3 hours light or ,1 hour hard,
$1 hour hard, unknown).
bThis category was excluded from the remainder of the analysis presented in the table.
doi:10.1371/journal.pone.0026621.t001
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was in the range of 2–5%. In comparison, smoking and systolic
blood pressure produced IDIs in the range of 5–6% for men
and 1.7–2.5% for women, using the same models. Some
discrepancies was noted between the IDIs and the NRIs (e.g. a
negative NRI 2 for WHtR among men, Table 4). This can be
explained by the choice of cut-points in combination with low
Table 2. Risk of death from all causes and from cardiovascular disease among women aged 20–79; associations with
anthropometric measures.
All causes Cardiovascular disease
Anthropometric measures
No. of
persons
No. of
deaths
Adjusteda
HR (95% CI) Ptrend
No. of
deaths
Adjusteda
HR (95% CI) Ptrend
Body mass index (kg/m2)
,18.5b 314 44 2.02 (1.49–2.74) 9 1.39 (0.71–2.71)
18.5–24.9 13,895 819 1.00 (Reference) 230 1.00 (Reference)
25.0–29.9 10,947 872 0.81 (0.74–0.90) 308 0.93 (0.78–1.10)
30.0–34.9 3,961 469 0.93 (0.83–1.05) 181 1.10 (0.90–1.35)
$35.0 1,393 204 1.24 (1.06–1.45) 0.26 74 1.41 (1.08–1.85) 0.02
per 5 kg/m2 30,196 2,364 1.03 (0.98–1.07) 0.27 793 1.10 (1.03–1.19) 0.009
per SD (4.5 kg/m2) 30,196 2,364 1.02 (0.98–1.07) 0.27 793 1.09 (1.02–1.17) 0.009
Waist circumference (cm)
,70 3,981 126 1.11 (0.92–1.35) 25 0.94 (0.62–1.44)
70–79 11,122 566 1.00 (Reference) 152 1.00 (Reference)
80–89 8,589 761 1.00 (0.90–1.12) 265 1.14 (0.93–1.40)
90–99 4,330 537 1.11 (0.99–1.23) 207 1.36 (1.10–1.68)
$100 2,174 374 1.48 (1.30–1.70) ,0.001 144 1.80 (1.43–2.27) ,0.001
per 10 cm 30,196 2,364 1.11 (1.07–1.16) ,0.001 793 1.20 (1.12–1.27) ,0.001
per SD (11.3 cm) 30,196 2,364 1.13 (1.09–1.18) ,0.001 793 1.22 (1.14–1.31) ,0.001
Hip circumference (cm)
,95 6,457 348 1.10 (0.95–1.27) 96 1.17 (0.89–1.54)
95–99 6,639 428 1.00 (Reference) 115 1.00 (Reference)
100–104 6,840 499 0.86 (0.75–0.98) 173 1.04 (0.82–1.31)
105–109 4,498 410 0.87 (0.76–1.00) 151 1.07 (0.84–1.36)
$110 5,762 679 1.02 (0.90–1.15) 0.33 258 1.27 (1.01–1.58) 0.14
per 10 cm 30,196 2,364 1.03 (0.98–1.07) 0.20 793 1.10 (1.02–1.18) 0.01
per SD (9.4 cm) 30,196 2,364 1.03 (0.99–1.07) 0.20 793 1.09 (1.02–1.17) 0.01
Waist-to-hip ratio
,0.74 6,040 191 1.01 (0.84–1.22) 46 0.94 (0.65–1.35)
0.74–0.77 6,011 282 1.00 (Reference) 83 1.00 (Reference)
0.78–0.79 5,988 413 1.08 (0.93–1.26) 134 1.11 (0.84–1.46)
0.80–0.83 6,125 572 1.16 (1.00–1.34) 189 1.17 (0.90–1.51)
$0.84 6,032 906 1.48 (1.29–1.69) ,0.001 341 1.65 (1.30–2.10) ,0.001
per 0.1 unit 30,196 2,364 1.34 (1.25–1.43) ,0.001 793 1.49 (1.33–1.66) ,0.001
per SD (0.06) 30,196 2,364 1.19 (1.15–1.24) ,0.001 793 1.27 (1.18–1.36) ,0.001
Waist-to-height ratio
,0.43 6,001 156 1.29 (1.05–1.59) 30 1.29 (0.83–2.02)
0.43–0.46 6,114 235 1.00 (Reference) 55 1.00 (Reference)
0.47–0.49 6,010 407 1.19 (1.01–1.40) 121 1.35 (0.98–1.86)
0.50–0.54 6,014 606 1.15 (0.99–1.34) 218 1.42 (1.05–1.91)
$0.55 6,057 960 1.35 (1.16–1.56) 0.005 369 1.71 (1.28–2.28) ,0.001
per 0.1 unit 30,196 2,364 1.20 (1.14–1.27) ,0.001 793 1.34 (1.21–1.47) ,0.001
per SD (0.07) 30,196 2,364 1.14 (1.10–1.19) ,0.001 793 1.23 (1.15–1.32) ,0.001
Abbreviations: HR = hazard ratio, SD = standard deviation, CI = confidence interval.
aAdjusted for age (in the time scale), smoking (never, former, current, unknown) and physical activity per week (no, ,3 hours light, $3 hours light or ,1 hour hard,
$1 hour hard, unknown).
bThis category was excluded from the remainder of the analysis presented in the table.
doi:10.1371/journal.pone.0026621.t002
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precision of the NRI estimates. The variation in NRIs
highlights the importance of careful selection of cut-points,
depending on the purpose. Identification of optimal cut-points
depends on chosen background factors as well as considerations
related to clinical relevance. Our results indicate that the best
discrimination is obtained by use of waist circumference, WHR
or WHtR.
The main strength of our investigation lies in the prospective
and comprehensive nature of the HUNT 2 study, its good
participation rates, and it being fairly representative for the entire
Norwegian nation. The fact that the HUNT population is
ethnically homogenous may also be considered a strength in this
context, since ethnic differences (genetic and epigenetic factors)
may influence the predictive properties of anthropometric
measures [42–44].
The HUNT 2 database lacks comprehensive information on the
participants’ dietary habits and cancer history. However, the
exclusion of participants with BMI ,18.5 kg/m2 and the
sensitivity analysis which excludes the first three years of follow-
up minimise the potential for confounding by cancer. Our
sensitivity analysis indicates that the impact of other potential
confounders is minimal.
Our study adds further knowledge to the evidence that BMI is
not the most appropriate measure of obesity in everyday clinical
practice. WHR is as easy to calculate as BMI and is presently
better documented than WHtR. It therefore appears reasonable
Table 3. Relative ‘‘informativeness’’ of different anthropometric measures in relation to mortality; x2 likelihood ratio statistics for
each measure and, within brackets, percentage of x2 for waist-to-hip ratio.
Informativeness
Anthropometric measures All cause mortality Cardiovascular disease mortality
Men
Body mass index 1.5 (3%) 13.3 (31%)
Waist circumference 26.3 (48%) 30.4 (70%)
Hip circumference 0.1 (0.2%) 3.7 (8%)
Waist-to-hip ratio 54.7 (100%) 43.5 (100%)
Waist-to-height ratio 34.4 (63%) 45.0 (104%)
Women
Body mass index 1.2 (2%) 6.6 (15%)
Waist circumference 33.4 (47%) 30.7 (69%)
Hip circumference 1.6 (2%) 6.3 (14%)
Waist-to-hip ratio 71.5 (100%) 44.4 (100%)
Waist-to-height ratio 38.7 (54%) 33.2 (75%)
doi:10.1371/journal.pone.0026621.t003
Table 4. Risk reclassification improvement among mena; anthropometric measures and risk of death from cardiovascular disease.
Anthropometric measures IDI (%) P NRI 1b (%) P NRI 2c (%) P NRI 3d (%) P
Model Ae
Body mass index 0.59 0.20 1.50 0.64 1.64 0.78 5.74 0.39
Waist circumference 1.99 0.009 4.32 0.28 1.09 0.88 9.62 0.23
Hip circumference 0.10 0.58 1.24 0.48 20.79 0.81 0.73 0.84
Waist-to-hip ratio 3.45 ,0.001 4.20 0.35 5.88 0.42 15.44 0.07
Waist-to-height ratio 3.64 ,0.001 2.86 0.52 5.39 0.47 13.37 0.12
Model Bf
Body mass index 0.40 0.42 21.94 0.61 24.16 0.39 22.41 0.69
Waist circumference 1.59 0.04 7.33 0.14 0.67 0.91 12.76 0.10
Hip circumference 0.09 0.72 20.04 0.99 4.20 0.27 5.78 0.21
Waist-to-hip ratio 2.63 0.007 3.69 0.46 4.32 0.53 13.64 0.11
Waist-to-height ratio 2.77 0.005 7.23 0.17 26.18 0.36 6.84 0.43
Abbreviations: IDI = integrated discrimination improvement, NRI = net reclassification improvement.
aParticipants with body mass index ,18.5 kg/m2 were excluded from the analysis.
bNRI when adding a given anthropometric measure to a prediction model using two risk categories (,5%, $5%).
cThree risk categories (,1%, 1–9%, $10%).
dFour risk categories (,1%, 1–4%, 5–9%, $10%).
eVariable included in model: Age.
fVariables included in model: Age, smoking status, systolic blood pressure, and total cholesterol.
doi:10.1371/journal.pone.0026621.t004
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to recommend WHR as the primary measure of body
composition and obesity, at least when it comes to assessing
risk of CVD. There is, however, need for further clarification
before determining whether WHtR should be considered an
even better alternative than WHR. Single (waist circumference
in isolation) or additional measures (involving weight and/or
height) may also be added to nuance estimations of CVD risk
when indicated, for instance in relation to clearly obese or
Table 5. Risk reclassification improvement among womena; anthropometric measures and risk of death from cardiovascular
disease.
Anthropometric measures IDI (%) P NRI 1b (%) P NRI 2c (%) P NRI 3d (%) P
Model Ae
Body mass index 0.94 0.07 0.28 0.95 28.41 0.23 26.63 0.43
Waist circumference 4.12 ,0.001 2.73 0.67 8.42 0.37 15.00 0.19
Hip circumference 1.12 0.03 20.98 0.81 27.35 0.28 27.38 0.35
Waist-to-hip ratio 5.01 ,0.001 2.15 0.77 26.76 0.009 32.21 0.01
Waist-to-height ratio 4.36 ,0.001 24.39 0.51 10.77 0.26 9.10 0.43
Model Bf
Body mass index 0.84 0.15 23.27 0.42 5.90 0.35 5.36 0.48
Waist circumference 3.46 0.002 7.09 0.26 30.25 0.001 43.01 ,0.001
Hip circumference 1.11 0.07 22.80 0.53 6.36 0.34 6.98 0.38
Waist-to-hip ratio 3.90 0.002 23.95 0.49 33.30 ,0.001 36.08 ,0.001
Waist-to-height ratio 3.65 0.001 4.37 0.47 25.41 0.006 35.50 0.001
Abbreviations: IDI = integrated discrimination improvement, NRI = net reclassification improvement.
aParticipants with body mass index ,18.5 kg/m2 were excluded from the analysis.
bNRI when adding a given anthropometric measure to a prediction model using two risk categories (,5%, $5%).
cThree risk categories (,1%, 1–9%, $10%).
dFour risk categories (,1%, 1–4%, 5–9%, $10%).
eVariable included in model: Age.
fVariables included in model: Age, smoking status, systolic blood pressure, and total cholesterol.
doi:10.1371/journal.pone.0026621.t005
Table 6. Risk of death from cardiovascular disease among men and women aged 20–79 yearsa; associations with anthropometric
measures stratified by age at baseline.
Adjustedb HR (95% CI)
Men Women
Anthropometric measures 20–59 years 60–79 years 20–59 years 60–79 years
Body mass index, per 5 kg/m2 1.55 (1.27–1.89) 1.11 (1.00–1.23) 1.26 (0.97–1.64) 1.09 (1.01–1.18)
Waist circumference, per 10 cm 1.49 (1.28–1.74) 1.15 (1.07–1.24) 1.36 (1.12–1.66) 1.18 (1.10–1.26)
Hip circumference, per 10 cm 1.45 (1.14–1.84) 1.04 (0.93–1.17) 1.12 (0.86–1.47) 1.09 (1.01–1.18)
Waist-to-hip ratio, per 0.1 unit 1.96 (1.52–2.53) 1.35 (1.20–1.51) 2.15 (1.60–2.89) 1.42 (1.26–1.60)
Waist-to-height ratio, per 0.1 unit 2.25 (1.73–2.93) 1.37 (1.21–1.55) 1.69 (1.23–2.33) 1.30 (1.18–1.44)
Per one SD increase
Body mass indexc 1.35 (1.18–1.55) 1.08 (1.00–1.15) 1.23 (0.97–1.56) 1.08 (1.01–1.16)
Waist circumferenced 1.44 (1.26–1.66) 1.14 (1.06–1.22) 1.42 (1.14–1.77) 1.20 (1.12–1.30)
Hip circumferencee 1.25 (1.08–1.45) 1.03 (0.96–1.10) 1.11 (0.86–1.44) 1.09 (1.01–1.17)
Waist-to-hip ratiof 1.47 (1.27–1.69) 1.18 (1.11–1.26) 1.58 (1.33–1.89) 1.24 (1.15–1.33)
Waist-to-height ratiog 1.54 (1.34–1.76) 1.18 (1.10–1.26) 1.46 (1.16–1.84) 1.21 (1.13–1.30)
Abbreviations: HR = hazard ratio, SD = standard deviation, CI = confidence interval.
aParticipants with body mass index ,18.5 kg/m2 were excluded from the analyses.
bAdjusted for age (in the time scale), smoking (never, former, current, unknown) and physical activity per week (no, ,3 hours light, $3 hours light or ,1 hour hard,
$1 hour hard, unknown).
cOne SD: men 3.5 kg/m2, women 4.5 kg/m2.
dOne SD: men 9.2 cm, women 11.5 cm.
eOne SD: men 9.2 cm, women 9.4 cm.
fOne SD: 0.06 for both sexes.
gOne SD: men 0.05, women 0.07.
doi:10.1371/journal.pone.0026621.t006
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under-weight individuals with a favourable WHR. A certain
weakness of the approach suggested here is the documented,
inter-personal variance in measurement of waist and hip
circumferences [45]. This problem can be addressed by
standardised measurement procedures [46] and adequate
training [45].
Table 7. Risk of death from cardiovascular disease among men and women aged 20–79 yearsa; associations with waist and hip
circumferences mutually adjusted.
Men Women
Anthropometric measures
No. of
persons
No. of
deaths
Adjustedb
HR (95% CI)
No. of
persons
No. of
deaths
Adjustedb
HR (95% CI)
Waist circumference (cm)
Men Women
,80 ,70 1,882 33 0.98 (0.67–1.42) 3,981 25 0.86 (0.56–1.32)
80–89 70–79 9,466 233 1.00 (Reference) 11,122 152 1.00 (Reference)
90–99 80–89 10,378 404 1.20 (1.00–1.44) 8,589 265 1.26 (1.02–1.56)
100–109 90–99 3,625 226 1.52 (1.20–1.93) 4,330 207 1.65 (1.28–2.14)
$110 $100 1,006 99 2.64 (1.91–3.67) 2,174 144 2.54 (1.81–3.58)
Waist circumference, per 10 cm 26,357 995 1.42 (1.28–1.58) 30,196 793 1.44 (1.29–1.61)
Hip circumference (cm)
,95 2,360 80 1.16 (0.89–1.50) 6,457 96 1.40 (1.06–1.84)
95–99 6,158 225 1.00 (Reference) 6,639 115 1.00 (Reference)
100–104 9,203 335 0.75 (0.63–0.90) 6,840 173 0.88 (0.69–1.12)
105–109 5,471 200 0.61 (0.49–0.76) 4,498 151 0.77 (0.60–1.01)
$110 3,165 155 0.65 (0.49–0.86) 5,762 258 0.67 (0.50–0.91)
Hip circumference, per 10 cm 26,357 995 0.73 (0.62–0.86) 30,196 793 0.77 (0.68–0.88)
Abbreviations: HR = hazard ratio, CI = confidence interval.
aParticipants with body mass index ,18.5 kg/m2 were excluded from all analyses.
bAdjusted for age (in the time scale), smoking (never, former, current, unknown), physical activity per week (no, ,3 hours light, $3 hours light or ,1 hour hard,
$1 hour hard, unknown), and either waist circumference or hip circumference.
doi:10.1371/journal.pone.0026621.t007
Table 8. Risk of death from cardiovascular disease among men and women aged 20–79 yearsa; associations with body mass index
and waist-to-hip ratio mutually adjusted.
Men Women
Anthropometric measures No. of persons No. of deaths Adjustedb HR (95% CI) No. of persons No. of deaths Adjustedb HR (95% CI)
Body mass index (kg/m2)
18.5–24.9 9,575 300 1.00 (Reference) 13,895 230 1.00 (Reference)
25.0–29.9 13,138 492 0.91 (0.78–1.07) 10,947 308 0.81 (0.68–0.97)
30.0–34.9 3,154 175 1.08 (0.87–1.34) 3,961 181 0.88 (0.71–1.08)
$35.0 490 28 1.23 (0.81–1.86) 1,393 74 1.07 (0.81–1.42)
per SD (M: 3.4, W: 4.5) 26,357 995 1.01 (0.94–1.09) 30,196 793 1.00 (0.93–1.08)
Waist-to-hip ratio
Men Women
,0.85 ,0.74 5,286 75 1.14 (0.85–1.53) 6,040 46 0.82 (0.55–1.21)
0.86–0.87 0.74–0.77 5,219 97 1.00 (Reference) 6,011 83 1.00 (Reference)
0.88–0.89 0.78–0.79 5,360 167 1.25 (0.96–1.62) 5,988 134 1.15 (0.87–1.51)
0.90–0.93 0.80–0.83 5,264 233 1.35 (1.07–1.70) 6,125 189 1.11 (0.88–1.40)
$0.94 $0.84 5,228 423 1.64 (1.30–2.07) 6,032 341 1.59 (1.27–2.00)
per SD (both sexes: 0.06) 26,357 995 1.22 (1.14–1.31) 30,196 793 1.27 (1.18–1.36)
Abbreviations: HR = hazard ratio, CI = confidence interval, SD = standard deviation.
aPersons with body mass index ,18.5 kg/m2 were excluded from all analyses.
bAdjusted for age (in the time scale), smoking (never, former, current, unknown), physical activity per week (no, ,3 hours light, $3 hours light or ,1 hour hard,
$1 hour hard, unknown), and either body mass index or waist-to-hip ratio.
doi:10.1371/journal.pone.0026621.t008
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It is hard to determine how much effort should be put into
training healthcare workers to measure WHR or WHtR in a
standardised and reproducible manner, as the potential for
predictive improvement will depend on the selected cut-off points
and also the choice of prediction model. In relation to combined risk
algorithms [47,48], our results indicate that a NRI of up to 4%
might be reached for women and 1.5% for men, depending on cut-
off points, by replacing BMI with waist circumference, WHR or
WHtR. Identification of the most appropriate cut-offs for a given
prediction model could eventually be addressed in a future study.
Most preventive CVD guidelines [33,34,49,50] however do not
include markers of obesity in their combined risk algorithms.
Authoritative guidelines currently treat body composition/config-
uration as an isolated risk factor and usually lack clear specifications
regarding the numerical impact on disease risk. As long as this
approach is recommended for use in clinical practice, we argue for
the use of the anthropometric measure with the best predictive
properties. From this perspective, it appears rational to replace BMI
by WHR or WHtR when evaluating CVD mortality risk.
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Supporting information
Table S1. Baseline characteristics of the study population aged 20-79a.
Variable
Men
(N = 26,463)
Women
(N = 30,505)
Mean age, years (SD) 46.7 (15.1) 47.5 (15.6)
Mean weight, kg (SD) 83.6 (12.2) 70.8 (12.4)
Mean body mass index, kg/m2 (SD) 26.4 (3.4) 26.2 (4.5)
Mean waist circumference, cm (SD) 91.5 (9.1) 81.1 (11.3)
Mean hip circumference, cm (SD) 102.3 (6.2) 101.9 (9.4)
Mean waist-to-hip ratio (SD) 0.89 (0.06) 0.79 (0.06)
Mean waist-to-height ratio (SD) 0.51 (0.05) 0.49 (0.07)
Mean systolic blood pressure, mmHg (SD) 138.9 (18.0) 133.8 (22.3)
Mean serum cholesterol, mmol/L (SD) 5.8 (1.2) 5.9 (1.3)
Diabetes mellitusb (%) 564 (2.1) 610 (2.0)
University degree (%) 5,392 (21.1) 6,153 (20.3)
Smoking (%)
Never smokers 10,298 (39.1) 13,595 (45.0)
Current smokers 7,582 (28.8) 5,680 (18.8)
Former smokers 7,224 (27.4) 9,116 (30.2)
Unknown smoking status 1,253 (4.8) 1,805 (6.0)
Physical activityc (%)
No activity 1,810 (6.9) 1,712 (5.7)
<3 h easy 6,157 (23.4) 9,664 (32.0)
3+ h easy, <1 h hard 8,100 (30.7) 9,409 (31.2)
1+ h hard 8,556 (32.5) 6,275 (20.8)
Unknown 1,734 (6.6) 3,136 (10.4)
Alcohol consumption, glasses/weekd (%)
Total abstinence 1,756 (6.7) 4,050 (13.4)
0-2 14,983 (56.8) 21,675 (71.8)
2.1-5 6,718 (25.5) 3,801 (12.6)
5.1-8 2,384 (9.0) 619 (2.0)
>8 516 (2.0) 51 (0.2)
SD = standard deviation.
aParticipants with body mass index lower than 18.5 kg/m2 are not included in the table.
bNumber of persons with self-reported diabetes.
cSelf-reported physical activity per week.
dSelf-reported weekly alcohol consumption (beer, wine, strong liqour), number of glasses.
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Figure C
Ten-year all-cause mortality per 1,000 person-years in the Nord-Trøndelag Health
Study (HUNT 2).
≥5% 10-year all-cause
mortality per 1000
person-years
1-5%
<1%
202
Women Men
Non-smoker Smoker Non-smoker Smoker
Age 60-74
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
(m
m
H
g) ≥140 1.4 1.7 0.0 4.1 2.7 3.1 6.1 6.5
<140 1.9 0.7 4.8 2.3 5.4 2.4 8.1 5.0
Age 40-59
≥140 0.2 0.1 0.4 0.6 0.3 0.5 1.5 2.4
<140 0.0 0.1 0.1 0.2 0.1 0.4 0.3 0.6
Age <40
≥140 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0
<140 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
<5.5 ≥5.5 <5.5 ≥5.5 <5.5 ≥5.5 <5.5 ≥5.5
Cholesterol levels (mmol/L)
Figure D
Ten-year incidence of fatal ischaemic heart disease (IHD) per 1,000 person-years in the
Nord-Trøndelag Health Study (HUNT 2).
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Figure E. CVD mortality per 1000 person-years among men in different BMI
categories.
Figure F. CVD mortality per 1000 person-years among women in different BMI
categories.
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Figure G. CVD mortality per 1000 person-years among men depending on waist
circumference.
Figure H. CVD mortality per 1000 person-years among women depending on waist
circumference.
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Figure I. CVD mortality per 1000 person-years among men depending on hip
circumference.
Figure J. CVD mortality per 1000 person-years among women depending on hip
circumference.
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Figure K. CVD mortality per 1000 person-years among men depending on waist-to-hip
ratio.
Figure L. CVD mortality per 1000 person-years among women depending on waist-to-
hip ratio.
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Figure M. CVD mortality per 1000 person-years among men depending on waist-to-
height ratio.
Figure N. CVD mortality per 1000 person-years among women depending on waist-to-
height ratio.
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Appendix III
Letter to the Editor
(Paper III)

Address:
Research Unit of General Practice,
Department of Public Health and General Practice,
Norwegian University of Science and Technology,
N-7489 Trondheim,
Norway
E-mail: halfdanpe@gmail.com
Telephone:+47 96686308
Professor Andrew Miles
Editor-in-Chief
Journal of Evaluation in Clinical Practice
World Health Organisation Collaborating Centre for Public Health Education and Training
Imperial College, London
c/o P.O. Box 64457,
London SE11 9AN
Trondheim, November 15, 2011
Dear Editor,
the results presented in our paper (1) are in discordance with the mainstream view of the
association between total cholesterol and mortality. However, our findings are in good accord
with many previous studies, as discussed in the paper and also another, recent publication (2).
We hereby provide an additional Table A to document the effect of stratification by age. This
helps explain, but does not alter, our previous conclusions. Within each age group, the age
stratified mortality rate per 1000 personyears is similar across the different cholesterol levels.
For our analyses (1), we used attained age as our time-scale, rather than the time-on-study. This
ensures that the estimated associations are adjusted for age, without age being included in the
regression model as a covariate. Thus, fewer variables are needed to be specified, and potential
proportional hazards violations between various age-categories are avoided. The method is
widely used and has been described in detail elsewhere (3). We realize that the impact of using
attained age could have been discussed more specifically in our paper.
As Professor Thelle et al. point out, the crude mortality rates are quite different from the age-
adjusted ones. The age-stratified mortality rates for the four different cholesterol categories
might have been presented in our paper to further clarify this discrepancy, since the paper’s
Figure 1 only includes two cholesterol categories.
Yours sincerely,
Halfdan Petursson, Johann A. Sigurdsson, Calle Bengtsson, Tom I. L. Nilsen, Linn Getz
1. Petursson, H., Sigurdsson, J. A., Bengtsson, C., Nilsen, T. I., Getz, L. (2011) Is the use
of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years
prospective data from the Norwegian HUNT 2 study. Journal of Evaluation in Clinical
Practice, Sep 25. doi: 10.1111/j.1365-2753.2011.01767.x. [Epub ahead of print]
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Address:
Research Unit of General Practice,
Department of Public Health and General Practice,
Norwegian University of Science and Technology,
N-7489 Trondheim,
Norway
E-mail: halfdanpe@gmail.com
Telephone:+47 96686308
2. Hamer, M., Batty, G.D., Stamatakis, E., Kivimaki, M. (2011) Comparison of risk factors
for fatal stroke and ischemic heart disease: A prospective follow up of the health survey
for England. Atherosclerosis, Aug 22. doi:10.1016/j.atherosclerosis.2011.08.016 [Epub
ahead of print]
3. Korn, E. L., Graubard, B. I., Midthune, D. (1997) Time-to-event analysis of longitudinal
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